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1 	   ABSTRACT	  
The	   present	   study	   proves	   that	   the	  mannose	   receptor	   (MR)	   bears	   beside	   its	   function	   as	  
endocytic	  receptor	  a	  second	  responsibility	  namely	  the	  induction	  of	  tolerance.	  	  
	  
The	  results	  of	  our	  experiments	  show	  that	  the	  decision,	  whether	  this	   immune-­‐suppressive	  
effect	   is	   carried	   out	   depends	   on	   the	   inflammatory	   status	   of	   the	   surrounding	   milieu.	  
Whereas	   at	   steady-­‐state	   conditions	   the	  MR	  has	   a	   tolerogenic	   effect	   during	   activation	   of	  
CD8+	   T	   cells,	   this	   suppressive	   phenotype	   is	   overcome	   under	   inflammatory	   conditions.	  
Thereby,	   the	  MR	   resembles	  a	  molecular	   switch	  between	   tolerance	   induction	  on	   the	  one	  
hand	  and	  allowance	  or	  even	  mediating	  immunity	  by	  antigen-­‐uptake	  on	  the	  other	  hand.	  
	  
The	  investigations	  of	  this	  thesis	  shed	  light	  into	  the	  underlying	  molecular	  mechanism	  of	  the	  
MR-­‐mediated	  induction	  of	  tolerance.	  The	  MR	  on	  DCs	  can	  bind	  to	  the	  tyrosine	  phosphatase	  
CD45	  on	  the	  T	  cell	  surface.	  This	   interaction	  leads	  to	  inhibition	  of	   its	  phosphatase	  activity,	  
which	   is	   responsible	   for	   a	   reduced	   cytotoxic	   capacity	   of	   activated	   CD8+	   T	   cells.	   The	  
executive	  molecule	  in	  this	  process	  is	  the	  inhibitory	  protein	  cytotoxic	  T-­‐lymphocyte	  antigen	  
4	  (CTLA-­‐4),	  being	  up-­‐regulated	  upon	  inactivation	  of	  CD45.	  	  
	  
After	  maturation	  of	  the	  DCs	  with	  the	  inflammatory	  molecule	  CpG,	  the	  immune	  suppressive	  
effect	  of	   the	  MR	   is	  overcome	  and	  a	  robust	   immune	  response	   is	   initiated.	  The	   findings	  of	  
this	   study	   pinpoint	   this	   effect	   to	   the	   abolished	   expression	   of	   CTLA-­‐4.	   It	   is	   furthermore	  
shown	   that	   signaling	   events	   via	   the	   co-­‐stimulatory	   molecule	   CD28	   are	   sufficient	   to	  
suppress	  CTLA-­‐4	  up-­‐regulation.	  Hence,	  a	  potent	  cytotoxic	  CD8+	  T	  cell	  response	  is	  induced.	  
	  
Finally,	   it	   can	   be	   demonstrated	   that	   the	   tolerogenic	   effect	   of	   the	   MR	   as	   well	   as	   its	  
molecular	  mechanism	  also	  holds	  true	  in	  vivo.	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2 	   INTRODUCTION	  
2.1 	   The	  immune	  system	  
The	   immune	  system	  protects	  organisms	  from	  pathogens	   like	  bacteria,	  viruses,	   funghi	  and	  
parasites.	  One	  discriminates	  between	  the	  faster	  but	  unspecific	  innate	  immune	  system	  and	  
the	  time-­‐consuming	  but	  very	  pathogen-­‐specific	  adaptive	  immune	  system.	  	  
	  
The	  innate	  immune	  system	  comprises	  of	  chemical,	  mechanical	  and	  microbiological	  barrier	  
mechanisms	  in	  addition	  to	  neutrophils,	  monocytes,	  macrophages,	  complement,	  cytokines	  
and	  acute	  phase	  proteins	  (1).	  This	  first	  line	  of	  defense	  prevents	  pathogen-­‐spreading	  from	  
the	  site	  of	  infection	  within	  the	  first	  96	  hours	  of	  infection.	  Afterwards	  the	  adaptive	  immune	  
system	  is	  initiated	  (2).	  	  
	  
Pathogenic	   composites	   which	   are	   absent	   in	   mammalian	   organisms,	   like	   bacterial	   wall	  
compounds,	   unmethylated	   CpG	   motifs	   or	   double-­‐stranded	   RNA	   are	   designated	   as	  
pathogen-­‐associated	   molecular	   patterns	   (PAMPs).	   These	   can	   be	   recognized	   by	   pattern	  
recognition	   receptors	   (PRRs)	   expressed	   by	   cells	   of	   the	   immune	   system.	   The	   most	  
prominent	   PRRs	   are	   the	   so-­‐called	   Toll-­‐like	   receptors	   (TLRs)	   whose	   encounter	   with	  
pathogenic	   ligands	   leads	   to	   inflammation	   on	   the	   site	   of	   infection	   and	   induction	   of	   the	  
adaptive	  immune	  response	  (3).	  	  
Fig.	  2-­‐1:	  Toll-­‐like	  receptors	  and	  their	  ligands	  
TLR1-­‐7	   and	   TLR9	   recognize	   microbial	   compounds	   not	   expressed	   by	   mammals.	   TLR2	   senses	   microbial	  
lipopeptides	   and	   is	   associated	   with	   TLR1	   or	   TLR6	   leading	   to	   a	   specific	   recognition	   of	   tri-­‐	   or	   diacetylated	  
lipoproteins	  respectively.	  Bacterial	  flagellins	  are	  recognized	  by	  TLR5,	  viral	  single	  stranded	  RNA	  by	  TLR7,	  CpG	  
DNA	  by	  TLR9,	  LPS	  by	  TLR4	  and	  viral	  double	  stranded	  RNA	  is	  sensed	  by	  TLR3.	  Thereby	  the	  immune	  system	  can	  
discriminate	   different	   pathogenic	   patterns	   by	   a	   variety	   of	   TLRs.	   Adopted	   from	   Takeda	   K	   in	   Seminars	   in	  
Immunology,	  2006.	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The	  adaptive	   immune	  system	   is	  a	  hallmark	  of	  higher	  animals	   (1)	  and	  besides	   its	  antigen-­‐
specificity	   one	   major	   peculiarity	   is	   the	   development	   of	   a	   immunological	   memory.	   The	  
immunological	  memory	  ensures	  an	  accelerated	   immune	  response	   in	  case	  of	  a	   secondary	  
infection	   (2).	   Activated	   B	   cells	   and	   T	   cells	   represent	   the	   effector	   cells	   of	   the	   adaptive	  
immune	   system.	  B	   cells	  produce	  antibodies,	  whereas	  T	   cells	   are	  diverse	   in	   function	  with	  
cytotoxic	  T	  cells,	  T	  helper	  cells	  and	  regulatory	  T	  cells	  as	  the	  main	  T	  cell	  subtypes.	  
	  
2.2 	   Necessity	  of	  dendritic	  cell	  maturation	  for	  T	  cell	  activation	  
T	  cells	  have	  to	  be	  activated	  by	  professional	  antigen-­‐presenting	  cells	  (APC)	  such	  as	  dendritic	  
cells	   (DC),	  macrophages	  and	  B	  cells	   (2).	  However,	  DCs	  drastically	  render	  their	  phenotypic	  
appearance	  upon	  pathogen-­‐encounter,	  thus	  enabling	  them	  for	  T	  cell	  priming	  (4).	  	  
	  
Under	   non-­‐inflammatory	   steady	   state	   conditions,	   DCs	   reside	   in	   and	   patrol	   through	  
peripheral	   tissue,	  blood,	   lymph	  and	  secondary	   lymphoid	  organs.	  Thereby	  they	  constantly	  
take	   up,	   process	   and	   load	   antigens	   onto	   major	   histocompatibility	   complexes	   (MHC),	   a	  
process	   called	   antigen	   presentation	   (3).	   However,	   this	   is	   quite	   ineffective	   and	   does	   not	  
lead	  to	  potent	  induction	  of	  immunity.	  	  
Upon	  pathogen	  recognition	  by	  for	  example	  TLRs,	  DCs	  undergo	  a	  process	  of	  maturation.	  As	  
consequence,	   migration	   capacities,	   expression	   of	   co-­‐stimulatory	   molecules,	   antigen	  
presentation	   on	   surface	   MHC	   molecules	   and	   secretion	   of	   cytokines	   are	   increased	   and	  
hence	  a	  potent	  immune	  response	  is	  initiated	  (3,	  4).	  
	  
2.2.1 DC	  maturation	  enhances	  expression	  of	  co-­‐stimulatory	  molecules	  
It	   is	   commonly	   accepted	   that	  up-­‐regulation	  of	   co-­‐stimulatory	  molecules	   like	  CD80,	  CD86	  
and	  CD40	  is	  initiated	  upon	  DC	  maturation	  and	  hence	  they	  serve	  as	  markers	  for	  mature	  DCs	  
(5).	  The	  binding	  of	  these	  molecules	  with	  their	  corresponding	  stimulatory	  counter-­‐receptors	  
CD28	  (for	  both	  CD80	  and	  CD86)	  and	  CD40	  ligand	  (CD40L)	  on	  the	  T	  cell	  surface	  is	  necessary	  
for	  prolonged	  T	  cell	  activation	  and	  survival	  (6).	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2.2.2 DC	  maturation	  enhances	  antigen	  presentation	  
The	   process	   of	   antigen	   presentation	   can	   be	   subdivided	   into	   the	   acquisition	   of	   antigens,	  
their	  degradation	  and	  their	  loading	  on	  MHC	  molecules.	  These	  MHC-­‐peptide	  complexes	  are	  
finally	  transported	  to	  the	  cell	  surface,	  where	  they	  are	  presented	  to	  T	  cells	  (7).	  	  
	  
Depending	  on	  the	  source	  of	  antigens,	  they	  can	  be	  presented	  on	  different	  MHC	  molecules.	  
Basically,	   intracellular	  antigenic	  peptides	  originating	  from	  viruses,	   intracellular	  bacteria	  or	  
cellular	   transformation	   are	   processed	   by	   the	   proteasome	   and	   transported	   via	   the	  
transporter	  associated	  with	  antigen	  processing	  (TAP)	  into	  the	  endoplasmic	  reticulum	  (ER),	  
where	  they	  are	  loaded	  on	  MHC	  class	  I	  (MHC	  I)	  molecules	  (8)	  (see	  Fig.	  2-­‐2).	  	  
On	   the	   other	   hand,	   peptides	   from	   extracellular	   antigens,	   like	   extracellular	   bacteria	   or	  
parasites,	   plus	   endogenous	   antigens	   acquired	   by	   autophagy	   are	   taken	   up,	   degraded	   in	  
lysosomal	  compartments	  and	  peptides	  are	  presented	  on	  MHC	  class	   II	   (MHC	  II)	  molecules	  
(9)	  (see	  Fig.	  2-­‐2).	  	  
	  
Corresponding	  to	  these	  different	  presentation	  pathways,	  distinct	  T	  cell	  subsets	  recognize	  
the	  MHC-­‐peptide	  complexes,	  as	  they	  are	  CD4+	  T	  cells	  for	  MHC	  II	  and	  CD8+	  T	  cells	  for	  MHC	  I.	  
Activated	  CD4+	  T	  cells	  gain	  T	  helper	  function	  and	  assist	   in	  DC	  maturation	  by	  CD40/CD40L	  
binding	  (10,	  11).	  Furthermore,	  they	  support	  activation	  of	  B	  cells	  and	  macrophages,	  which	  
leads	   to	  antibody	  production	  and	  destruction	  of	  extracellular	  antigens	   (9).	   In	   contrast	   to	  
that,	  CD8+	  T	  cells	  achieve	  cytotoxic	  capacities,	  resulting	   in	  a	  specific	  elimination	  of	  target	  
cells	  displaying	  the	  antigenic	  peptides	  on	  surface	  MHC	  I	  molecules	  (8).	  	  
A	   bypass	   of	   this	   strict	   discrimination	   exists	   in	   presentation	   of	   extracellular	   antigens	   on	  
MHC	  I,	  a	  process	  called	  cross-­‐presentation	  (12).	  This	  ensures	   immunity	  against	  viruses	  or	  
tumor	   antigens	   that	   do	   not	   affect	   the	   DCs	   themselves	   and	   would	   otherwise	   escape	  
annihilation	  by	  the	  immune	  system	  (see	  Fig.	  2-­‐2).	  
	  
In	   the	   process	   of	   maturation,	   antigen	   capture	   is	   reduced.	   Thus,	   mainly	   antigens	   are	  
presented	   on	   MHC	   molecules,	   which	   have	   been	   acquired	   during	   maturation	   (3).	  
Furthermore,	   surface	   expression	   of	   antigen-­‐loaded	  MHC	  molecules	   on	   immature	   DCs	   is	  
rather	   transient	   and	   is	   enhanced	   and	   prolonged	   after	   DC	   maturation	   (13),	   leading	   to	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increased	   antigen	   presentation	   after	   pathogen	   recognition.	   Besides	   the	   decision	   which	  
kind	   of	   responder	   cell	   is	   activated,	   the	   characteristics	   of	   pathogens	   also	   induce	   the	  
secretion	  of	  a	  specific	  set	  of	  cytokines	  (14).	  	  
Fig.	  2-­‐2:	  Antigen	  presentation	  pathways	  
Endogenous	  antigens	  are	  degraded	  by	   the	  proteasome	  and	   resulting	  peptides	  are	   transported	  via	   the	  TAP	  
transporter	  into	  the	  ER	  and	  loaded	  onto	  MHC	  I.	  Subsequently,	  they	  are	  presented	  on	  the	  cell	  surface	  towards	  
CD8+	   T	   cells.	   In	   contrast	   to	   that,	   endocytosed	   exogenous	   antigens	   or	   endogenous	   antigens	   taken	   up	   by	  
autophagy	  are	  lysed	  in	  endo-­‐lysosomes,	  which	  fuse	  with	  MHC	  II-­‐bearing	  vesicles.	  In	  these	  compartments	  the	  
loading	  of	  antigens	  on	  MHC	  II	  takes	  place	  and	  after	  transfer	  to	  the	  cell	  surface	  presentation	  to	  CD4+	  T	  cells	  
occurs.	  The	  third	  pathway	  of	  antigen	  presentation	  is	  the	  cross-­‐presentation	  in	  which	  exogenous	  antigens	  are	  
loaded	  on	  MHC	  I	  molecules	  and	  are	  presented	  towards	  CD8+	  T	  cells.	  Adopted	  from	  Villadangos	  JA	  in	  Nature	  
Reviews	  Immunology,	  2007.	  
	  
2.2.3 DC	  maturation	  enhances	  and	  switches	  cytokine	  secretion	  
During	   DC	  maturation	   the	   profile	   of	   secreted	   cytokines	   is	   affected	   by	   the	   nature	   of	   the	  
recognized	  pathogen.	   Intracellular	  pathogens	   trigger	   the	  DC	  to	   release	   interleukin	  12	   (IL-­‐
12)	  which	   in	  turn	  results	   in	  the	  differentiation	  of	  naive	  CD4+	  T	  helper	  cells	  towards	  a	  TH1	  
phenotype	   accompanied	   with	   secretion	   of	   cytokines	   like	   IFN-­‐γ,	   IL-­‐2	   and	   tumor	   necrosis	  
factor	  (TNF)	  (15,	  16)	  (see	  Fig.	  2-­‐3).	  TH1	  differentiated	  cells	  and	  the	  secreted	  cytokines	  act	  in	  
concert	  to	  activate	  cytotoxic	  T	  cells	  and	  macrophages,	  resulting	  in	  a	  cell-­‐mediated	  immune	  
response	  against	  infected	  or	  transformed	  cells.	  	  
In	  contrast	  to	  that,	  identification	  of	  extracellular	  pathogens	  fails	  to	  induce	  IL-­‐12	  secretion,	  
which	  leads	  to	  secretion	  of	  IL-­‐4	  and	  IL-­‐10	  by	  the	  DC	  instead.	  This	  results	  in	  differentiation	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of	  naive	  CD4+	  T	  cells	  of	  a	  TH2	  phenotype	  with	  cytokine	  release	  of	  IL-­‐4,	  IL-­‐5,	  IL-­‐6,	  IL-­‐9,	  IL-­‐10,	  
IL-­‐13	  and	  transforming	  growth	  factor	  beta	  (TGF-­‐β)	  (15,	  16)	  (see	  Fig.	  2-­‐3).	  Hence,	  a	  humoral	  
immune	   response	   against	   extracellular	   pathogens	   is	   initiated	   by	   activation	   of	   B	   cells	  
accompanied	  with	  antibody	  production.	  
	  
In	  addition	  to	  these	  paracrine	  cytokine	  effects	  on	  T	  cells,	  secreted	  cytokines	  also	  possess	  
autocrine	   functions	   on	   the	  producing	  DCs	   themselves.	   IFN-­‐γ	   for	   example	   enhances	   IL-­‐12	  
secretion	  and	  the	  expression	  of	  co-­‐stimulatory	  molecules	  (e.g.	  CD80,	  CD86	  and	  CD40)	  (17),	  
whereas	  secretion	  of	  IL-­‐10	  has	  the	  opposing	  effect	  (18,	  19).	  The	  combination	  of	  increased	  
expression	   of	   co-­‐stimulatory	   molecules	   and	   surface	   MHC-­‐peptide	   complexes	   plus	   the	  
enhanced	  and	  altered	  cytokine	  secretion,	  qualify	  mature	  DCs	  for	  potent	  T	  cell	  activation.	  
	  
Fig.	  2-­‐3:	  TH1	  and	  TH2-­‐cell	  differentiation	  
Activated	   DCs	   present	   pathogenic	   antigens	   in	   combination	   with	   co-­‐stimulatory	   molecules	   in	   the	   local	  
cytokine	  milieu	  towards	  CD4+	  T	  cells	  which	  lead	  to	  their	  differentiation	  into	  either	  TH1	  or	  TH2	  helper	  T	  cells.	  
Certain	   pathogens	   are	   sensed	   by	   the	   DC	   via	   PRRs	   which	   lead	   to	   IL-­‐12	   secretion.	   Thus,	   IL-­‐12	   promotes	  
differentiation	  of	  CD4+	  T	  cells	  into	  IFN-­‐γ-­‐	  and	  TNF-­‐secreting	  TH1	  cells.	  The	  inability	  of	  pathogens	  to	  induce	  IL-­‐
12	  secretion	  in	  DCs	  results	  in	  IL-­‐4	  and	  IL-­‐10	  production.	  Hence,	  TH2-­‐cell	  differentiation	  accompanied	  with	  the	  
secretion	   of	   interleukins	   4	   and	   5	   and	   13	   is	   induced.	   Modified	   from	   Kapsenberg	   ML	   in	   Nature	   Reviews	  
Immunology,	  2003.	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2.3 	   Three	  signals	  required	  for	  T	  cell	  activation	  
Three	  signals	  are	  necessary	  for	  an	  efficient	  T	  cell	  activation.	  Signal	  one	  is	  the	  T	  cell-­‐specific	  
antigen	  presented	  on	  MHC	  molecules,	  signal	  two	  is	  provided	  by	  co-­‐stimulatory	  molecules	  
and	  the	  third	  signal	  is	  delivered	  by	  inflammatory	  cytokines.	  	  
The	   T	   cell	   receptor	   (TCR)	   recognizes	   the	   haplotype-­‐matching	   MHC	   loaded	   with	   foreign	  
antigenic	  peptides.	  Mismatching	  of	  either	  of	  the	  two	  components	  normally	  leads	  to	  T	  cell	  
unresponsiveness	  (2).	  One	  particularity	  resembles	  the	  alloreaction	  in	  which	  the	  TCR	  either	  
strongly	   interacts	   with	   a	   well	   fitting	   peptide	   even	   if	   it	   is	   presented	   on	   a	   nonself	   MHC	  
molecule	   (peptide-­‐dominant	   binding),	   or	   the	   TCR	   binds	   the	   nonself	   MHC	   molecule	  
independent	  of	  the	  associated	  peptide	  (MHC-­‐dominant	  binding)	  (2).	  The	  interaction	  of	  the	  
TCR	   and	  MHC/peptide	   complexes	   is	   respectively	   stabilized	   by	   the	   TCR	   co-­‐receptors	   CD4	  
and	   CD8.	   Especially	   when	   low-­‐affinity	   ligands	   are	   bound,	   this	   stabilization	   takes	   place.	  
Furthermore,	  the	  co-­‐receptors	  recruit	  signaling	  molecules	  to	  the	  site	  of	  antigen	  recognition	  
(2,	  20).	  
	  
Co-­‐stimulatory	  molecules	   on	  DCs	   and	   their	   respective	   counter-­‐receptors	   on	   T	   cells	   form	  
complexes	   leading	  either	  to	  stimulatory	  or	   inhibitory	  T	  cell	  signaling.	  A	  multitude	  of	  such	  
complexes	   exist	   such	   as	   CD80/CD86-­‐CD28/CTLA-­‐4,	   ICOSL-­‐ICOS,	   PD-­‐L1/PD-­‐L2-­‐PD1/PD2,	  
CD40-­‐CD40L	   and	   OX40L-­‐OX40	   just	   to	   state	   the	   major	   molecules	   (21).	   In	   the	   case	   of	  
CD80/CD86-­‐CD28/CTLA-­‐4,	  the	  molecules	  CD80	  and	  CD86	  can	  either	  bind	  to	  the	  stimulatory	  
receptor	   CD28	   resulting	   in	   T	   cell	   activation	   or	   they	   can	   bind	   to	   the	   inhibitory	   receptor	  
CTLA-­‐4	  with	  a	  ten-­‐fold	  increased	  affinity	  (22),	  which	  induces	  T	  cell	  tolerance	  (23).	  
	  
Whereas	  already	  signal	  one	  and	  two	  can	  trigger	  T	  cell	  proliferation	  and	  IL-­‐2	  secretion	  (24),	  
only	  signal	  three	  causes	  development	  of	  full	  effector	  function	  of	  CD8+	  cytotoxic	  T	  cells	  (25).	  
Inflammatory	   cytokines	   deliver	   a	   “danger”	   signal	   in	   case	   of	   an	   infection.	   CD8+	   T	   cells	  
require	  IL-­‐12	  or	  Type	  I	  interferons	  (IFN-­‐α/β)	  for	  increased	  survival,	  formation	  of	  a	  memory	  
population	  and	  induction	  of	  optimal	  cytotoxic	  effector	  function	  along	  with	  IFN-­‐γ	  secretion	  
(26)	  (see	  Fig.	  2-­‐4).	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Fig.	  2-­‐4:	  The	  three	  signals	  for	  T	  cell	  activation	  
Signal	  one	   is	   the	   immunogenic	  antigen	  presented	  on	  MHC	  molecules	  on	  DCs,	  which	  are	   recognized	  by	   the	  
antigen-­‐specific	   TCR.	   Signal	   two	   is	   provided	   by	   the	  DC	   in	   form	  of	   co-­‐stimulatory	  molecules	  with	   a	   binding	  
molecule	   on	   the	   T	   cell	   side.	   To	   achieve	   CD8+	   cytotoxic	   T	   cell	   activation,	   the	   third	   signal	   is	   predominantly	  
delivered	  by	  IL-­‐12	  and	  Type	  I	  IFNs.	  Modified	  from	  Sun	  JC	  in	  Nature	  Reviews	  Immunology,	  2011.	  
	  
2.4 	   Killing	  mechanisms	  of	  CD8+	  cytotoxic	  T	  lymphocytes	  
CD8+	  cytotoxic	  T	  lymphocytes	  (CTLs)	  and	  natural	  killer	  cells	  (NK)	  are	  the	  two	  main	  cytotoxic	  
effector	  cells	  with	  common	  pathways	  to	   induce	  cell	  death.	  The	  triggering	  of	  apoptosis	  of	  
condemned	  cells	  is	  preferred	  to	  necrosis	  since	  it	  is	  a	  non-­‐inflammatory	  elimination	  (27).	  	  
Two	  main	   routes	   of	   apoptosis	   induction	   are	   used:	   the	   calcium-­‐dependent	   exocytosis	   of	  
granzyme	   and	   perforin	   containing	   granules	   and	   the	   calcium-­‐independent	   FAS	   pathway.	  
Both	  are	  conditional	  on	  direct	  contact	  with	  the	  target	  cell	  in	  which	  caspases	  are	  activated	  
leading	  to	  the	  induction	  of	  apoptosis.	  Besides	  these	  two	  pathways,	  also	  cytokines	  like	  IFN-­‐γ	  
and	  TNF	  can	  mediate	  cytotoxicity	  by	  either	   increasing	  cytotoxic	  capacities	  of	  CTLs	  (28)	  or	  
respectively	  by	  direct	  induction	  of	  apoptosis	  via	  cell	  surface	  receptors	  (29)	  (see	  Fig.	  2-­‐5).	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Fig.	  2-­‐5:	  Induction	  of	  apoptosis	  by	  cytotoxic	  T	  cells	  
The	  two	  main	  routes	  of	  inducing	  apoptosis	  in	  cancer	  cells	  or	  virally	  infected	  cells	  are	  via	  ligation	  of	  Fas	  with	  
its	   ligand	  FasL	  and	  exocytosis	  of	  cytotoxic	  granules.	  Both	  pathways	  lead	  to	  activation	  of	  several	  caspases	  in	  
the	  condemned	  cell,	  which	  in	  the	  end	  result	  in	  induction	  of	  apoptosis.	  Additionally,	  cytokines	  like	  interferons	  
are	  able	  to	  increase	  the	  cytotoxic	  capacity	  of	  CTLs	  by	  binding	  to	  their	  receptor	  (IFNR).	  Modified	  from	  Trapani	  
JA	  in	  Nature	  Reviews	  Immunology,	  2002.	  
	  
2.5 	   CD28	  triggers	  the	  effector	  function	  of	  CD8+	  cytotoxic	  T	  cells	  
For	   a	   proper	   CD8+	   T	   cell	   activation	   accompanied	   with	   the	   obtainment	   of	   cytotoxic	  
capacities,	  a	  series	  of	  signaling	  events	  are	  initiated	  within	  the	  T	  cell.	  	  
As	   already	   indicated,	   stimulation	   of	   the	   TCR	   alone	   leads	   to	   T	   cell	   irresponsiveness	   and	  
anergy	   (see	   Fig.	   2-­‐6).	   Despite	   activation	   of	   signaling	   pathways	   like	   the	   Calcineurin/	  
Calmodulin	   pathway,	   no	   T	   cell	   effector	   function	   can	   be	   achieved.	   Although	   signaling	  
molecules	  like	  the	  nuclear	  factor	  of	  activated	  T	  cells	  (NFAT)	  are	  activated	  and	  are	  able	  to	  
translocate	  into	  the	  nucleus,	   lacking	  expression	  of	  the	  activator	  protein	  1	  (AP1)	  results	   in	  
transcription	  of	  anergy	  inducing	  genes	  (see	  Fig.	  2-­‐6).	  
	  
This	  anergic	  state	  can	  be	  circumvented	  by	  signals	  via	  co-­‐stimulatory	  molecules,	  primarily	  
by	  CD28	  on	  DCs.	  CD28	   interacts	  with	  CD80/86	  on	   the	  T	   cell	   surface	  and	  promotes	  T	   cell	  
proliferation,	  cytokine	  production,	  cell	  survival	  and	  cellular	  metabolism	  (30).	  This	  is	  due	  to	  
the	   fact	   that	   additional	   signaling	   pathways	   (e.g.	   RAS-­‐MAPK,	   IKK	   and	   PKC)	   are	   induced,	  
leading	   to	  NF-­‐κB	  and	  AP1	  expression.	  These	   transcription	   factors	  can	  act	   in	  concert	  with	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NFAT,	   as	   for	  AP1,	  or	  by	   themselves	   to	   target	   a	   set	  of	   genes	  whose	  expression	   results	   in	  
effective	  T	  cell	  activation.	  
Fig.	  2-­‐6:	  TCR	  signaling	  in	  the	  absence	  and	  the	  presence	  of	  co-­‐stimulatory	  molecules	  
Co-­‐stimulatory	  molecules	  lead	  to	  the	  induction	  of	  signaling	  events,	  which	  are	  necessary	  for	  productive	  T	  cell	  
activation	  and	  prevention	  of	  anergy.	  a)	  TCR	  stimulation	  in	  the	  absence	  of	  co-­‐stimulation	  only	  activates	  NFAT	  
which	  translocates	  into	  the	  nucleus	  and	  induces	  transcription	  of	  anergy-­‐related	  genes.	  b)	  In	  contrast	  to	  that,	  
the	   presence	   of	   co-­‐stimulatory	   molecules	   triggers	   additional	   pathways	   like	   RAS-­‐MAPK,	   PKC	   or	   IKK.	   These	  
pathways	  result	  in	  synthesis	  of	  transcription	  factors	  like	  AP1	  and	  NF-­‐κB	  finally	  targeting	  T	  cell	  effector	  genes.	  
Modified	  from	  Macian	  F	  in	  Nature	  Immunology	  Review,	  2005.	  
	  
2.6 	   T	  cell	  signaling	  in	  CD8+	  cytotoxic	  T	  cells	  
The	   molecular	   mechanism	   leading	   to	   the	   cytotoxic	   effector	   function	   of	   CD8+	   T	   cells	  
comprises	  a	  cascade	  of	  protein	  interactions	  combined	  with	  their	  successive	  activation.	  This	  
cascade	   delivers	   the	   signal	   coming	   from	   the	   surface	   TCR	   into	   the	   nucleus	   of	   the	   T	   cell.	  
Here,	  the	  transcription	  of	  specific	  target	  genes	  mediates	  the	  differentiation	  into	  cytotoxic	  
effector	  T	  cells.	  
	  
The	  functional	  TCR	  is	  composed	  of	  two	  elements.	  The	  highly	  variable	  heterodimer	  of	  TCRα	  
and	   TCRβ	   chains	   form	   the	   antigen-­‐binding	   pocket	   whereas	   the	   invariant	   CD3	   complex,	  
consisting	  of	  CD3γ,	  δ	  and	  ε in	  association	  with	  the	  cytoplasmic	  ζ	  homodimer,	  is	  responsible	  
for	  efficient	  TCR	  surface	  expression	  and	  intracellular	  signaling	  (2).	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Located	  in	  close	  proximity,	  the	  CD8	  co-­‐receptor	  stabilizes	  the	   interaction	  of	  the	  TCR	  with	  
MHC	   I-­‐peptide	   complexes	   (2,	   20)	   and	   recruits,	   bound	   to	   its	   cytoplasmic	   tail,	   the	  
lymphocyte-­‐specific	  protein	  tyrosine	  kinase	  (Lck)	  towards	  the	  TCR	  (31,	  32).	  Each	  of	  the	  two	  
CD3	   ζ-­‐chains	   harbor	   three	   ITAM	   (immunoreceptor	   tyrosine-­‐based	   activation	   motif)	  
tyrosines.	  Upon	  TCR	  ligation,	  they	  are	  substrates	  for	  phosphorylation	  by	  Lck	  (33)	  resulting	  
in	  the	  recruitment	  of	  ZAP-­‐70	  (ζ-­‐chain-­‐associated	  protein	  kinase	  of	  70kDa)	  (see	  Fig.	  2-­‐7).	  	  
	  
Smith-­‐Garvin	   reviewed	   in	   2009	   (34)	   the	   afterwards	   events	  of	   the	  TCR	   signaling.	  A	  multi-­‐
molecular	  complex,	  designated	  as	  proximal	  signaling	  complex,	   is	  formed.	  The	  core	  of	  this	  
complex	  consists	  of	  the	  transmembrane	  adaptor	  molecule	  LAT	  (linker	  for	  the	  activation	  of	  
T	   cells)	   and	   the	   cytosolic	   adapter	   SLP76	   (Src	   homology	   2	   (SH2)	   domain-­‐containing	  
leukocyte	  phosphoprotein	  of	  76kDa)	  arranging	  all	   later	  recruited	  molecules	  in	  the	  correct	  
spatiotemporal	  manner	  (see	  Fig.	  2-­‐7).	  	  
	  
This	   proximal	   signaling	   complex	   initiates	   a	   cascade	   of	   phosphorylation	   events	   and	   a	  
recruitment	  of	  further	  molecules	  being	  mostly	  kinases.	  As	  a	  result,	  a	  series	  of	  phenotypic	  
changes	  are	  initiated	  within	  the	  T	  cells	  including	  rearrangement	  of	  the	  Actin	  cytoskeleton,	  
increased	   cell	   adhesion	   by	   enhanced	   surface	   expression	   of	   integrins	   and	   activation	   of	  
transcription	  factors	  like	  NFAT,	  NF-­‐κB	  and	  AP1.	  
The	   initiation	   of	   transcription	   factor	   expression	   is	   mediated	   via	   three	   main	   routes,	   all	  
starting	  with	  the	  hydrolyzation	  of	  the	  membrane	  lipid	  PtdIns(4,5)P2	  (phosphatidylinositol-­‐
4,5-­‐bisphosphate)	  into	  the	  second	  messengers	  InsP3	  (inositol-­‐1,4,5-­‐triphosphate	  )	  and	  DAG	  
(diacyl	  glycerol).	  This	  hydrolyzation	  is	  performed	  by	  the	  phospholipase	  Cγ1	  (PLCγ1),	  which	  
is	  recruited	  to	  the	  proximal	  signaling	  complex	  after	  TCR-­‐ligation.	  
InsP3	   induces	   the	   first	   pathway,	   comprising	   the	   calcium	   release	   via	   the	   molecules	  
Calcineurin/Calmodulin	   which	   in	   turn	   results	   in	   NFAT	   activation	   accompanied	   with	  
transcription	  of	  genes	  involved	  in	  T	  cell	  activation,	  amongst	  them	  IL-­‐2	  (34).	  
DAG	  activates	  two	  diverse	  signaling	  pathways,	  being	  the	  Ras	  and	  the	  protein	  kinase	  C	  (PKC)	  
pathways.	  	  
Ras	  itself	  induces	  the	  MAPK	  (mitogen-­‐associated	  protein	  kinase)	  signaling	  cascade	  which	  in	  
turn	  initiates	  the	  synthesis	  of	  AP1	  and	  thereby	  the	  transcription	  of	  IL-­‐2	  transcription,	  T	  cell	  
proliferation,	  growth	  and	  differentiation	  (34).	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The	  second	  pathway	  being	  initiated	  by	  DAG	  is	  the	  one	  including	  activation	  of	  PKC.	  At	  the	  
end,	   active	   PKC	   triggers	   the	   NF-­‐κB	   pathway	   leading	   to	   transcription	   of	   several	   genes	  
important	  for	  survival,	  proliferation	  and	  effector	  function	  development	  (35)	  (see	  Fig.	  2-­‐7).	  
Fig.	  2-­‐7:	  TCR-­‐induced	  signaling	  pathways	  
Upon	   TCR	   stimulation,	   the	   kinase	   Lck	   is	   recruited	   to	   the	   TCR	   and	   initiates	   the	   formation	   of	   the	   proximal	  
signaling	   complex.	   This	   complex	   is	   the	   starting	   point	   for	   the	   induction	   of	   several	   signaling	   pathways.	   The	  
second	  messengers	  DAG	  and	  IP3	  are	  generated	  by	  activated	  PLC-­‐γ1	  and	  trigger	  the	  Ras-­‐MAPK	  pathway,	  the	  
NF-­‐κB	  pathway	  and	  the	  NFAT	  pathway,	  all	  being	  essential	  for	  T	  cell	  activation	  and	  regulation.	  Modified	  from	  
Brownlie	  RJ	  in	  Nature	  Immunology	  Review,	  2013.	  
	  
Besides	  these	  stimulatory	  signaling	  events,	  it	  is	  not	  less	  important	  to	  prevent	  overreaching	  
or	  long-­‐lasting	  T	  cell	  activation	  which	  could	  lead	  to	  T	  cell	  hyperproliferation,	  destruction	  of	  
healthy	  tissue	  and	  increased	  susceptibility	  to	  autoimmune	  disease	  (36,	  37).	  	  
	  
One	  very	   important	  mediator	   in	   this	  shutdown	  process	   is	   the	   inhibitory	  molecule	  CTLA-­‐4	  
whose	   expression	   is	   induced	   after	   T	   cell	   activation	   (38).	   CTLA-­‐4	   binds	   with	   increased	  
affinity	  to	  CD80/86	  compared	  to	  CD28,	  countering	  its	  signaling	  and	  results	  in	  prevention	  of	  
IL-­‐2	   production	   and	   cell	   cycle	   arrest	   (39).	   Another	   very	   effective	   way	   in	   disabling	   TCR	  
signaling	  events	  is	  to	  negatively	  regulate	  the	  proximal	  signaling	  complex.	  	  
	  
The	  most	  prominently	  controlled	  protein	   in	   this	   regulation	  process	   is	  Lck.	  Lck	  bears	  both	  
stimulatory	   (tyrosine	   Y394)	   and	   inhibitory	   tyrosine	   sites	   (tyrosine	   Y505),	   whose	  
phosphorylation	  status	  determines	  the	  kinase	  activity	  of	  Lck	  (see	  Fig.	  2-­‐8a).	  To	  terminate	  
the	  TCR	  signaling,	  the	  inhibitory	  Y505	  is	  phosphorylated	  by	  the	  C-­‐terminal	  Src	  kinase	  (Csk).	  
Additionally,	   the	   phosphatase	   PTPN22	   (Protein	   tyrosine	   phosphatase,	   non-­‐receptor	   type	  
	   INTRODUCTION	   	  
	   16	  
22)	  dephosphorylates	  the	  active	  site	  Y394.	  These	  two	  events	  render	  Lck	  in	  an	  inactive	  state	  
accompanied	   with	   interrupted	   TCR	   signaling	   (see	   Fig.	   2-­‐8b).	   Davis	   et	   al.	   also	   ascribe	   a	  
crucial	  role	  to	  CD45	  during	  Y394	  dephosphorylation	  in	  this	  shutdown	  process	  (40).	  
Interestingly,	   also	   for	   mediating	   the	   initial	   activation	   of	   the	   TCR	   signaling	   cascade,	   the	  
phosphorylation	   status	   of	   Lck	   is	   regulated.	   In	   resting	   cells,	   CD45	   predominantly	  
dephosphorylates	   Y505,	   leading	   to	   basally	   active	   Lck.	   Upon	   TCR	   engagement,	   CD45	   is	  
excluded	   from	   the	   proximal	   signaling	   complex.	   Subsequently,	   Lck	   undergoes	  
autophosphorylation	   at	   the	   catalytic	   tyrosine	   Y394	   and	   becomes	   fully	   active.	   Just	   later,	  
CD45	   is	   recruited	   back	   to	   the	   TCR	   and	   can	   dephosphorylate	   the	   activating	   Y394	   site	   in	  
order	   to	   interrupt	   the	   TCR	   signaling	   cascade	   (see	   Fig.	   2-­‐8b).	   The	   dual	   function	   of	   CD45,	  
being	   important	  both	  for	  the	   initiation	  as	  well	  as	  for	  the	  shutdown	  of	  the	  T	  cell	  signaling	  
cascade,	  highlights	  CD45	  as	  crucial	  regulator	  in	  T	  cell	  activation.	  
Fig.	  2-­‐8:	  CD45-­‐mediated	  regulation	  of	  Lck	  
(a)	  CD45	  preferentially	  dephosphorylates	  the	  inhibitory	  Y505	  which	  results	  in	  a	  basally	  active	  or	  primed	  state	  
of	  Lck.	  Autophosphorylation	  at	  the	  stimulatory	  Y394	  results	  in	  fully	  active	  Lck.	  To	  a	  lesser	  extend,	  CD45	  can	  
dephoshorylate	   also	   the	   tyrosine	   Y394,	   rendering	   the	   active	   Lck	   into	   the	   basally	   active	   form.	   Finally,	   the	  
kinase	  Csk	   can	  completely	   inactivate	   Lck	  by	  phosphorylation	  of	   the	   tyrosine	  Y505.	   (b)	   For	   induction	  of	   the	  
TCR	   signaling	   cascade,	   the	   inactive	   Lck	   has	   to	   be	   activated	   by	   CD45-­‐mediated	   dephosporylation	   of	   the	  
tyrosine	  Y505	  and	  autophosphorylation	  of	  the	  tyrosine	  Y394.	  To	  shutdown	  the	  TCR	  signaling	  cascade	  via	  Lck,	  
the	  tyrosine	  Y505	  is	  phosphorylated	  by	  Csk	  plus	  Y394	  is	  dephosphorylated	  by	  the	  phosphatases	  PTPN22	  and	  
CD45.	  Besides	  the	  shown	  mono-­‐phosphorylated	  forms	  of	  Lck,	  phosphorylation	  on	  both	  tyrosines	  is	  possible	  
and	  leads	  to	  active	  Lck.	  Modified	  from	  Rhee	  I	  in	  Nature	  Immunology	  Review,	  2012.	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2.7 	   The	  phosphatase	  CD45	  
In	  1989,	  Matthew	  L.	  Thomas	  first	  mentioned	  the	  prototypic	  receptor-­‐like	  protein	  tyrosine	  
phosphatase	   (PTP)	   CD45.	   CD45	   bears	   an	   abundant	   expression	   on	   all	   nucleated	  
hematopoietic	   cells	  of	  up	   to	  10%	  of	   the	  cell	   surface	  area	   (41).	  The	  protein	  comprises	  an	  
extracellular	   domain	   of	   variable	   length,	   a	   single	   transmembrane	   region	   and	   a	   constant	  
cytoplasmic	  domain,	  which	  is	  95%	  homologous	  in	  all	  mammals	  (42).	  
	  
The	  variability	  in	  the	  extracellular	  domain	  is	  due	  to	  alternative	  splicing	  events	  of	  the	  exons	  
four,	   five,	   six	   and	   seven	   resulting	   in	   five	   different	   isoforms	   being	   R0,	   RB,	   RAB,	   RBC	   and	  
RABC.	  The	  expression	  and	  glycosylation	  pattern	  of	   the	   isoforms	  depend	  on	  the	  cell	   type,	  
developmental	  stage	  and	  the	  activation	  status	  (see	  Fig.	  2-­‐9).	  These	  alternatively	  expressed	  
parts	   are	   heavily	   O-­‐glycosylated	   together	   with	   variable	   sialylation	   resulting	   in	   divergent	  
molecular	   weights	   of	   about	   180kDa	   (R0)	   and	   up	   to	   230kDa	   (RABC)	   together	   with	  
differences	  in	  shape	  and	  negative	  charge	  (42).	  	  
	  
Fig.	  2-­‐9:	  CD45	  isoform	  expression	  in	  lymphoid	  lineages	  
Depending	   on	   the	   cell	   type	   together	   with	   the	   status	   of	   differentiation	   and	   activation,	   divergent	   CD45	  
isoforms	   are	   expressed	   and	   isotype-­‐switching	   occurs.	   Modified	   from	   Hermiston	  ML	   in	   Annual	   Reviews	   in	  
Immunology,	  2003.	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Besides	  this	  inconstant	  part	  of	  the	  extracellular	  domain,	  the	  remaining	  extracellular	  part	  is	  
heavily	   N-­‐glycosylated	   and	   consists	   of	   three	   membrane-­‐proximal	   type	   III	   fibronectin	  
domains	  followed	  by	  a	  cystein-­‐rich	  region	  (see	  Fig.	  2-­‐10).	  
The	   large	   intracellular	   part	   is	   composed	   of	   two	   tandemly	   duplicated	   PTPase	   homology	  
domains,	  D1	  and	  D2,	   separated	  by	  a	   spacer	   region.	  Whereas	  only	  D1	   forms	  a	   substrate-­‐
binding	   wedge	   and	   bears	   phosphatase	   activity,	   the	   function	   of	   D2	   is	   not	   yet	   fully	  
understood.	   Even	   so,	   it	   seems	   to	   have	   regulatory	   capacities	   by	   binding	   Lck	   and	   thereby	  
increasing	  its	  availableness	  for	  D1	  (43).	  	  
Fig.	  2-­‐10:	  Structure	  of	  CD45	  isoforms	  
The	  extracellular	  domain	  of	  CD45	  comprises	  three	  FN	  III-­‐like	  repeats,	  a	  cystein-­‐rich	  domain	  and,	  if	  expressed,	  
a	  varying	  number	  of	  alternatively	  spliced	  exons,	  which	  are	  absent	  in	  CD45R0.	  Intracellularly	  one	  can	  find	  the	  
tandemly	  repeated	  PTPase	  domains	  D1	  and	  D2.	  Whereas	  only	  D1	  posses	  phosphatase	  activity,	  the	  function	  
of	   D2	   is	   still	   unclear,	   although	   regulatory	   capacities	   are	   discussed.	   Adopted	   from	   Penninger	   JM	   In	   Nature	  
Immunology,	  2001.	  
	  
Within	  three	  days	  after	  T	  cell	  stimulation,	  the	  expression	  of	  larger	  CD45	  isoforms	  switches	  
towards	  the	  isoform	  R0	  (44,	  45)	  depending	  on	  the	  activation	  of	  PKC	  and	  Ras	  (46).	  Defects	  
in	   this	   isoform	   switch	   are	   linked	   with	   the	   development	   of	   multiple	   sclerosis	   (MS)	   (47)	  
whereas	   CD45-­‐deficient	   humans	   and	   mice	   develop	   severe-­‐combined	   immunodeficiency	  
(SCID)	   (48,	   49).	   This	   is	   due	   to	   disordered	   positive	   and	   negative	   selection	   in	   the	   thymus	  
resulting	  in	  far	  less	  thymocytes	  but	  bearing	  auto-­‐reactive	  features	  (50,	  51).	  
	  
As	  already	  described	  in	  chapter	  2.6,	  CD45	  has	  a	  dual	  role	  in	  the	  regulation	  of	  TCR	  signaling	  
events	  by	  dephosphorylation	  of	  either	  negative	  regulatory	  or	  catalytic	  tyrosine	  residues	  in	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the	  kinase	  Lck.	  The	   regulation	  of	   the	   initiative	  T	  cell	   signaling	  molecule	  Lck	   is	   tightly	  and	  
complexly	   regulated	   by	   interplay	   of	   the	   phosphatase	   CD45	   and	   the	   kinases	   Csk	   and	   Lck	  
itself.	  	  
In	  resting	  T	  cells,	  CD45	  predominantly	  dephosphorylates	  the	  negative	  regulatory	  Y505	  site	  
resulting	   in	   a	   signaling-­‐disposed	   unphosphorylated	   pool	   of	   Lck.	   Upon	   TCR	   stimulation,	  
CD45	   is	   segregated	   (52)	   from	   its	   substrate	   Lck	   which	   autophosphorylates	   its	   catalytic	  
tyrosine	   motive	   Y394	   and	   thereby	   becomes	   activated.	   To	   terminate	   TCR	   signaling,	   the	  
kinase	   Csk	   phosphorylates	   the	   negative	   regulatory	   tyrosine	   residue	   Y505,	   with	   Lck	   still	  
remaining	   active.	   Yet,	   the	   subsequent	   recruitment	   of	   CD45	   (and	   PTPN22)	   leads	   to	  
dephosphorylation	  of	   the	   tyrosine	  Y394	  accompanied	  with	   intramolecular	   interactions	  of	  
Lck	  and	  hence	  its	  inactivation	  (40).	  The	  favorable	  dephosphorylation	  of	  Y394	  by	  CD45	  after	  
phosphorylation	  of	  Y505	  by	  Csk	  might	  most	  likely	  be	  due	  to	  blocked	  accessibility	  of	  Y505	  by	  
Csk.	  	  
	  
Shenoi	   et	   al.	   (53)	   and	  Roach	  et	   al.	   (54)	   could	  observe	  an	   increased	  Src	   kinase	  activity	   in	  
CD45-­‐deficient	   macrophages	   and	   T	   cells.	   This	   is	   warranted	   by	   an	   enhanced	   overall	  
phosphorylation	  status	  of	  e.g.	  Lck.	  Additionally	   to	   the	  autocatalytic	   tyrosine	  motives,	   the	  
negative	   regulatory	   tyrosines	   are	   also	   phosphorylated.	   Despite	   hyperphosphorylation	   of	  
these	   negative	   regulatory	   tyrosines,	   the	   kinase	   activity	   is	   enhanced.	   Thereby,	   the	   bias	  
towards	  kinase	  activity	  in	  the	  absence	  of	  CD45	  activity	  is	  underlined.	  
	  
The	   importance	   of	   CD45	   in	   modulating	   the	   strength	   of	   TCR	   signaling	   requires	   strong	  
regulation	   of	   CD45	   activity.	   Dimerizing	   CD45	   antibodies	   leads	   to	   inhibited	   phosphatase	  
activity.	  Further	  investigations	  on	  related	  proteins	  reveal	  a	  blocking	  effect	  on	  the	  catalytic	  
site	  of	  one	  molecule	  after	   interaction	  with	  a	  structural	  wedge	  in	  the	  membrane-­‐proximal	  
region	  of	   the	  second	  molecule	   (55).	  Comparative	  mechanisms	   for	  CD45	  are	   likely	  due	   to	  
structural	  similarities.	  	  
	  
Dimerization	   of	   CD45	   appears	   in	   a	   spontaneous	   and	   isoform-­‐dependent	   manner.	   The	  
tendency	  of	  the	  isoform	  R0	  to	  form	  dimers	  exceeds	  the	  one	  of	  the	  larger	  isoforms.	  This	  is	  
due	  to	  the	  fact	  that	  R0	  lacks	  great	  amounts	  of	  O-­‐glycosylation,	  whereas	  in	  larger	  isoforms	  
the	  voluminous	  sugar	  side	  chains	  prevent	  dimerization	  and	  thereby	  CD45	  shut-­‐off	  (see	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Fig.	   2-­‐11).	   Resting	   T	   cells	   preferentially	   express	   larger	   and	   therefore	   more	   active	   CD45	  
isoforms	   which	   lead	   to	   signaling-­‐competent	   Lck.	   TCR	   signaling	   also	   induces	   enhanced	  
splicing	   (46)	   and	   within	   three	   days	   after	   T	   cell	   stimulation,	   the	   expression	   of	   larger	  
isoforms	   is	   augmented	   by	   R0	   (44,	   45)	   with	   increased	   tendencies	   for	   dimerization	   and	  
reduced	  phosphatase	  activity.	  	  
	  
The	   observation	   that	   dimerization-­‐incompetent	   mice	   develop	   a	   lymphoproliferative	  
syndrome	  and	  autoimmune	  nephritis	  co-­‐occurring	  with	  early	  death	  (56),	  highlights	  the	   in	  
vivo	  relevance	  for	  CD45	  inactivation	  by	  dimerization.	  	  
Fig.	  2-­‐11:	  Isoform-­‐dependent	  dimerization	  of	  CD45	  
Larger	   CD45	   isoforms	   bear	   voluminous	   sugar	   side	   chains,	   which	   prevent	   dimerization	   and	   lead	   to	   active	  
phosphatase.	  The	   isoform	  R0	   is	   less	  glycosylated	  and	   is	  prone	  to	  formation	  of	  dimers,	  which	  reduces	  CD45	  
activity.	  Adopted	  from	  Hang	  HC	  in	  Bioorganic	  and	  Medicinal	  Chemistry,	  2005.	  
	  
Besides	  spontaneous	  self-­‐ligation,	  it	  was	  shown	  by	  van	  Vliet	  et	  al.	  (57)	  that	  the	  lectin	  MGL	  
(macrophage	   galactose-­‐type	   lectin)	   binds	   and	   inactivates	   CD45.	   This	   process	   is	   also	  
possible	   for	   other	   lectins	   like	   the	   mannose	   receptor	   whose	   interaction	   with	   CD45	   was	  
reported	  by	  Martinez-­‐Pomares	  et	  al.	  (58).	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2.8 	   The	  Mannose	  Receptor	  
In	   the	   late	  1970s,	   the	  MR	  was	  mentioned	  as	  being	   involved	   in	   clearance	  of	   endogenous	  
proteins	   (59),	   which	   up	   to	   now	   was	   extended	   with	   further	   functions	   like	   promotion	   of	  
antigen	  presentation	  and	  modulation	  of	  cellular	  activity	  and	  trafficking	  (60).	  It	  is	  expressed	  
by	  some	  DCs	  and	  most	  murine	  tissue	  macrophages.	  Whereas	  the	  expression	  of	  the	  MR	  on	  
steady-­‐state	   splenic	   CD8+	   DCs	   in	   mice	   is	   controversially	   discussed	   (61-­‐63),	   there	   is	   no	  
question	  about	  its	  expression	  on	  inflammatory	  splenic	  DCs	  (61).	  	  
	  
The	  MR	  is	  a	  carbohydrate-­‐binding	  molecule	  of	  180kDa	  belonging	  to	  the	  MR	  family	  of	  the	  C-­‐
type	   lectins.	   This	   family	   also	   comprises	   the	  molecules	   Endo180,	   the	  M-­‐type	   PLA2R	   and	  
DEC205.	  
The	  extracellular	  structure	  of	  the	  MR	  is	  a	  N-­‐terminal	  cystein	  rich	  (CR)	  domain,	  a	  fibronectin	  
type	   II	   (FNII)	   domain	   and	   eight	   C-­‐type	   lectin-­‐like	   carbohydrate	   recognition	   domains	  
(CTLDs),	  also	  referred	  to	  as	  carbohydrate	  recognition	  domains	  (CRDs).	   In	  addition	  to	  this,	  
there	  is	  a	  single	  membrane-­‐spanning	  portion	  and	  a	  short	  intracellular	  tail	  (64)	  (see	  	  
Fig.	  2-­‐12).	  	  
The	  most	  distal	  domain	  of	  the	  MR	  is	  the	  CR	  domain.	  Within	  the	  MR	  family,	  the	  mannose	  
receptor	   is	   the	   only	   one	   bearing	   a	   functional	   CR	   domain	   (65).	   The	   CR	   domain	   binds	  
calcium-­‐independently	   to	   sulfated	   sugars,	   especially	   galactose	   or	   N-­‐Acetylgalactosamine	  
(GalNAc)	  sulfated	  in	  position	  3	  or	  4	  (65-­‐68)	  (see	  	  
Fig.	  2-­‐12).	  	  
C-­‐terminally	  to	  the	  CR	  domain	  resides	  the	  collagen	  binding	  FNII	  domain.	  This	   is	   the	  most	  
conserved	  domain	  among	  the	  MR	  family	  members	  (66).	  For	  the	  MR,	  there	  is	  strong	  affinity	  
for	  the	  collagens	  I,	  II,	  III	  and	  IV	  and	  a	  weak	  binding	  of	  collagen	  V	  (69,	  70)	  (see	  	  
Fig.	  2-­‐12).	  Importantly,	  binding	  via	  the	  FNII	  domain	  is	  neither	  dependent	  on	  glycosylation	  
nor	  on	  the	  lectin	  activity	  of	  the	  MR	  (71).	  
Being	  inherent	  in	  its	  name	  is	  the	  ability	  of	  the	  MR	  to	  bind	  mannosylated	  antigens.	  Besides	  
these,	  also	  glycoconjugates	  terminated	  in	  fucose	  or	  GalNAc	  (67,	  72,	  73)	  are	  taken	  up	  by	  the	  
MR	   in	  a	  calcium-­‐dependent	  manner.	  Noteworthy,	   this	  uptake	   is	  mediated	  only	  by	  CTLD4	  
whereas	  the	  remaining	  CTLDs	  ensure	  the	  required	  conformational	   folding	  of	   the	  MR	  and	  
thereby	  contribute	  to	  antigen	  binding	  (64,	  72)	  (see	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Fig.	  2-­‐12:	  Structure	  and	  antigen	  binding	  of	  the	  mannose	  receptor	  
The	  MR	  comprises	  a	  short	  C-­‐terminal	  intracellular	  domain	  with	  an	  internalization	  motif,	  one	  transmembrane	  
domain,	  eight	  C-­‐type	  carbohydrate	  recognition	  domains	  (CRD)	  followed	  by	  a	  fibronectin	  type	   II	   (FnII)	  and	  a	  
cystein-­‐rich	   domain	   (CR).	   Mannosylated	   antigens	   can	   bind	   to	   the	   CRD,	   preferentially	   to	   CRD4.	   Collagens	  
interact	  with	  the	  FNII	  domain	  and	  the	  CR	  domain	  recognizes	  sulfated	  sugars.	  
Modified	  from	  http://www.functionalglycomics.org/CFGparadigms/images/b/ba/Mannose_receptor.jpg	  
	  
	  
Though	   the	   very	   short	   intracellular	   domain	   of	   the	  MR	   lacks	   any	   signaling	   motives,	   it	   is	  
responsible	   for	   receptor	   internalization	   and	   recycling	   (74).	   Only	   10-­‐30%	   of	   the	   total	  MR	  
amount	  is	  expressed	  on	  the	  cell	  surface	  whereas	  70-­‐90%	  are	  located	  intracellularly	  in	  early	  
endosomal	   compartments.	   Clathrin-­‐coated	   vesicles	   mediate	   the	   continuous	   recycling	   of	  
surficial	  MR	   to	   intracellular	   compartments.	  This	  process	  of	  endocytosis	   strongly	  depends	  
on	   Actin	   polymerization	   (75)	   and	   is	   essential	   for	   MR	   recycling	   (76).	   Besides	   these	   cell-­‐
resident	  forms,	  also	  a	  shed	  variant	  of	  the	  MR	  exists.	  Herein,	  the	  whole	  extracellular	  region	  
of	   the	   MR	   is	   proteolytically	   cleaved	   off	   by	   a	   metalloprotease	   and	   released	   into	   the	  
surrounding	  (77).	  This	  soluble	  form	  of	  the	  MR	  is	  reported	  to	  be	  detectable	  in	  mouse	  serum	  
(77).	   The	   shedding	  of	   the	  MR	  directly	   correlates	  with	   its	   expression	   (78)	   and	  due	   to	   the	  
necessity	  of	  surface	  expression,	  Actin	  polymerization	  is	  needed	  for	  this	  process	  (75).	  	  
	  
The	  function	  of	  the	  soluble	  MR	  is	  thought	  to	  be	  the	  delivery	  of	  pathogenic	  antigens	  under	  
inflammatory	   conditions	   to	   cells	   that	   do	   not	   express	   the	   MR	   (60).	   Since	   mannosylated	  
antigens	   are	   frequently	   found	   on	   pathogen	   surfaces	   (e.g.	   Candida	   albicans	   (77,	   79),	  
Leishmania	   (80),	   Mycobacterium	   tuberculosis	   (81),	   HIV	   (82),	   Pneumocystis	   carnii	   (83),	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Dengue	  virus	  (84),	  Klebsiella	  pneumoniae	  (85),	  Streptococcus	  pneumoniae	  (85))	  and	  the	  MR	  
is	  designated	  as	  PRR	  (86),	  this	  potential	  function	  is	  feasible.	  	  
	  
The	  immunogenic	  properties	  of	  the	  MR	  could	  further	  be	  confirmed	  by	  Burgdorf	  et	  al..	  They	  
reported	  that	  under	  inflammatory	  conditions,	  soluble	  antigens	  which	  have	  been	  taken	  up	  
by	   the	  MR	  were	   transported	   into	   a	   specialized	   endocytic	   compartment,	   the	   stable	   early	  
endosomes,	   and	   are	   exclusively	   loaded	   onto	   MHC	   I	   molecules	   for	   subsequent	   cross-­‐
presentation	  to	  CD8+	  T	  cells	  (87-­‐89).	  Hence,	  many	  attempts	  at	  MR-­‐targeting	  in	  vaccination	  
strategies	   were	   ventured.	   Surprisingly,	   these	   trials	   resulted	   in	   tolerance	   instead	   of	  
immunity	  (90-­‐92).	  Yet,	  after	  the	  addition	  of	  endotoxins,	  a	  potent	  immune	  response	  could	  
be	  induced	  (90,	  93).	  These	  results	  raised	  the	  possibility	  that	  the	  MR	  might	  not	  solely	  have	  
immunogenic	  functions.	  
	  
Supportive	   to	   this	   is	   the	   fact	   that	  anti-­‐inflammatory	  cytokines	   (e.g.	   IL-­‐4,	   IL-­‐10,	   IL-­‐13)	  and	  
the	  glycocorticoid	  dexamethasone	   increase	  MR	  expression	   (59,	   78,	   94,	   95)	  whereas	  pro-­‐
inflammatory	  stimuli	  like	  IFN-­‐γ	  and	  LPS	  have	  inhibitory	  functions	  (67,	  96).	  
Furthermore	   it	   is	   known	   that	   several	   tolerance-­‐inducing	   and	   immune-­‐suppressive	   cells	  
extensively	   express	   the	  MR.	   Examples	   are	   given	   for	   liver	   sinusoidal	   endothelia	   cells	   (97,	  
98),	  uterine	  mucosal	  macrophages	  (99),	  oral	  macrophages	  and	  macrophages	  in	  the	  lamina	  
propria	   of	   the	   small	   intestine	   (100).	   In	   addition	   to	   this,	   the	   MR	   is	   found	   on	   M2-­‐
differentiated	  macrophages	  in	  reoccurring	  and	  vaccine-­‐resistant	  tumors,	  whose	  resistance	  
towards	  treatment	  could	  be	  pinpointed	  to	  these	  MR-­‐bearing	  macrophages	  (101-­‐103).	  	  
Finally,	   it	   is	   reported	   that	   expression	   of	   the	   MR	   is	   induced	   by	   the	   immunosuppressive	  
transcription	   factor	   PPARγ	   (Peroxisome	   proliferator-­‐activated	   receptor	   gamma)	   and	   is	  
directly	  linked	  to	  the	  expression	  of	  the	  co-­‐inhibitory	  molecule	  B7H1	  (104).	  	  
	  
All	   these	  hints	   lead	   to	   assumption	   that	   first	   of	   all,	   the	  MR	   is	   not	  only	   capable	   to	   impart	  
immunity	  but	  also	  tolerance	  and	  second	  of	  all,	  the	  help	  of	  additional	  factors	  regulated	  by	  
the	  MR	  might	  accomplish	  this	  tolerogenic	  effect.	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2.9 	   Aims	  of	  the	  thesis	  
The	  question	  to	  be	  answered	  in	  my	  thesis	  was	  whether	  the	  mannose	  receptor	  (MR)	  has	  an	  
additional	  role	  during	  T	  cell	  activation	  apart	  from	  leading	  to	  cross-­‐presentation	  of	  antigens.	  
This	  question	  arouse	  due	  to	  the	  divergent	  observations	  showing	  that	  on	  the	  one	  hand	  the	  
MR	  is	  a	  potent	  mediator	  of	  cross-­‐presentation	  under	  inflammatory	  conditions	  and	  on	  the	  
other	   hand	   many	   tolerance-­‐inducing	   cells	   bear	   a	   strong	   expression	   of	   the	   MR.	  
Furthermore,	   there	   have	   been	   several	   attempts	   to	   target	   the	   MR	   in	   vaccination	  
approaches	  which	  surprisingly	  led	  to	  anergy	  instead	  of	  immunity.	  Therefore,	  my	  task	  was	  
to	  investigate	  a	  putative	  effect	  of	  the	  MR	  during	  CD8+	  T	  cell	  activation	  by	  DCs.	  Importantly,	  
this	   was	   done	   in	   a	   system	   completely	   independent	   from	   antigen-­‐uptake	   by	   the	   MR.	  
Amendatory	  to	  a	  descriptive	  examination,	  the	  molecular	  mechanisms	  underlying	  the	  MR-­‐
mediated	  influence	  were	  investigated.	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3 	   MATERIAL	  AND	  METHODS	  
3.1 	   Material	  
3.1.1 Equipment	  
DEVICE	   COMPANY	  
0.75	  Plan	  S	  Apo	  20x	  objective	   Olympus	  
ChemiDoc	  MP	  System	   Bio	  Rad	  
Climate	  chamber	   Evotec	  
FACS	  LSR	  II	   BD	  Biosciences	  
HiScanSQ	   Illumnia	  
Inverted	  Fluoview	  1000	  confocal	  miroscope	   Olympus	  
Motorized	  xyz-­‐stage	   Märzhäuser	  
NanoDrop	  2000	  Spectrophotometer	   Thermo	  Scientific	  
Thermo	  MultiskanEX	  Plate	  reader	   Thermo	  Scientific	  
	  
3.1.2 Software	  
SOFTWARE	   COMPANY	  
Ascent	  Software	   Thermo	  Scientific	  
Endnote	  9	   Thomson	  Reuters	  
FACS	  DIVA	  Software	   BD	  Biosciences	  
FlowCytomixPro	  Software	   Bender	  
FlowJo	  V8.8.4	   Tree	  Star,	  Inc.	  
Fluoview	  3.0	   Olympus	  
GenomeStudio	  V2011.1	   Illumnia	  
Illustrator	  CS4	   Adobe	  
Image	  Lab™	  Software	   Bio	  Rad	  
ImageJ64	   National	  Institute	  of	  Health	  
Mayday	   Center	  for	  Bioinformatics	  Tuebingen	  (ZBIT),	  
University	  of	  Tuebingen	  
Microsoft	  Office	  2008	   Microsoft	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NanoDrop	  2000	  Software	   Thermo	  Scientific	  
Partek®	  Genomics	  Suite	  V6.6	  (PGS)	   Partek	  Inc	  
Photoshop	  CS4	   Adobe	  
Prism	  4	  for	  Macintosh	   GraphPad	  Software,	  Inc.	  
	  
3.1.3 Consumables	  
CONSUMABLE	   COMPANY	  
∅	  10cm	  Petri	  dishes	   Sarstedt	  
∅	  15cm	  tissue	  culture	  plates	   Sarstedt	  
1000mL	  Bottle	  Top	  Vacuum	  Filter,	  0.22µm	  pore	   Corning®	  
24-­‐well	  tissue	  culture	  plate	   TPP	  
6-­‐well	  tissue	  culture	  plate	   TPP	  
96-­‐well	  tissue	  culture	  plate	   TPP	  
ELISA-­‐Plate	  Microlon	  96W,	  Flat-­‐bottom,	  High	  binding	   Greiner	  
FACS	  tubes,	  5mL,	  ∅12mm,	  PP	   Sarstedt	  
Falcon	  cell	  strainer,	  40	  µm	   BD	  Biosciences	  
IBIDI	  chamber	  µ-­‐Slide	  I	   IBIDI®	  
Sterile	  syringe	  filter,	  0,45µm,	  Cellulose	  acetate	   VWR	  
	  
3.1.4 Chemicals	  and	  reagents	  
All	  unlisted	  standard	  chemicals	  were	  purchased	  at	  the	  company	  Carl	  Roth.	  
	  




4-­‐Nitrophenolphosphate	   Sigma-­‐Aldrich	  
Adenovirus	  Luciferase	  OVA	  GFP	  (AdLOG)	   Kindly	  provided	  by	  	  
Dr.	  Andreas	  Limmer	  
Ammonium	  persulfate	  (APS)	   Sigma-­‐Aldrich	  
Ampicillin	  Sodiumsalt	  (Amp)	   Sigma-­‐Aldrich	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Bovine	  serum	  albumin	  (BSA)	   Roth	  
Bromphenolblue	   Roth	  
Carboxyfluorescein	  succinimidyl	  ester	  (CFSE)	   BD	  Biosciences	  
CD8a	  (Ly-­‐2)	  MACS	  beads	   Miltenyi	  Biotec	  
CD8a+	  T	  Cell	  Isolation	  Kit	  II	   Miltenyi	  Biotec	  
Chloramphenicol	   Sigma-­‐Aldrich	  
Collagen	  (TypeI)	  R	   Serva	  
ColorPlus™	  Prestained	  Protein	  Ladder,	  	  
Broad	  Range	  (10-­‐230	  kDa)	  
New	  England	  Biolabs	  
Complete	  EDTA-­‐free	  Protease	  Inhibitor	  Cocktail	  Tablets	   Roche	  
CpG	  ODN	  1668	   Invitrogen	  
CTLA-­‐4-­‐IgG	  Fusion	  Protein	   BD	  Biosciences	  
Dephostatin	   Santa	  Cruz	  Biotechnology,	  Inc.	  
Dithiothreitol	  (DTT)	   Roth	  
DMEM,	  high	  glucose	  (4,5g/L),	  with	  L-­‐Glutamine	   PAA	  
EZ-­‐Link	  Sulfo-­‐NHS-­‐Biotin	   Thermo	  Scientific	  
FCS	  Clone	   PAA	  
Ficoll-­‐Paque™	  Premium	  1.084	   GE	  Healthcare	  
FlowCytomix	  Th1/Th2	  10plex	  Sample	  Kit	  	   Bender	  MedSystems	  
Hoechst	  33258	  1mg/mL	   Invitrogen	  
ICAM-­‐1	  Fc	  chimera	   R&D	  Systems	  
IFN-­‐γ	  recombinant	  protein	  as	  ELISA	  standard	   eBioscience,	  Inc.	  
IL-­‐2	  recombinant	  protein	  as	  ELISA	  standard	   eBioscience,	  Inc.	  
IMDM,	  with	  L-­‐Glutamine	   PAA	  
Kanamycinsulphate	  (Kana)	   Roth	  
L-­‐Glutamine,	  200mM	   PAA	  
Lipofectamine	  ™2000	   Invitrogen	  
Low	  fat	  dry	  milk	  powder	   Roth	  
Mouse	  serum	   PAA	  
MouseWG-­‐6	  v2.0	  Beadchips	   Illumnia	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N-­‐(9,10-­‐Dioxo-­‐9,10-­‐dihydro-­‐phenanthren-­‐2-­‐yl)-­‐2,2-­‐
dimethyl-­‐propionamide	  (SF1670),	  CD45	  Inhibitor	  	  
Calbiochem	  
NeutrAvidin™-­‐Horseradish	  peroxidase	   Thermo	  Scientific	  
NucleoBond®	  Xtra	  Midi	  Kit	   Macherey-­‐Nagel	  
OptiMEM	   Invitrogen	  
OVA	  (257-­‐264)	  SIINFEKL	  peptide	   Tebu-­‐Bio	  
Penicillin	  (10.000	  Units/mL)	  /	  Streptomycin	  (10mg/mL),	  
(Pen/Strep)	  
PAA	  
pFuse-­‐hIgG1-­‐Fc2	  vector	   Invitrogen	  
Phosphate	  buffered	  saline	  (PBS)	   Sigma-­‐Aldrich	  
Pierce	  Protein	  G	  Agarose	   Thermo	  Scientific	  
pIgplus	  vectors	  including	  MR	  domains	   Kindly	  provided	  by	  Dr.	  Luisa	  
Martinez-­‐Pomares	  
Protein	  G	  UltraLink	  Resin	   Thermo	  Scientific	  
PVDF	  Blotting	  membrane	   GE	  Healthcare	  
RNeasy	  Mini	  Kit	   Qiagen	  
RPMI-­‐1640,	  without	  L-­‐Glutamine,	  with	  HEPES	   PAA	  
Sodium	  Pyrovate,	  100mM	   PAA	  
Sulfo-­‐NHS-­‐LC-­‐Biotin	   Thermo	  Scientific	  
SuperSignal	  West	  Pico	  ECL	  Substrate	   Thermo	  Scientific	  
TargetAmp™-­‐Nano	  Labeling	  Kit	  for	  Illumina®	  Expression	  
BeadChip®	  
Epicentre®	  Biotechnologies	  
TRIzol®	   Invitrogen	  
Ultracomp™	  E.coli	   Invitrogen	  
Vivaspin	  6	  MWCO	  30.000	   GE	  Healthcare	  
X-­‐ray	  films,	  CL-­‐XPosure	   Thermo	  Scientific	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3.1.5 Buffers	  and	  solutions	  
Buffers	  were	  pH-­‐adjusted	  with	  HCl	  respectively	  NaOH.	  
	  
3.1.5.1 	   Common	  buffers	  
1x	  PBS	  	  
138mM	  NaCl,	  2,7mM	  KCl,	  adjusted	  to	  pH	  7,4,	  autoclaved.	  Storage	  at	  RT.	  
	  
500mM	  EDTA	  
500mM	  EDTA	  in	  H2O,	  adjusted	  to	  pH	  7,6,	  sterile	  filtered.	  Stored	  at	  -­‐20°C.	  
	  
2mM	  EDTA	  
500mM	  EDTA	  diluted	  1/250	  in	  sterile	  PBS.	  Storage	  at	  4°C.	  
	  
FACS	  Buffer	  
0,1%	  [w/v]	  BSA,	  0,1%	  [w/v]	  NaN3	  in	  1x	  PBS.	  Storage	  at	  4°C.	  
	  
3.1.5.2 	   ELISA	  buffers	  
ELISA	  coating	  buffer	  
0,1M	  NaHCO3	  in	  H2O	  adjusted	  to	  pH	  8,2.	  Storage	  at	  4°C.	  
	  
ELISA	  washing	  buffer	  
0,05%	  Tween20	  in	  PBS.	  Storage	  at	  RT.	  
	  
ELISA	  coating	  buffer	  for	  chimeric	  MR	  constructs	  
154mM	  NaCl	  in	  H2O.	  Storage	  at	  RT.	  
	  
ELISA	  washing	  and	  incubation	  buffer	  for	  chimeric	  MR	  constructs	  
10mM	  Tris-­‐HCl,	  10mM	  Ca2+	  (as	  CaCl2),	  154mM	  NaCl,	  0,05%	  Tween20.	  Storage	  at	  4°C.	  
	  
ABTS	  buffer	  
0,1M	  Citric	  acid,	  adjusted	  to	  pH	  4,35.	  Storage	  at	  4°C.	  
	  
ABTS	  substrate	  solution	  
1mg/mL	  ABTS,	  15µL	  H2O2	  in	  10mL	  ABTS	  buffer.	  Used	  freshly.	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3.1.5.3 	   Protein	  lysis	  and	  Western	  blot	  buffers	  
Protein	  lysis	  buffer	  
10mM	  Tris-­‐HCl	   (pH	  8,2),	  2%	  TritonX-­‐100,	  10mM	  NaN3,	  150mM	  NaCl,	  2mM	  EDTA	   in	  H2O.	  
Storage	  at	  4°C.	  Before	  usage	  1x	  Proteinase	  Inhibitor	  was	  added.	  
	  
Protein	  lysis	  buffer	  for	  CD45	  detection	  by	  chimeric	  MR	  
10mM	  Triethanolamine	  (pH	  8,2),	  150mM	  NaCl,	  1mM	  MgCl2,	  1mM	  CaCl2,	  1%	  (v/v)	  TritonX-­‐
100	  in	  H2O.	  Storage	  at	  4°C.	  Before	  usage	  1x	  Proteinase	  Inhibitor	  was	  added.	  
	  
4x	  Laemmli	  buffer	  
240mM	  Tris	   (pH	  6,8),	   8%	   (w/v)	   SDS,	   40%	   (v/v)	  Glycerol,	   0,01%	   (w/v)	  Bromphenolblue	   in	  
H2O.	  Storage	  at	  -­‐20°C.	  
	  
10x	  SDS	  running	  buffer	  
250mM	  Tris,	  1,92M	  Glycin,	  1%	  SDS	  in	  H2O.	  Storage	  at	  RT.	  
	  
1x	  SDS	  running	  buffer	  
10x	  SDS	  running	  buffer	  diluted	  1/10	  in	  H2O.	  Storage	  at	  RT.	  
	  
10x	  Towbin	  transfer	  buffer	  
250mM	  Tris,	  1,92M	  Glycin	  in	  H2O,	  adjusted	  to	  pH	  8,53.	  Storage	  at	  RT.	  
	  
1x	  Towbin	  transfer	  buffer	  
10%	  (v/v)	  10x	  Towbin	  transfer	  buffer,	  20%	  (v/v)	  Methanol,	  70%	  (v/v)	  H2O.	  Used	  freshly.	  
	  
Western	  blot	  blocking	  buffer	  
5%	  Milk	  in	  TBST.	  Storage	  at	  4°C.	  
	  
Western	  blot	  blocking	  buffer	  for	  WB	  with	  chimeric	  MR	  
5%	  Milk	  in	  PBST.	  Storage	  at	  4°C.	  
	  
10x	  TBS	  (Tris	  buffered	  saline)	  buffer	  
500mM	  Tris,	  1,5M	  NaCl	  in	  H2O,	  adjusted	  to	  pH	  7,5.	  Storage	  at	  RT.	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1x	  TBST	  buffer	  
10x	  TBS	  diluted	  1/10	  in	  H2O.	  0,1%	  Tween20	  were	  added.	  Storage	  at	  RT.	  
	  
1x	  PBST	  buffer	  
10x	  PBS	  diluted	  1/10	  in	  H2O.	  0,05%	  Tween20	  were	  added.	  Storage	  at	  RT.	  
	  
3.1.5.4 	   Buffers	  for	  Protein	  G	  agarose	  columns	  
Binding	  buffer	  Protein	  G	  columns	  
50mM	  Sodium	  acetate	  in	  H2O,	  adjusted	  to	  pH	  5,0.	  Storage	  at	  RT.	  
	  
Elution	  buffer	  Protein	  G	  columns	  
0,1M	  Glycin	  in	  H2O,	  adjusted	  to	  pH	  2-­‐3.	  Storage	  at	  RT.	  
	  
Neutralization	  buffer	  Protein	  G	  columns	  
1M	  Tris	  in	  H2O,	  adjusted	  to	  pH	  8-­‐9.	  Storage	  at	  RT.	  
	  
3.1.5.5 	   Phosphatase	  assay	  buffers	  
Phosphatase	  assay	  lysis	  buffer	  
20mM	  HEPES,	  2mM	  EDTA,	  2mM	  Dithiothreitol,	  1%	  (v/v)	  Glycerol	  in	  H2O.	  Storage	  at	  4°C.	  
	  
Phosphatase	  assay	  buffer	  
100mM	  HEPES,	  2mM	  EDTA	  in	  PBS.	  Storage	  at	  4°C.	  
	  
Complexation	  buffer	  for	  chimeric	  MR	  constructs	  
0,3%	  [w/v]	  BSA	  in	  1x	  PBS.	  Storage	  at	  4°C.	  
	  
3.1.5.6 	   Cell	  culture	  buffers	  
Red	  cell	  lysis	  buffer	  (RCB)	  
155mM	  NH4Cl,	  12mM	  NaHCO3,	  0,1mM	  EDTA	  in	  H2O,	  sterile	  filtered.	  Storage	  at	  -­‐20°C.	  
	  
MACS	  buffer	  
0,1%	  [w/v]	  BSA,	  2mM	  EDTA	  in	  1x	  sterile	  PBS.	  Storage	  at	  4°C.	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3.1.5.7 	   Solutions	  
Fetal	  calf	  serum	  (FCS)	  
500mL	  FCS	  were	  heat-­‐inactivated	  at	  56°C	  for	  30	  minutes	  and	  aliquots	  of	  50mL	  were	  stored	  
at	  -­‐20°C.	  
	  
25x	  Protease	  Inhibitor	  
One	  Proteinase	  Inhibitor	  Cocktail	  tablet	  in	  2mL	  H2O.	  Storage	  at	  4°C.	  
	  
3.1.6 Media	  
BMDC	  culture	  medium	  
IMDM,	   10%	   FCS	   Clone,	   100	   Units/mL	   Penicillin,	   0,1mg/mL	   Streptomycin,	   50mM	   β-­‐
Mercaptoethanol,	  2,5%	  R1	  supernatant.	  
	  
T	  cell	  medium	  
RPMI	   1640,	   10%	   FCS	   Clone,	   100	   Units/mL	   Penicillin,	   0,1mg/mL	   Streptomycin,	   50mM	   β-­‐
Mercaptoethanol,	  2mM	  L-­‐Glutamine.	  
	  
HEK293T	  cell	  medium	  
DMEM,	  10%	  FCS	  Clone,	  1mM	  Sodium	  Pyrovate.	  
	  
R1	  cell	  medium	  




If	   not	   indicated	   otherwise,	   all	   antibodies	   were	   purchased	   from	   eBioscience.	   Antibodies	  
against	   Actin	   were	   purchased	   form	   Sigma	   Aldrich,	   CD45	   was	   purified	   form	   YBM42.2.2	  
hybridoma-­‐supernatant,	  αMR	  was	  received	  from	  AbD	  Serotec,	  H2-­‐Kb	  SIINFEKL	  dextramers	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ANTIGEN	   CLONE	   CONJUGATE	   APPLICATION	  
Actin	   AA20-­‐33	   Unconjugated	   Western	  Blot	  
B7H1	   MIH5	   PE	   Flow	  cytometry	  
CD11c	   N418	   PerCP/Cy5.5	   Flow	  cytometry	  
CD28	   37.51	   Unconjugated	   In	  vitro	  assays	  
CD3	   145-­‐2C11	   Unconjugated	   Restimulation	  
CD40	   3/23	   PE	   Flow	  cytometry	  
CD45	   YBM42.2.2	   Unconjugated	   Western	  blot	  
CD8	   53-­‐6.7	   Pacific	  Blue	   Flow	  cytometry	  
CD80	   16-­‐10A1	   FITC	   Flow	  cytometry	  
CD86	   PO3	   PE	   Flow	  cytometry	  
CTLA-­‐4	   UC10-­‐4B9	   APC	   Flow	  cytometry	  
H2-­‐Kb	  SIINFEKL	  Dextramer	   	   APC	   Flow	  cytometry	  
IFN-­‐γ	   AN-­‐18	   Unconjugated	   ELISA	  
IFN-­‐γ	   R4-­‐6A2	   Biotinylated	   ELISA	  
IL-­‐2	   JES6-­‐1A12	   Unconjugated	   ELISA	  
IL-­‐2	   JES6-­‐5H4	   Biotinylated	   ELISA	  
MHC-­‐II	   M5/114.15.2	   PerCP/Cy5.5	   Flow	  cytometry	  
MR	   MR5D3	   APC	   Flow	  cytometry	  
pLck	   2751	   Unconjugated	   Western	  blot	  
	  
3.1.8 Mouse	  strains	  
STRAIN	   DESCRIPTION	   BACKGROUND	   HAPLOTYPE	  
C57/BL6J	   Wildtype	  strain	   C57/BL6J	   H-­‐2Kb	  
DesTCR	   Transgenic	  expression	  of	  a	  Kb-­‐specific	  	  
T	  cell	  receptor	  (KB5.C20	  TCR)	  in	  	  
CD8+	  thymocytes	  (105).	  
B10.BR	   H-­‐2Kk	  
MR-­‐/-­‐	   Stop-­‐codon	  inserted	  at	  the	  Mannose	  
receptor	  start	  codon	  of	  Exon	  1,	  	  
preventing	  its	  expression	  (106).	  
C57/BL6J	   H-­‐2Kb	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3.1.9 Cell	  lines	  
CELL	  LINE	   DESCRIPTION	  
HEK293T	   Human	  embryonic	  kidney	  cells	  
HEK293T-­‐MR	   Human	  embryonic	  kidney	  cells,	  transduced	  with	  murine	  MR	  (107)	  
R1	  cells	   NIH3T3	  cells	  stably	  transfected	  with	  GM-­‐CSF	  gene	  
RMA	   Murine	  T	  cell	  tumor	  
RMA-­‐S	   Mutagenized	  RMA,	  reduced	  surface	  MHC-­‐I	  (108)	  
YBM42.2.2	   Rat	  Hybridoma,	  production	  of	  CD45	  antibody,	  (109),	  kindly	  provided	  by	  
Prof.	  Stephen	  Cobbold	  and	  Prof.	  Hermann	  Waldmann	  
	  
3.2 	   Methods	  
3.2.1 Generation	  and	  handling	  of	  BMDCs	  
3.2.1.1 	   Cell	  culture	  conditions	  
Standard	  cell	  culture	  conditions	  were	  at	  37°C	  at	  levels	  of	  5%	  CO2	  and	  a	  relative	  humidity	  of	  
90%.	  Cell	  lines	  and	  BMDCs	  were	  spun	  at	  290xg	  for	  five	  minutes,	  whereas	  splenocytes	  were	  
centrifuged	  at	  300xg	  for	  ten	  minutes.	  
	  
3.2.1.2 	   Generation	  of	  GM-­‐CSF-­‐containing	  R1	  cell	  supernatant	  
GM-­‐CSF-­‐containing	   supernatant	  was	  produced	  by	  R1	   cells.	   1*106	  R1	   cells	  were	  plated	   in	  
30mL	   R1	   cell	   medium	   in	   ∅	   15cm	   tissue	   culture	   plates	   and	   incubated	   for	   four	   days.	  
Afterwards,	  cell	  supernatant	  was	  collected,	  sterile	  filtered	  and	  stored	  in	  50mL	  aliquots	  at	  	  	  	  
-­‐20°C.	  
	  
3.2.1.3 	   Differentiation	  of	  bone-­‐marrow	  derived	  dendritic	  cells	  (BMDC)	  
Hind	  limbs	  were	  isolated	  from	  one	  mouse	  and	  bone	  marrow	  was	  flushed	  out	  with	  1x	  PBS.	  
Cell	  clusters	  were	  dissociated	  by	  pipetting,	  cell	  suspension	  was	  filtered	  through	  a	  40µm	  cell	  
strainer	   and	   centrifuged.	   Afterwards,	   cells	   were	   resuspended	   in	   30mL	   BMDC	   culture	  
medium,	   distributed	   to	   three	   Petri	   dishes	   (∅	   10cm)	   and	   cultured	   under	   standard	  
conditions.	  Three	  days	  later,	  cell	  supernatant	  was	  collected,	  cells	  were	  harvested	  (3.2.1.4),	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resuspended	  in	  60mL	  BMDC	  culture	  medium	  and	  distributed	  to	  six	  Petri	  dishes	  (∅	  10cm).	  
By	  default,	  at	  day	  seven	  of	  culture,	  experiments	  were	  performed.	  
	  
3.2.1.4 	   Harvesting	  of	  BMDCs	  
Cell	   supernatant	  was	  collected,	  2mM	  EDTA	  was	  added	  and	   incubated	   for	   five	  minutes	  at	  
RT.	   Adherent	   cells	  were	   detached	   by	   pipetting,	   added	   to	   the	   collected	   supernatant	   and	  
spun.	  Cell	  pellet	  was	  resuspended	  assay-­‐dependent	  in	  appropriate	  medium	  and	  volume.	  
	  
3.2.1.5 	   CpG	  activation	  of	  BMDCs	  
On	  day	   six	  of	  BMDC	  differentiation,	   cell	   supernatant	  was	   collected,	   spun,	   cell	   pellet	  was	  
resuspended	   in	  BMDC	  culture	  medium	  supplemented	  with	  5µg/mL	  CpG	  and	   returned	   to	  
original	  plate.	  BMDC	  activation	  took	  place	  for	  18	  hours.	  
	  
3.2.2 In	  vitro	  proliferation	  assay	  
3.2.2.1 	   Isolation	  of	  splenocytes	  
Spleens	  were	   isolated,	   smashed	   into	  1x	  cold	  PBS	  with	  a	  syringe	  plunger	   through	  a	  metal	  
cell	   strainer,	   cell	   aggregates	   were	   dissolved	   by	   pipetting	   and	   cells	   were	   centrifuged.	  
Supernatant	  was	  discarded,	  cell	  pellet	  resuspended	  by	  flicking	  the	  tube	  and	  2mL	  RCB	  was	  
applied	   for	   five	  minutes	   at	   RT.	   Afterwards,	   erythrocyte	   lysis	  was	   stopped	   by	   addition	   of	  
8mL	   cold	   T	   cell	   medium,	   cell	   suspension	   was	   filtered	   through	   a	   40µm	   cell	   strainer	   and	  
centrifuged.	  
	  
3.2.2.2 	   CFSE-­‐staining	  of	  cells	  
Cells	  were	  washed	  once	  with	  1x	  PBS	  and	  spun	  at	  their	  respective	  G	  forces	  and	  durations,	  
resuspended	  in	  1x	  PBS	  and	  CFSE	  was	  added.	  For	  T	  cell	  proliferation	  assays,	  1µM	  CFSE	  were	  
used.	  For	  cytotoxicity	  assays,	  target	  cells	  received	  1µM	  and	  non-­‐target	  cells	  were	  stained	  
with	  0,1µM	  CFSE.	  For	   live	  cell	   imaging,	  T	  cells	  were	  stained	  with	  0,1µM	  CFSE.	   Incubation	  
was	  performed	   for	   15	  minutes	   at	   37°C,	   staining	  was	   stopped	  by	   addition	  of	   30mL	  T	   cell	  
medium	  and	  cells	  were	  spun	  down.	  Washing	  took	  place	  twice	  with	  10mL	  T	  cell	  medium.	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3.2.2.3 	   In	  vitro	  proliferation	  assay	  of	  CD8+	  T	  cells	  
5*104	  wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  plated	  in	  a	  96-­‐well	  tissue	  culture	  plate	  and	  let	  adhere	  
for	  one	  hour.	   In	  the	  meantime,	  splenocytes	  form	  DesTCR	  mice	  were	  isolated	  and	  labeled	  
with	   CFSE	   (see	   3.2.2.1	   and	   3.2.2.2).	   T	   cells	   were	   resuspended	   in	   10mL	   T	   cell	   medium,	  
counted	  in	  a	  Neubauer	  chamber	  and	  adjusted	  to	  5*105	  cells/mL.	  Finally,	  supernatant	  from	  
plated	  BMDCs	  was	  removed,	  1*105	  total	  T	  cells	  in	  200µL	  T	  cell	  medium	  added	  per	  well	  and	  
incubated	  for	  three	  days.	  After	  24	  hours,	  50µL	  supernatant	  was	  removed	  for	  IL-­‐2	  ELISA.	  On	  
day	  three,	  T	  cells	  were	  resuspended	  and	  CD8	  FACS	  staining	  was	  performed	  as	  described	  in	  
3.2.2.4.	  
	  
3.2.2.4 	   Flow	  cytometry	  
Harvested	  cells	  were	  transferred	  into	  FACS	  tubes,	  washed	  once	  with	  4mL	  FACS	  buffer	  and	  
spun.	   Supernatant	   was	   decanted	   and	   staining	   solution	   was	   added.	   If	   not	   indicated	  
otherwise,	  all	   stainings	  were	  performed	   in	  FACS	  buffer	  supplemented	  with	  1/100	  diluted	  
mouse	   serum	   and	   1µg/mL	   antibodies.	   Staining	   was	   performed	   at	   4°C	   under	   dark	  
conditions,	   followed	   by	   washing	   and	   final	   resuspension	   in	   FACS	   buffer.	   Staining	   of	  
SIINFEKL-­‐dextramers	   was	   performed	   in	   1/50	   dilution	   in	   1x	   PBS	   for	   15	  minutes	   at	   room	  
temperature,	  followed	  by	  default	  FACS	  staining	  procedures	  for	  further	  surface	  markers.	  
	  
3.2.3 In	  vitro	  cytotoxicity	  assay	  and	  re-­‐stimulation	  
3.2.3.1 	   In	  vitro	  cytotoxicity	  assay	  
4*105	  CpG-­‐activated	  (3.2.1.5)	  or	  untreated	  wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  plated	  in	  a	  24-­‐
well	  tissue	  culture	  plate	  and	  let	  adhere	  for	  one	  hour.	   In	  the	  meantime,	  splenocytes	  form	  
DesTCR	  mice	  were	  isolated	  (see	  3.2.2.1).	  T	  cells	  were	  resuspended	  in	  10mL	  T	  cell	  medium,	  
counted	  in	  a	  Neubauer	  chamber	  and	  adjusted	  to	  1*106	  cells/mL.	  Finally,	  supernatant	  from	  
plated	  BMDCs	  was	  removed,	  5*105	  total	  T	  cells	  in	  500µL	  T	  cell	  medium	  added	  per	  well	  and	  
incubated	  for	  four	  days.	  24	  hours	  later	  another	  2mL	  T	  cell	  medium	  were	  added.	  After	  four	  
days	   T	   cells	   were	   purified	   by	   density	   gradient	   centrifugation	   (see	   3.2.3.2).	   Target	   cells	  
(RMA)	   and	   non-­‐target	   cells	   (RMA-­‐S)	   were	   stained	   with	   CFSE	   as	   described	   in	   3.2.2.2,	  
counted,	   adjusted	   to	   4*104	   cells/mL	   and	  mixed	   equally.	   100µL	   cell	  mixture	   (2*103	   total	  
cells	  each)	  was	  co-­‐cultured	  for	  four	  hours	  with	  different	  ratios	  of	  T	  cells,	  added	  in	  100µL.	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Afterwards,	  cells	  were	  resuspended,	  transferred	  into	  FACS	  tubes	  and	  stained	  immediately	  
before	  analysis	  with	  10µg/mL	  Hoechst	  33258.	  Cells	  were	  analyzed	  by	  Flow	  cytometry	  and	  
specific	  cytotoxicity	  was	  calculated	  with	  the	  following	  formula:	  
	  
For	  cytotoxicity	  assays	  in	  the	  presence	  of	  chimeric	  MR	  protein,	  during	  BMDC	  and	  T	  cell	  co-­‐
culture,	  10µg/mL	  indicated	  chimeric	  protein	  was	  added,	  non-­‐supplemented	  2mL	  medium	  
was	  appended	  24	  hours	   later.	  CD45	   inhibitor	  N-­‐(9,10-­‐Dioxo-­‐9,10-­‐dihydro-­‐phenanthren-­‐2-­‐
yl)-­‐2,2-­‐dimethyl-­‐propionamide	   (SF1670)	   was	   added	   during	   the	   four	   days	   lasting	   T	   cell	  
priming	  phase	  with	  a	  constant	  concentration	  of	  40mM.	  Soluble	  CTLA-­‐4	  fusion	  protein	  and	  
inhibitory	  αCTLA-­‐4	  antibody	  were	  applied	  with	  a	  concentration	  of	  1µg/mL.	  
	  
3.2.3.2 	   T	  cell	  purification	  by	  density	  gradient	  centrifugation	  
Activated	   T	   cells	   that	  were	   co-­‐cultured	  with	   BMDCs	  were	   resuspended	   and	   spun	   down.	  
Afterwards,	  T	  cells	  were	  resuspended	  in	  5mL	  T	  cell	  medium,	  underlaid	  with	  2mL	  Ficoll	  and	  
centrifuged	   at	   805xg,	   acceleration	   7	   and	   break	   0	   for	   ten	  minutes.	   The	   T	   cell-­‐containing	  
interphase	  was	  collected,	  washed	  with	  1x	  PBS	  and	  resuspended	  in	  1mL	  T	  cell	  medium.	  
	  
3.2.3.3 	   Re-­‐stimulation	  of	  primed	  DesTCR	  T	  cells	  	  
A	  96-­‐well	  tissue	  culture	  plate	  was	  coated	  with	  10µg/mL	  αCD3	  antibody	  diluted	  in	  100µL	  1x	  
PBS	   for	   one	   hour	   at	   37°C.	   Wells	   were	   washed	   twice	   with	   excess	   of	   PBS,	   purified	   (see	  
3.2.3.2)	  activated	  T	  cells	  were	  adjusted	  to	  5*105	  cells/mL	  and	  200µL	  were	  applied	  to	  the	  
coated	   plate.	   After	   18	   hours,	   the	   plate	   was	   spun	   at	   300xg	   for	   five	   minutes,	   150µL	  
supernatant	  was	  fetched	  and	  the	  IFN-­‐γ	  concentration	  determined	  by	  ELISA	  (see	  3.2.4).	  
	  
3.2.4 Enzyme-­‐linked	  immuno	  sorbent	  assay	  (ELISA)	  
ELISA	  plates	  were	  coated	  with	  0,5µg/mL	  purified	  capture	  antibody	  in	  50µL	  coating	  buffer	  
for	  one	  hour	  at	  37°C,	  followed	  by	  three	  washing	  steps	  with	  150µL	  washing	  buffer.	  Blocking	  
took	   place	  with	   100µL	   blocking	   buffer	   for	   30	  minutes	   at	   RT,	   followed	   by	   three	  washing	  
steps.	   IL-­‐2	   standard	   protein	   was	   1/4	   serially	   diluted	   in	   the	   corresponding	   cell	   medium,	  
standard	   protein	   and	   samples	   were	   applied	   to	   ELISA	   plates	   and	   incubated	   o.n.	   at	   4°C.	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Afterwards,	   three	   washing	   steps	   took	   place	   and	   50µL	   biotinylated	   detection antibody	  
(0,5µg/mL)	  in	  blocking	  solution	  were	  added	  for	  one	  hour	  at	  37°C.	  After	  three-­‐fold	  washing,	  
1µg/mL	   horseradish	   peroxidase-­‐coupled	   Neutravidin	   was	   diluted	   in	   1x	   PBS,	   applied	   and	  
incubated	   for	   30	  minutes	   at	   RT.	   Finally,	   three	  washing	   steps	  were	   performed	   and	   50µL	  
ABTS	  substrate	  solution	  added.	  Colorimetric	  changes	  were	  analyzed	  with	  an	  ELISA	  reader	  
at	  450nm.	  
	  
3.2.5 Cell	  surface	  molecules	  and	  cytokine	  secretion	  of	  BMDCs	  
3.2.5.1 Staining	  of	  cell	  surface	  molecules	  
4*105	  BMDCs	  were	  plated	   in	  a	  24-­‐well	   tissue	  culture	  plate	  and	   let	  adhere	   for	  about	  one	  
hour.	   Isolated	   DesTCR	   splenocytes	   (see	   3.2.2.1)	   were	   counted	   and	   adjusted	   to	   1*106	  
cells/mL.	   Supernatant	  was	   removed	   from	  BMDCs,	   5*105	  DesTCR	  T	   cells	  were	  added	  and	  
incubated	   for	   18	   hours.	   Afterwards,	   cell	   supernatants	   were	   collected	   and	   secreted	  
cytokines	   and	   chemokines	   were	   determined	   by	   Fluorescent	   bead	   immuno	   assay	   (see	  
3.2.5.2).	  Adherent	  BMDCs	  were	  scraped	  off	  with	  a	  rubber	  scraper	  and	  stained	  for	  CD11c	  
plus	  either	  other	  marker	   like	  CD86,	  CD80,	  CD40,	  MHC	   II	  or	  B7H1	  as	  described	   in	  3.2.2.4.	  
CD11c	  was	  used	  as	  marker	  for	  BMDCs.	  
	  
3.2.5.2 	   Fluorescent	  bead	  immuno	  assay	  
A	  Fluorescent	  bead	   immuno	  10plex	  assay	  allows	  quantification	  of	   ten	  different	  cytokines	  
and	  chemokines	  simultaneously	  in	  a	  FACS-­‐based	  method.	  Cell	  supernatant	  was	  treated	  as	  
described	   in	   the	  manufacturers	  manual.	  Briefly,	  a	  mixture	  of	  beads,	  which	  were	  coupled	  
with	   ten	   different	   capture	   antibodies	   against	   cytokines,	   was	   added	   to	   the	   collected	   cell	  
BMDCs	  supernatant.	  Afterwards,	  biotinylated	  detection	  antibodies	  were	  added,	   followed	  
by	   Streptavidin-­‐PE.	   The	   read-­‐out	   was	   performed	   by	   flow	   cytometry.	   Beads	   can	   be	  
distinguished	   from	   each	   other,	   firstly,	   by	   two	   different	   sizes	   and,	   secondly,	   by	   different	  
fluorescent	  intensities	  for	  the	  channel	  Far	  Red.	  The	  amount	  of	  detected	  antigen	  is	  analyzed	  
by	   measurement	   of	   the	   intensity	   in	   the	   PE	   channel.	   Internal	   standard	   curves	   for	   all	  
examined	   cytokines	   and	   chemokines	   allow	   quantification	   with	   the	   FlowCytomixPro	  
Software.	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3.2.6 MACS	  sorting	  of	  CD8+	  T	  cells	  
T	   cell	   isolation	   was	   performed	   as	   described	   in	   the	   manufacturers	   manual.	   Briefly,	  
splenocytes	  were	   incubated	  with	  αCD8a	   (Ly-­‐2)-­‐coupled	  magnetic	  beads	  and	   loaded	  onto	  
separation	  columns	  within	  a	  magnetic	   field.	  Contaminating,	  unlabeled	  cells	  were	  washed	  
away	   and	   magnetically	   labeled	   cells	   of	   interest	   were	   eluted	   from	   column	   beyond	   the	  
magnetic	  field,	  washed	  and	  resuspended	  in	  an	  appropriate	  volume	  of	  T	  cell	  medium.	  
For	  gene	  array	  samples,	  the	  T	  cell	  isolation	  kit	  was	  used	  in	  which	  all	  other	  cell	  types	  in	  the	  
spleen	  were	  isolated	  and	  untouched	  T	  cells	  were	  collected	  in	  the	  flow-­‐through.	  
	  
3.2.7 Live	  cell	  imaging	  
3.2.7.1 	   ICAM-­‐coating	  of	  IBIDI	  chambers	  
Plastic	   channel	   µ-­‐slides	   were	   coated	   with	   5µg/mL	   ICAM-­‐1	   chimeric	   protein	   which	   is	  
coupled	   to	   the	   FC	   part	   of	   human	   IgG1.	   To	   block	   lumen-­‐directed	   FC	   parts,	   12µg/mL	   goat	  
αhuman	  IgG	  antibody	  (Dianova)	  were	  added.	  
	  
3.2.7.2 	   Live-­‐cell	  imaging	  
DesTCR	   splenocytes	   were	   isolated	   as	   described	   above	   (see	   3.2.2.1),	   CD8+	   T	   cells	   MACS	  
sorted	   (see	   3.2.6)	   and	   stained	   with	   CFSE	   (see	   3.2.2.2).	   1,6*105	   T	   cells	   were	  mixed	   with	  
4*105	   wildtype	   or	   MR-­‐/-­‐	   BMDCs	   in	   a	   total	   volume	   of	   110µL	   T	   cell	   medium.	   100µL	   cell	  
mixture	  was	   loaded	   in	   ITAM-­‐coated	   (see	  3.2.7.1)	  plastic	   channel	  µ-­‐slides.	   In	   cooperation	  
with	  Thomas	  Quast,	  time-­‐lapse	  microscopy	  was	  performed	  in	  a	  climate	  chamber (Evotec;	  
37°C	   and	   5%	   CO2	   with	   humidity)	   with	   an	   inverted	   Olympus	   Fluoview	   1000	   confocal	  
microscope,	   equipped	   with	   an	   automated	  motorized	   xyz-­‐stage	   (Märzhäuser).	   Every	   two	  
minutes,	   the	   green	   fluorescence	   and	   differential	   interference	  was	   recorded	  with	   a	   0.75	  
Plan	   S	   Apo	   20x	   objective	   over	   a	   period	   of	   12	   hours.	   Subsequently,	   the	   duration	   of	  
interaction	  between	  BMDCs	  and	  T	  cells	  was	  analyzed	  with	  the	  Fluoview	  Software.	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3.2.8 Generation	  of	  chimeric	  MR	  proteins	  
3.2.8.1 	   Vectors	  encoding	  for	  chimeric	  MR	  constructs	  
The	  vector	  pFuse-­‐hIgG1-­‐Fc2	  bears	  a	  Zeocin™	   resistance	  and	  encodes	   the	   isotype	  control	  
protein.	  The	  chimeric	  MR	  proteins	  MR-­‐FN	  (consisting	  of	  CR-­‐domain,	  FN-­‐domain	  and	  CTLD	  







	   MATERIAL	  AND	  METHODS	   	  
	   41	  
	  
	  
Fig.	  3-­‐1:	  Maps	  of	  vectors	  encoding	  for	  the	  control	  protein	  or	  two	  different	  chimeric	  MR	  constructs	  
The	  control	  protein	  is	  encoded	  on	  the	  vector	  pFuse-­‐hIgG1-­‐Fc2	  containing	  the	  gene	  for	  the	  human	  Fc2	  part	  of	  
IgG1.	  The	  vector	  pIgplus	  contains	  besides	  the	  human	  Fc	  part	  of	   IgG1	  also	  the	  FN,	  CR	  and	  CTLD1-­‐3	  domains	  
(pIgplus-­‐CR-­‐FN-­‐CTLD1-­‐3)	  or	  the	  domains	  CTLD1-­‐4	  (pIgplus-­‐CTLD1-­‐4)	  of	  the	  murine	  MR.	  
	  
3.2.8.2 	   Transformation	  of	  Ultracomp™ 	  E.coli	  with	  vector	  DNA	  
Transformation	  was	  performed	  by	  standard	  methods	   (110).	  Cells	  were	  plated	  afterwards	  
on	  antibiotics-­‐supplemented	  LB	  agar.	  25µg/mL	  Zeocin™	  were	  used	   for	   transformation	  of	  
the	   pFuse-­‐hIgG1-­‐Fc2	   vector	   and	   a	   combination	   of	   40µg/mL	   Ampicillin	   and	   50µg/mL	  
Kanamycin	  were	  used	  for	  pIgplus	  vectors.	  
	  
3.2.8.3 	   Midi	  cultures	  of	  E.coli	  	  
Over	  night	  cultures	  were	  performed	  under	  standard	  conditions.	  E.coli	  cells	  that	  had	  been	  
transformed	   with	   the	   low-­‐copy	   vector	   pIgplus	   received	   200µg/mL	   Chloramphenicol	   for	  
four	   hours	   to	   inhibit	   cell	   division	   and	   increase	   DNA	   yield.	   Plasmid	   DNA	  was	   isolated	   as	  
describes	  in	  3.2.8.4.	  
	  
3.2.8.4 	   Plasmid	  DNA	  isolation	  
Plasmid	  DNA	  was	  isolated	  referring	  to	  the	  manufacturers	  manual	  of	  the	  NucloeBond®	  Xtra	  
Midi	  Kit.	  The	  concentration	  and	  purity	  (A260/A280)	  of	   isolated	  DNA	  was	  determined	  with	  a	  
Nanodrop	  spectral	  photometer.	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3.2.8.5 	   Transfection	  of	  HEK293T	  cells	  
For	   production	   of	   chimeric	  MR	   constructs,	   cells	  were	   transfected	  with	   vectors	   encoding	  
either	  only	   the	  human	   IgG1	  FC	   (Isotype	  control)	  or	   the	  FC	  part	  which	  was	   coupled	   to	   the	  
Cystein-­‐rich	   (CR)	   domain,	   the	   Fibronectin-­‐like	   (FN)	   domain	   and	   the	   C-­‐type	   lectin-­‐like	  
domains	  1-­‐3	  (CTLD)	  (MR-­‐FN)	  or	  with	  vectors	  whose	  FC	  part	  was	  coupled	  to	  the	  CTLDs	  4-­‐7	  of	  
the	   murine	   MR	   (MR-­‐CTLD)	   (69)	   (see	   vector	   cards	   3.2.8.1;	   Fig.	   3-­‐1).	   24	   hours	   before	  
transfection,	  4*106	  HEK293T	  cells	  were	  plated	   in	  10mL	  HEK	  cell	  medium	   in	  75cm2	   flasks.	  
On	  the	  day	  of	  transfection,	  medium	  was	  replaced	  by	  10mL	  fresh	  HEK293T	  cell	  medium.	  For	  
Lipofectamine™	  2000	  transfection,	  10µg	  DNA	  were	  mixed	  with	  2mL	  Opti-­‐MEM®	  as	  well	  as	  
25µL	  Lipofectamine™	  2000	  were	  mixed	  with	  2mL	  Opti-­‐MEM®.	  Afterwards,	  mixtures	  were	  
combined	   and	   incubated	   at	   RT	   for	   five	  minutes	   and	   added	   to	   the	   plated	  HEK293T	   cells.	  
After	  24	  hours	  of	   culture,	   the	  medium	  containing	   the	   transfection	   solution	  was	  carefully	  
replaced	  by	  20mL	  Opti-­‐MEM	  and	  protein	  production	  and	  secretion	  took	  place	  for	  four	  days	  
under	  standard	  cell	  culture	  conditions.	  
	  
3.2.8.6 	   Isolation	  of	  chimeric	  MR	  proteins	  by	  Protein	  G	  column	  
For	  protein	  purification	  with	  Protein	  G	  columns,	  the	  manufacturers	  manual	  was	  followed	  
and	  a	  constant	  fluidic	  flow	  of	  1ml/minute	  was	  ensured	  by	  using	  a	  peristaltic	  pump.	  Briefly,	  
cell	   supernatants	   from	   transfected	   HEK293T	   cells	   (see	   3.2.8.5)	  were	  mixed	  with	   binding	  
buffer,	   loaded	   on	   the	   Protein	   G	   column,	   washed	   and	   captured	   proteins	   were	   eluted	   in	  
eight	   fractions	   of	   900µL	   in	   100µL	   neutralization	   buffer.	   To	   concentrate	   and	   wash	   the	  
protein,	   plus	   performing	   a	   buffer-­‐exchange	   to	   1x	   PBS,	   eluted	   fractions	  were	  pooled	   and	  
applied	  to	  30kDa	  Vivaspin	  ultrafiltration	  columns.	  Centrifugation	  took	  place	  at	  4000xg	  for	  
20	   minutes,	   two	   times	   6mL	   1x	   PBS	   were	   added	   and	   centrifuged	   as	   before.	   The	   last	  
centrifugation	  resulted	  in	  about	  1mL	  final	  volume	  of	  concentrated	  protein	  dissolved	  in	  1x	  
PBS.	  The	  protein	  concentration	  was	  determined	  by	  spectral	  photometry	  at	  280nm.	  
	  
3.2.8.7 	   Complexation	  of	  chimeric	  MR	  protein	  
The	   indicated	   amount	   of	   chimeric	  MR	   protein	   or	   isotype	   control	   protein	  was	   incubated	  
with	   1µg/mL	   horseradish	   peroxidase-­‐coupled	   αhuman	   antibody	   in	   0,3%BSA/PBS	   in	   the	  
presence	  of	  1x	  proteinase	  inhibitor	  for	  one	  hour	  at	  RT.	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3.2.9 Co-­‐Immunoprecipitation	  and	  analysis	  of	  pLck	  
3.2.9.1 	   Surface	  biotinylation	  of	  T	  cells	  
Isolated	  splenocytes	  (see	  3.2.2.1)	  were	  washed	  with	  1x	  PBS,	  adjusted	  to	  25*106	  cells/ml	  in	  
PBS,	  2mM	  biotin	  reagent	  was	  added	  and	  incubated	  for	  30	  minutes	  at	  RT.	  Afterwards,	  cells	  
were	  washed	  twice	  with	  T	  cell	  medium	  and	  finally	  with	  1x	  PBS.	  
	  
3.2.9.2 	   Generation	  of	  protein	  lysates	  
1*107	   PBS-­‐washed	   cells	   were	   incubated	   with	   1mL	   appropriate	   cold	   cell	   lysis	   buffer	   and	  
incubated	  on	  ice	  for	  30	  minutes.	  Cell	  debris	  was	  removed	  by	  centrifugation	  at	  14000xg	  for	  
ten	  minutes.	  Supernatant	  was	  collected	  and	  further	  assays	  performed.	  
	  
3.2.9.3 	   Co-­‐Immunoprecipitation	  
Surface	   biotinylated	  DesTCR	   splenocytes	   (3.2.9.1)	  were	   lysed	   (3.2.9.2)	   and	   incubated	   for	  
one	  hour	  on	  ice	  with	  10µg/mL	  complexed	  (3.2.8.7)	  chimeric	  MR	  or	  isotype	  control	  protein.	  
Protein	  G	  agarose	  beads	  were	  washed	  twice	  with	  1x	  PBS,	  20µL	  bead	  solution	  was	  added	  to	  
lysates,	  incubated	  under	  inverting	  conditions	  at	  4°C	  for	  one	  hour.	  Afterwards,	  beads	  were	  
spun	  down	  at	  5900xg	  for	  30	  seconds,	  washed	  once	  with	   lysis	  buffer,	  and	  bound	  proteins	  
were	  eluted	  by	  addition	  of	  50µL	  Laemmli	  buffer	  and	   incubation	  at	  50°C	  for	   five	  minutes.	  
Beads	   were	   spun	   for	   one	   minute	   at	   16.100xg,	   supernatant	   collected	   and	  Western	   blot	  
performed.	  
	  
3.2.9.4 	   Analysis	  of	  pLck	  	  
4*105	  wildtype	   or	  MR-­‐/-­‐	   BMDCs	  were	   plated	   in	   a	   24-­‐well	   tissue	   culture	   plate.	   One	   hour	  
later,	  supernatant	  was	  removed,	  1,35*106	  CD8+	  MACSed	  (3.2.6)	  DesTCR	  T	  cells	  were	  added	  
in	   200µL	   T	   cell	  medium	  and	   incubated	   for	   the	   indicated	   time	  points.	   Afterwards,	   T	   cells	  
were	  resuspended,	   lysed	  (3.2.9.2)	  and	  Western	  blot	  performed	  as	  described	   in	  3.2.10.	   In	  
case	  of	  addition	  of	  chimeric	  MR	  protein,	  MR-­‐/-­‐	  BMDCs	  were	  plated	  and	  T	  cells	  were	  added	  
in	  the	  presence	  of	  10µg/mL	  complexed	  (3.2.8.7)	  chimeric	  proteins.	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3.2.10 Western	  blotting	  
20µL	  sample	  and	  5µL	  protein	  ladder	  were	  loaded	  onto	  an	  8%	  SDS	  gel	  and	  electrophoresis	  
was	  conducted	  at	  30mA	  const.,	  120V	  and	  100W	  for	  60	  minutes	  in	  1x	  SDS	  running	  buffer.	  
Semi-­‐dry	   transfer	   to	  methanol-­‐equilibrated	  PVDF-­‐membrane	  was	  done	   at	   200mA	   const.,	  
25V	  and	  300W	  for	  75	  minutes	  with	  blotting	  paper	  soaked	  in	  1x	  Towbin	  transfer	  buffer.	  
Membranes	  were	  blocked	  o.n.	  at	  4°C	  under	  rocking	  conditions	  in	  the	  appropriate	  blocking	  
solution	   and	   primary	   antibodies	   were	   added	   in	   TBST	   for	   one	   hour	   at	   RT.	  Washing	   took	  
place	   three	   times	   for	   10	  minutes	  with	   TBST,	   followed	   by	   incubation	   of	   the	   horseradish-­‐
coupled	  secondary	  antibodies	  diluted	   in	  TBST.	  Finally,	  another	   three	  washing	   steps	  were	  
carried	  out,	   ECL	   substrate	  was	   added	  and	   chemiluminescence	  was	   analyzed	  either	  by	  X-­‐
array	   films	   or	   ChemiDoc™	   Systems.	   For	   Western	   blotting,	   0,2µg/mL	   horseradish	  
peroxidase-­‐coupled	  Neutravidin,	  1µg/mL	  αCD45,	  1/1000	  αActin,	  1/1000	  αpLck	  and	  1/5000	  
diluted	   secondary	  antibodies	  were	  used.	   For	   stainings	  with	   chimeric	  MR	  proteins,	   100µL	  
10µg/mL	  complexed	  protein	  (3.2.8.7)	  were	  added	  to	  900µL	  blocking	  solution	  and	  applied	  
to	  the	  membrane.	  PBST	  was	  used	  instead	  of	  TBST.	  
	  
3.2.11 CD45	  Phosphatase	  assay	  
1,5*106	   HEK	   or	   HEK-­‐MR	   respectively	   wildtype	   or	   MR-­‐/-­‐	   BMDCs	   were	   plated	   in	   a	   6-­‐well	  
tissue	   culture	   plate.	   24	   respectively	   four	   hours	   later,	   supernatant	   was	   removed,	   CD8+	  
MACSed	  (see	  3.2.6)	  DesTCR	  T	  cells	  were	  added	  in	  1,5mL	  T	  cell	  medium	  and	  incubated	  for	  
one	  hour.	  Afterwards,	  cells	  were	  lysed	  as	  described	  above	  (3.2.9.2)	  in	  600µL	  phosphatase	  
lysis	  buffer,	  separated	  into	  triplicates,	  50ng/mL	  αCD45	  antibody	  was	  added	  and	  incubated	  
for	  one	  hour	   at	   4°C.	   20µL	  Protein	  G	  agarose	  beads	  were	  washed	   twice	  with	  1x	  PBS	  and	  
coupled	  with	  50ng/mL	  αrat	  antibody	   in	  200µL	  1x	  PBS	  for	  one	  hour	  at	  4°C.	  Subsequently,	  
beads	  were	  spun	  at	  5900xg	  for	  30	  seconds	  and	  cell	   lysates	  were	  added	  for	  another	  hour	  
under	   inverting	  conditions	  at	  4°C.	   Samples	  were	  washed	   twice	  with	  100mM	  HEPES,	   split	  
into	   two	  and	  70µL	  phosphatase	  assay	  buffer	  with	  2mM	  4-­‐Nitrophenylphosphate	   (4-­‐NPP)	  
was	  added	  in	  the	  presence	  or	  absence	  of	  1µM	  CD45	  inhibitor	  SF1670.	  The	  substrate	  was	  
incubated	  over	  night	  at	  37°C	  in	  the	  dark,	  beads	  were	  spun	  down,	  35µL	  supernatant	  were	  
transferred	  into	  ELISA	  plates	  and	  absorption	  at	  405nm	  was	  determined.	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3.2.12 Gene	  array	  of	  activated	  DesTCR	  T	  cells	  
3.2.12.1 RNA	  isolation	  and	  microarray	  analysis	  
4*105	  wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  plated	  in	  a	  24-­‐well	  tissue	  culture	  plate.	  CD8+	  DesTCR	  
T	  cells	   from	  three	  different	  mice	   (natural	   replicates)	  were	  MACS	   isolated	  using	  the	  T	  cell	  
isolation	  kit	  (see	  3.2.6).	  5*105	  DesTCR	  T	  cells	  and	  BMDCs	  were	  co-­‐cultured	  for	  four,	  18	  or	  
48	  hours	  in	  the	  presence	  of	  10µg/mL	  either	  Fc-­‐MR	  or	  isotype	  control	  protein.	  Afterwards,	  	  
T	  cells	  were	  resuspended	  and	  FACS	  stained	  with	  αCD8	  as	  described	  in	  3.2.2.4.	  CD8+	  T	  cells	  
were	   FACS	   sorted	   in	   TRIzol®	   and	   kept	   at	   -­‐80°C	   until	   RNA	   was	   isolated	   following	   the	  
manufacturers	   instructions	   in	   the	  Qiagen	  RNeasy	  kit.	  By	   reverse	   transcription,	   cDNA	  was	  
generated	   and	   biotinylated	   using	   the	   TargetAmp™-­‐Nano	   Labeling	   Kit	   for	   Illumina®	  
Expression	   BeadChip®.	   1,5µg	   biotinylated	   cDNA	   was	   hybridized	   to	   MouseWG-­‐6	   v2.0	  
Beadchips	   (Illumina)	   and	   scanned	   on	   an	   Illumina	   HiScanSQ	   system.	   The	   department	   of	  
Genomics	  and	  Immunoregulation,	  LIMES	  institute	  performed	  RNA	  isolation	  and	  microarray	  
analysis.	  
	  
3.2.12.2 Bioinformatical	  analysis	  
With	   the	  program	  GenomeStudio	  V2011.1	   (Illumina),	   raw	   intensity	  microarray	  data	  were	  
processed	   followed	   by	   bioinformatical	   analysis	   with	   Partek®	   Genomics	   Suite	   V6.6	   (PGS).	  
Data	   were	   normalized	   and	   application	   of	   a	   two-­‐way	   ANOVA	  model,	   variable	   transcripts	  
and	   significantly	   differentially	   expressed	   transcripts	   were	   determined.	   The	   definition	   of	  
variable	   and	   significantly	  differentially	   transcripts	  was	   set	   as	   a	   false	  discovery	   rate	   (FDR)	  
with	  a	  corrected	  p-­‐value	  <0,05	  and	  a	  fold	  change	  ±2.	  By	  PGS	  hierarchical	  clustering	  among	  
the	   variable	   genes,	   similarities	   or	   differences	   in	   gene	   expression	   depending	   on	   the	  
different	   conditions	   were	   highlighted.	   Literature	   research	   revealed	   49	   tolerance-­‐	   and	  
anergy-­‐associated	  genes,	  whose	  differential	  expression	  was	  visualized	  in	  heat-­‐maps	  of	  the	  
z-­‐transformed	   log2	   expression	   profiles	   (Mayday	   open	   source	   software). The	   microarray	  
data	   have	   been	   deposited	   on	   GEO	   under	   accession	   number	   GSE45805	  
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45805).	  
Dr.	  Astrid	  M.	  Draffehn	  performed	   the	  bioinformatical	   analysis	   (Department	  of	  Genomics	  
and	  Immunoregulation,	  LIMES	  institute).	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3.2.13 CTLA-­‐4	  expression	  
5*104	  CpG-­‐activated	  (3.2.1.5)	  or	  untreated	  wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  incubated	  with	  
isolated	   DesTCR	   splenocytes	   (3.2.2.1)	   in	   200µL	   T	   cell	   medium	   for	   three	   days	   in	   the	  
presence	  or	  absence	  of	  40mM	  CD45	  specific	  inhibitor	  SF1670	  or	  1µg/mL	  αCD28	  antibody.	  
On	   day	   three,	   1µg/mL	   fluorescently	   labeled	   αCTLA-­‐4	   antibody	   or	   isotype	   control	   was	  
added	  for	  four	  hours.	  Afterwards,	  T	  cells	  were	  resuspended	  and	  FACS	  stained	  with	  αCD8	  
antibody	  as	  described	  in	  3.2.2.4.	  
	  
3.2.14 Surface	  expression	  on	  BMDCs	  
4*105	  CpG-­‐activated	  (3.2.1.5)	  or	  untreated	  wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  plated	  in	  a	  24-­‐
well	  plate	  and	  let	  adhere	  for	  one	  hour	  or	  directly	  FACS	  stained	  for	  CD11c,	  CD80	  and	  CD86	  
(3.2.2.4).	   Supernatant	   was	   replaced	   by	   medium	   supplemented	   with	   250ng/mL	  
fluorescently	   labeled	   OVA	   and	   incubated	   for	   15	  minutes.	   Cells	   were	   scraped	   off	   with	   a	  
rubber-­‐scraper	  and	  stained	  for	  CD11c.	  
	  
3.2.15 In	  vivo	  experiments	  
3.2.15.1 In	  vivo	  CTLA-­‐4	  expression	  
Wildtype	   or	  MR-­‐/-­‐	   BMDCs	  were	   transduced	  with	   an	   Adenovirus	   encoding	   for	   Luciferase,	  
OVA	  and	  GFP	  (AdLOG)	  with	  a	  MOI	  of	  20	  for	  three	  hours	  under	  cell	  culture	  conditions	  or	  left	  
untransduced.	  0,75*106	  washed	  cells	  were	  injected	  i.v.	   into	  C57/BL6	  mice	  and	  priming	  of	  
endogenous	  T	  cells	  took	  place	  for	  six	  days.	  Afterwards,	  C57/BL6	  splenocytes	  were	  isolated	  
(3.2.2.1)	   and	   5*106	   cells	   were	   incubated	   with	   2µg/mL	   fluorescently	   labeled	   αCTLA-­‐4	  
antibody	  or	  isotype	  control	  for	  four	  hours.	  Afterwards	  splenocytes	  were	  resuspended	  and	  
FACS	  stained	  with	  SIINFEKL-­‐dextramers	  and	  αCD8	  antibody	  as	  described	  in	  3.2.2.4.	  
	  
3.2.15.2 In	  vivo	  cytotoxicity	  
Wildtype	   or	  MR-­‐/-­‐	   BMDCs	  were	   transduced	  with	   an	   Adenovirus	   encoding	   for	   Luciferase,	  
OVA	  and	  GFP	  (AdLOG)	  with	  a	  MOI	  of	  20	  for	  three	  hours	  under	  cell	  culture	  conditions	  or	  left	  
untransduced.	   1*106	   washed	   cells	   were	   injected	   i.v.	   into	   C57/BL6J	  mice	   and	   priming	   of	  
endogenous	   T	   cells	   took	   place	   for	   four	   days.	   Afterwards,	   C57/BL6J	   splenocytes	   were	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isolated	   (3.2.2.1)	  and	   loaded	  with	  2µM	  OVA	  minimal	  peptide	  SIINFEKL	   for	  30	  minutes	  or	  
left	  untreated.	  Loaded	  target	  cells	  and	  unloaded	  non-­‐target	  cells	  were	   labeled	  with	  CFSE	  
(3.2.2.2),	  mixed	   at	   equal	   ratios	   and	   1*107	   total	   cells	  were	   injected	   i.v.	   per	  mouse.	   After	  
four	   hours,	   splenocytes	   were	   isolated	   (3.2.2.1)	   and	   specific	   cytotoxicity	   determined	   as	  
described	  in	  3.2.3.1.	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4 	   RESULTS	  
4.1 	   The	   Mannose	   receptor	   affected	   T	   cell	   activation	   under	  
steady-­‐state	  conditions	  
4.1.1 The	  MR	  had	  no	  influence	  on	  T	  cell	  proliferation	  or	  IL-­‐2	  secretion	  
In	  the	  present	  study,	  the	  effect	  of	  the	  MR	  on	  T	  cell	  activation	  was	  investigated.	  To	  prevent	  
influences	  of	   the	  MR	  during	  antigen	  uptake	  or	  presentation,	  use	  was	  made	  of	  DesTCR	  T	  
cells	  (105).	  The	  haplotype	  of	  Des	  TCR	  transgenic	  mice	  is	  H-­‐2KK.	  The	  T	  cell	  receptor	  of	  CD8+	  
DesTCR	   T	   cells	   recognizes	   in	   an	   alloreaction	   three	   endogenous	   peptides,	   pKB1,	   2,	   and	   3	  
(111)	  presented	  on	  MHC-­‐I	  molecules	  of	   the	  haplotype	  H-­‐2Kb	  which	   is	   expressed	  on	   cells	  
with	  C57/BL6J	  background.	  	  
	  
First,	   the	   influence	  of	   the	  MR	  on	  T	  cell	  proliferation	  was	   investigated.	  To	   this	  end,	  CFSE-­‐
labeled	  DesTCR	   T	   cells	  were	   co-­‐cultured	   for	   three	  days	   in	   the	   presence	  of	  wildtype	   (wt)	  
respectively	   MR-­‐deficient	   (MR-­‐/-­‐)	   BMDCs.	   Afterwards,	   the	   proliferation	   profile	   was	  
analyzed	  by	  flow	  cytometry.	  No	  difference	  could	  be	  observed	  in	  the	  proliferation	  behavior	  
of	   DesTCR	   T	   cells	   being	   activated	   by	  wildtype	   or	  MR-­‐/-­‐	   BMDCs	   (Fig.	   4-­‐1a).	   This	  was	   also	  
confirmed	  by	  measuring	  the	  secreted	  IL-­‐2	  amount	  in	  supernatants	  of	  co-­‐cultures	  of	  DesTCR	  
T	  cells	  with	  either	  wildtype	  or	  MR-­‐/-­‐	  BMDCs	  by	  ELISA	  (Fig.	  4-­‐1b).	  	  
Fig.	  4-­‐1:	  The	  MR	  had	  no	  influence	  on	  T	  cell	  proliferation	  or	  IL-­‐2	  secretion.	  
a)	  Wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  co-­‐cultured	  for	  three	  days	  with	  CFSE-­‐labeled	  DesTCR	  T	  cells.	  CFSE-­‐dilution	  
profile	  of	  CD8+	  T	  cells	  was	  determined	  by	   flow	  cytometry.	  b)	  DesTCR	  T	  cells	  were	  co-­‐cultured	   for	  24	  hours	  
with	  or	  without	  wildtype	  or	  MR-­‐/-­‐	  BMDCs.	  IL-­‐2	  concentration	  in	  the	  supernatant	  was	  determined	  by	  ELISA.	  
n.s.:	  not	  significant.	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4.1.2 The	  MR	  on	  BMDCs	  decreased	  T	  cell	  cytotoxicity	  and	  IFN-­‐γ 	  secretion	  
Since	  T	  cell	  proliferation	  is	  just	  the	  first	  step	  during	  T	  cell	  activation,	  further	  studies	  dealt	  
with	  the	  cytotoxic	  capacities	  of	  DesTCR	  T	  cells	  activated	  by	  wildtype	  or	  MR-­‐/-­‐	  BMDCs	  in	  an	  
in	  vitro	  cytotoxicity	  assay.	  On	  that	  account,	  DesTCR	  T	  cells	  were	  primed	  for	  three	  days	  by	  
either	   type	   of	   BMDCs.	   Afterwards,	   T	   cells	   were	   isolated	   and	   separated	   from	   BMDCs	   by	  
density	   gradient	   centrifugation.	   Purified	   T	   cells	   were	   cultured	   for	   four	   hours	   with	  
differentially	  CFSE-­‐labeled	  antigen-­‐bearing	  RMA	   target	   cells	   (CFSEhigh)	   and	  RMA-­‐S	   control	  
cells	  lacking	  cell	  surface	  antigens	  (TAP2	  deficient	  mutant	  of	  RMA;	  CFSElow).	  Finally,	  the	  cells	  
were	  analyzed	  by	  Flow	  cytometry	  and	  the	  specific	  cytotoxic	  T	  cell	  activity	  was	  determined.	  	  
	  
Figure	  4-­‐2a	  shows	  a	  strongly	  decreased	  cytotoxic	  capacity	  of	  T	  cells	  which	  were	  primed	  by	  
wildtype	  BMDCs	  compared	  to	  T	  cells	  after	  activation	  with	  MR-­‐/-­‐	  BMDCs.	  In	  addition	  to	  this,	  
re-­‐stimulation	   of	   activated	   T	   cells	   with	   an	  αCD3	   antibody	   revealed	   a	   significantly	   lower	  	  
IFN-­‐γ	  secretion	  of	  T	  cells	  that	  were	  activated	  in	  the	  presence	  of	  the	  MR	  compared	  to	  T	  cells	  
activated	  in	  the	  absence	  of	  the	  MR	  (Fig.	  4-­‐2b).	  This	  indicated	  that	  the	  presence	  of	  the	  MR	  
on	  DCs	  during	  T	  cell	  activation	  results	  in	  T	  cell	  development	  into	  a	  more	  tolerogenic	  state	  
represented	  by	  suppressed	  cytotoxicity	  and	  IFN-­‐γ	  secretion.	  
Fig.	  4-­‐2:	  The	  MR	  on	  BMDCs	  decreased	  cytotoxic	  capacities	  of	  DesTCR	  T	  cells.	  
a)	  Wildtype	  or	  MR-­‐/-­‐	   BMDCs	  were	   co-­‐cultured	   for	   three	  days	  with	  DesTCR	   T	   cells.	   T	   cells	  were	   purified	   by	  
density	   gradient	   centrifugation	   and	   distinctly	   CFSE-­‐labeled	   target	   or	   control	   cells	   were	   added	   in	   different	  
ratios	  to	  the	  T	  cells.	  After	  four	  hours,	  the	  ratio	  of	  target	  cells	  to	  control	  cells	  was	  analyzed	  by	  flow	  cytometry	  
and	  the	  specific	  cytotoxicity	  was	  calculated.	  b)	  Purified	  T	  cells	  from	  a)	  were	  re-­‐stimulated	  for	  24	  hours	  with	  
an	  αCD3	  antibody	  and	  the	  IFN-­‐γ	  concentration	  in	  the	  supernatant	  was	  determined	  by	  ELISA.	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4.1.3 Wildtype	  and	  MR-­‐/-­‐	  BMDCs	  were	  phenotypically	  equivalent	  
This	   inhibitory	  effect	  of	   the	  MR	  on	  cytotoxicity	  might	  be	  due	  to	   two	  reasons.	  First,	  upon	  
binding	  of	  an	   interaction	  partner,	  the	  MR	  might	  alter	  the	   immunogenic	  properties	  of	  the	  
DCs	   themselves.	  Alternatively,	   the	  MR	  might	   recognize	  an	   interaction	  partner	   located	  on	  
the	  T	  cell	  surface,	  altering	  the	  immunogenic	  properties	  of	  the	  T	  cells	  directly.	  
	  
To	  discriminate	  between	  these	  two	  possibilities,	  the	  phenotype	  of	  either	  wildtype	  or	  MR-­‐/-­‐	  
CD11c+	   BMDCs	   after	   co-­‐culture	   for	   18	   hours	  with	   DesTCR	   T	   cells	  was	   analyzed.	   On	   that	  
account,	  the	  surface	  expression	  of	  co-­‐stimulatory	  molecules	  like	  CD86,	  CD86	  and	  CD40,	  the	  
expression	  of	  MHC	  II,	  the	  co-­‐inhibitory	  molecule	  B7H1	  and	  the	  secretion	  of	  the	  cytokines	  
IL-­‐6	  and	  IL-­‐10	  were	  determined.	  Controls	  were	  either	  unstained	  cells	  or,	  in	  case	  of	  cytokine	  
secretion,	  BMDCs	  in	  the	  absence	  of	  T	  cells.	  	  
No	  significant	  differences	  between	  wildtype	  and	  MR-­‐/-­‐	  BMDCs	  were	  detectable	   (Fig.	  4-­‐3a	  
and	  b),	   indicating	  that	  influences	  of	  the	  MR	  onto	  the	  immunogenic	  properties	  of	  the	  DCs	  
were	  unlikely.	  
Fig.	  4-­‐3:	  Wildtype	  and	  MR-­‐/-­‐	  BMDCs	  were	  phenotypically	  equivalent.	  
(a)	   Wildtype	   or	   MR-­‐/-­‐	   BMDCs	   were	   co-­‐cultured	   for	   18	   hours	   with	   DesTCR	   T	   cells.	   Surface	   expression	   of	  
indicated	  molecules	  on	  BMDCs	  was	  determined	  by	  flow	  cytometry.	  Unstained	  cells	  served	  as	  control.	  All	  cells	  
were	   gated	   on	   CD11c+	   cells	   as	   marker	   for	   BMDCs.	   (b)	   IL-­‐6	   and	   IL-­‐10	   concentration	   was	   analyzed	   in	   the	  
supernatant	  of	  (a)	  by	  BD™	  Cytometric	  Bead	  Array	  (CBA).	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4.1.4 The	  MR	  on	  BMDCs	  resulted	  in	  prolonged	  interaction	  with	  T	  cells	  
Since	   the	   MR	   did	   not	   seem	   to	   alter	   the	   immunogenic	   properties	   of	   DCs,	   it	   was	   then	  
investigated	  whether	  the	  influence	  of	  MR	  might	  be	  due	  to	  an	  interaction	  with	  proteins	  on	  
the	   T	   cell	   surface.	   To	   this	   end,	   analysis	   considering	   the	   contact	   duration	   of	   wildtype	   or	  	  	  
MR-­‐/-­‐	  DCs	  with	  T	  cells	  were	  performed	  by	  time-­‐lapse	  microscopy	  (in	  close	  cooperation	  with	  
Prof.	  Waldemar	  Kolanus	  and	  Dr.	  Thomas	  Quast).	  
	  
Figure	   4-­‐4	   shows	   that	   the	   presence	   of	   the	   MR	   on	   DCs	   led	   to	   a	   significantly	   prolonged	  
interaction	  with	  T	  cells	   compared	   to	  BMDCs	   lacking	   the	  MR.	  These	   results	  emphasized	  a	  
possible	  interplay	  of	  the	  MR	  with	  T	  cell	  surface	  molecules.	  	  
Fig.	  4-­‐4:	  The	  MR	  on	  BMDCs	  resulted	  in	  prolonged	  interaction	  with	  T	  cells.	  
Wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  co-­‐cultured	  with	  CFSE-­‐labeled	  CD8+	  MACS-­‐isolated	  DesTCR	  T	  cells	  in	  a	  plastic	  
channel	   µ-­‐slide	   for	   12	  hours.	   Every	   two	  minutes,	   the	   green	   fluorescence	   and	  differential	   interference	  was	  
recorded	  at	  20-­‐fold	  magnification.	  At	  least	  40	  randomly	  chosen	  interaction	  events	  were	  analyzed	  considering	  
their	  contact	  duration.	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4.1.5 Chimeric	  MR	  constructs	  displayed	  distinct	  binding	  characteristics	  
To	  irrevocably	  test	  whether	  the	  MR-­‐mediated	  decrease	  in	  cytotoxicity	  in	  deed	  was	  due	  to	  
interactions	   with	   T	   cell	   surface	   molecules,	   chimeric	   MR	   proteins	   were	   used.	   These	  
consisted	  of	  the	  human	  IgG1	  Fc	  portion	  (Isotype	  control)	  coupled	  either	  to	  the	  Cystein-­‐rich	  
(CR)	   domain,	   the	   Fibronectin-­‐like	   (FN)	   domain	   and	   the	   C-­‐type	   lectin-­‐like	   domains	   1-­‐3	  
(CTLD)	  (MR-­‐FN)	  or	  coupled	  to	  the	  CTLDs	  4-­‐7	  (MR-­‐CTLD)	  (69).	  Whereas	  the	  isotype	  control	  
lacks	  domains	  which	  are	  capable	  of	  binding	  to	  antigens,	  the	  FN	  domain	  is	  able	  to	  bind	  to	  
Collagens	   and	   the	   CTLDs	   4-­‐7	   possess	   binding	   capacities	   for	   glycosylated	   proteins,	   as	   for	  
example	  the	  model	  antigen	  ovalbumin	  (OVA).	  
	  
First	  of	  all,	  these	  binding	  properties	  of	  the	  chimeric	  proteins	  were	  tested.	  On	  this	  account,	  
the	  constructs	  were	  applied	  to	  an	  either	  OVA-­‐	  or	  Collagen-­‐coated	  ELISA	  plate,	  washed	  and	  
detected	  by	  conversion	  of	  ABTS	  via	   colorimetry	  at	  450nm.	  As	   isotype	  control	   served	   the	  
human	  IgG1	  Fc	  portion.	  	  
	  
There	  was	  a	  significant	  binding	  of	  the	  chimeric	  protein	  comprising	  the	  CTLDs	  4-­‐7	  to	  OVA-­‐
coated	  plates,	  lacking	  any	  binding	  capacity	  towards	  Collagen	  (Fig.	  4-­‐5).	  In	  contrast	  to	  that,	  
the	   chimeric	   protein	   consisting	   of	   the	   CR	   and	   FN	   domain,	   strongly	   bound	   to	   Collagen	  
without	   any	   binding	   towards	   OVA	   (Fig.	   4-­‐5).	   This	   approved	   the	   functional	   binding	  
capacities	  of	  the	  chimeric	  proteins.	  
Fig.	  4-­‐5:	  Chimeric	  MR	  constructs	  displayed	  distinct	  binding	  characteristics.	  
10µg/mL	   chimeric	   MR	   constructs	   comprising	   the	   human	   IgG1	   Fc	   part	   plus	   either	   the	   CR	   domain,	   the	   FN	  
domain	   and	   the	   CTLDs	   1-­‐3	   (MR-­‐FN)	   or	   comprising	   the	   CTLDs	   4-­‐7	   (MR-­‐CTLD)	   were	   complexed	   using	   an	  
αhuman	   antibody	   coupled	   to	   horseradish	   peroxidase.	   Complexed	   constructs	   were	   then	   applied	   to	   either	  
OVA-­‐coated	  (0,5mg/mL)	  or	  Collagen-­‐coated	  (0,1mg/mL)	  ELISA	  plates,	  washed	  and	  detected	  by	  conversion	  of	  
ABTS	  via	  colorimetry	  at	  450nm.	  As	  isotype	  control	  served	  the	  human	  IgG1	  Fc	  part	  only.	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4.1.6 Addition	  of	  soluble	  MR	  suppressed	  cytotoxicity	  and	  IFN-­‐γ 	  secretion	  
With	   the	   soluble,	   chimeric	   MR	   it	   is	   possible	   to	   discriminate	   in	   an	   in	   vitro	   cytotoxicity	  
experiment	  whether	   the	  MR	  has	  any	  direct	   influence	  on	   the	  BMDCs	  or	  on	   the	  DesTCR	  T	  
cells.	   In	  case	  the	  MR	  renders	  the	  properties	  of	  the	  BMDCs,	  this	  would	  only	  be	  possible	   if	  
the	   MR	   were	   attached	   to	   the	   BMDCs	   leading	   to	   intracellular	   signaling	   events	   via	   its	  
cytoplasmic	   domain.	   Hence,	   addition	   of	   the	   soluble	   MR	   should	   have	   no	   effect	   on	   the	  
outcome	  of	  experiments.	  
In	  contrast	  to	  that,	  if	  the	  MR	  binds	  an	  interaction	  partner	  on	  the	  T	  cell	  surface	  and	  thereby	  
alters	  their	  phenotype,	  no	  contact	  to	  the	  BMDCs	  would	  be	  necessary.	  Hence,	  the	  addition	  
of	  the	  soluble	  form	  of	  the	  MR	  should	  still	  lead	  to	  decreasing	  cytotoxic	  capacities	  of	  T	  cells.	  	  
	  
Therefore,	  an	   in	  vitro	  cytotoxicity	  assay	  was	  carried	  out.	  To	  this	  end,	  DesTCR	  T	  cells	  were	  
activated	  with	  wildtype	  or	  MR-­‐/-­‐	  BMDCs	  in	  the	  presence	  of	  either	  a	  soluble	  form	  of	  the	  MR	  
protein	   comprising	   the	  CR-­‐domain,	   the	   FN-­‐domain	   and	   the	  CTLD1-­‐3	   (FcMR)	   or	   a	   control	  
protein.	  	  
	  
Addition	  of	  neither	  the	  control	  protein	  nor	  of	  FcMR,	  had	  any	  effect	  on	  the	  cytotoxicity	  of	  T	  
cells	  being	  primed	  by	  wildtype	  BMDCs	  (Fig.	  4-­‐6a).	  Furthermore,	  in	  the	  presence	  of	  control	  
protein	  the	  cytotoxicity	  of	  T	  cells	  primed	  by	  MR-­‐/-­‐	  was	  still	  higher	  compared	  to	  T	  cells	  that	  
were	  primed	  by	  wildtype	  BMDCs	  (Fig.	  4-­‐6a).	  In	  contrast	  to	  that,	  addition	  of	  FcMR	  to	  T	  cells	  
that	  were	  activated	  by	  MR-­‐/-­‐	  BMDCs	  strongly	  diminished	  the	  cytotoxic	  capacity	  (Fig.	  4-­‐6a).	  
This	  cytotoxic	  capacity	  was	  comparable	  to	  T	  cells	  activated	  by	  wildtype	  BMDCs	  (Fig.	  4-­‐6a).	  
No	   such	   effect	   could	   be	   detected	   by	   addition	   of	   the	   chimeric	   protein	   consisting	   of	   the	  
CTLDs4-­‐7	  (data	  not	  shown).	  	  
Restimulation	  of	  T	  cells	  with	  an	  αCD3	  antibody	  revealed	  decreased	   IFN-­‐γ	  amounts	   in	  the	  
supernatant	  when	  T	  cells	  were	  primed	  by	  MR-­‐/-­‐	  BMDCs	  in	  the	  presence	  of	  FcMR	  compared	  
to	  control	  protein	   (Fig.	  4-­‐6b).	  These	  results	  evidence	  that	   the	  decreased	  cytotoxicity	  and	  
secretion	   of	   IFN-­‐γ	   in	   the	   presence	   of	   the	   MR	   indeed	   was	   due	   to	   an	   interaction	   with	  
proteins	  on	  the	  T	  cell	  surface.	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Fig.	  4-­‐6:	  Addition	  of	  the	  MR	  suppressed	  cytotoxicity	  and	  IFN-­‐γ 	  secretion.	  
(a)	  Wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  co-­‐cultured	  for	  three	  days	  with	  DesTCR	  T	  cells	  in	  the	  presence	  of	  10µg/mL	  
complexed	  FcMR	  or	  control	  protein	  consisting	  of	  the	  human	  IgG1	  Fc	  part	  only.	  T	  cells	  were	  purified	  by	  density	  
gradient	  centrifugation	  and	  distinctly	  CFSE-­‐labeled	  target	  cells	  or	  control	  cells	  were	  added	  in	  different	  ratios	  
to	  the	  T	  cells.	  After	  four	  hours,	  the	  ratio	  of	  target	  cells	  to	  control	  cells	  was	  analyzed	  by	  flow	  cytometry	  and	  
the	  specific	  cytotoxicity	  was	  calculated.	  (b)	  Purified	  T	  cells	  from	  (a)	  were	  re-­‐stimulated	  for	  24	  hours	  with	  an	  
αCD3	  antibody	  and	  the	  IFN-­‐γ	  concentration	  in	  the	  supernatant	  was	  determined	  by	  ELISA.	  	  
	  
4.2 	   The	  influence	  of	  the	  Mannose	  Receptor	  on	  CD45	  
4.2.1 CD45	  was	  one	  interaction	  partner	  of	  the	  MR	  
As	  a	  matter	  of	  course,	  it	  was	  of	  interest	  to	  find	  out	  which	  molecule	  on	  the	  T	  cell	  interacted	  
with	   the	   MR	   on	   BMDCs.	   To	   answer	   this	   question,	   co-­‐immunoprecipitation	   experiments	  
were	   performed	   with	   FcMR	   or	   control	   protein	   as	   bait	   in	   lysates	   of	   surface-­‐biotinylated	  
DesTCR	   cell.	   The	   subsequent	   Western	   blot	   was	   detected	   with	   horseradish	   peroxidase-­‐
coupled	  NeutrAvidin	  (NA).	  	  
	  
No	  signal	  could	  be	  achieved	  using	  the	  control	  protein	  as	  bait	  (Fig.	  4-­‐7a).	  In	  contrast	  to	  that,	  
when	  FcMR	  was	  used	  as	  bait,	  there	  was	  a	  double	  band	  visible	  of	  about	  180-­‐230kDa	  and	  a	  
double	  band	  between	  70-­‐80kDa	  (Fig.	  4-­‐7a).	  	  
Since	  it	  has	  been	  published	  that	  the	  MR	  and	  a	  related	  lectin	  called	  Macrophage	  galactose	  
lectin	   (MGL)	   are	   capable	   to	   bind	   CD45	   (57,	   58),	   whose	   isotype-­‐dependent	   molecular	  
weight	   is	   between	   180kDa	   and	   230kDa,	   it	   was	   specifically	   stained	   for	   CD45.	   Indeed,	   a	  
CD45-­‐specific	  signal	  could	  be	  detected	  after	  co-­‐immunoprecipitation	  with	  FcMR	  (Fig.	  4-­‐7b).	  	  
To	   further	  validate	   the	   interaction	  between	   the	  MR	  and	  CD45,	  a	  different	  approach	  was	  
followed	  together	  with	  Maria	  Embgenbroich.	  Herein,	  CD45	  was	  immunoprecipitated	  from	  
DesTCR	  T	  cell	   lysates	  and	   loaded	  onto	  a	  Western	  blot.	  As	  detection	  reagent	  either	  FcMR	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was	  applied	  to	  the	  Western	  blot	  or	  an	  αCD45	  antibody.	  CD45	  led	  to	  four	  bands	  between	  
180kDa	   and	   230kDa	   resembling	   different	   isoforms	   of	   CD45	   (Fig.	   4-­‐7c).	   FcMR	   revealed	   a	  
single	  signal	  at	  about	  200kDa	  corresponding	  to	  one	  of	  the	  CD45	  isoform	  bands	  (Fig.	  4-­‐7c).	  
This	  effectively	  proved	  that	  CD45	  on	  T	  cells	  was	  actually	  an	  interaction	  partner	  of	  the	  MR.	  	  
Fig.	  4-­‐7:	  CD45	  was	  one	  interaction	  partner	  of	  the	  MR.	  
(a)	   FcMR	   or	   huIgG1-­‐control	   protein	   were	   complexed	   with	   an	   αhuman	   antibody.	   10µg/mL	   complexed	  
constructs	  were	  added	  to	   lysates	  of	   surface-­‐biotinylated	  DesTCR	  T	  cells,	   incubated	   for	  one	  hour,	  Protein	  G	  
agarose	   beads	   were	   added	   and	   incubated	   for	   one	   hour,	   washed	   and	   bead	   bound	   proteins	   were	   eluted.	  
Western	  blot	  was	  performed	  and	  detection	  occurred	  with	  HRP-­‐coupled	  NeutrAvidin	  (NA).	  (b)	  Samples	  from	  
(a)	  were	  stained	  with	  an	  αCD45	  antibody	  followed	  by	  HRP-­‐coupled	  secondary	  antibody.	  (c)	  Lysates	  of	  DesTCR	  
T	  cells	  were	  incubated	  for	  one	  hour	  with	  Protein	  G	  agarose	  beads	  which	  were	  either	  coupled	  with	  αCD45	  or	  
left	  untreated,	  washed	  and	  bead	  bound	  proteins	  were	  eluted.	  Western	  blot	  was	  performed	  and	  detection	  
occurred	   either	   with	   an	   αCD45	   antibody	   followed	   by	   HRP-­‐coupled	   secondary	   antibody	   or	   with	   10µg/mL	  
FcMR	  constructs	  which	  had	  been	  complexed	  with	  an	  αhuman-­‐HRP	  antibody.	  
	  
	  
4.2.2 Impairment	   of	   CD45	   activity	   led	   to	   decreased	   T	   cell	   cytotoxicity	   and	  
was	  induced	  by	  the	  MR	  	  
To	   investigate	  whether	  CD45	  was	  responsible	   for	   the	  reduced	  T	  cell	  effector	   functions	   in	  
ther	   presence	   of	   the	   MR,	   we	   performed	   in	   vitro	   cytotoxicity	   assay	   in	   the	   presence	   or	  
absence	   of	   the	   CD45	   specific	   phosphatase	   inhibitor	   N-­‐(9,10-­‐Dioxo-­‐9,10-­‐dihydro-­‐
phenanthren-­‐2-­‐yl)-­‐2,2-­‐dimethyl-­‐propionamide	  (SF1670)	  (112)	  during	  the	  priming	  phase.	  	  
	  
In	  the	  absence	  of	  the	  CD45	  inhibitor,	  there	  was	  an	   increased	  cytotoxic	  capacity	  of	  T	  cells	  
that	  were	  primed	  with	  MR-­‐/-­‐	  BMDCs	  compared	  to	  T	  cells	  primed	  by	  wildtype	  BMDCs	  (Fig.	  
4-­‐8a).	   This	   effect	  was	   completely	   abolished	   in	   the	  presence	  of	  CD45	   inhibitor,	   indicating	  
that	  inactivation	  of	  CD45	  led	  to	  the	  reduction	  in	  T	  cell	  cytotoxicity	  (Fig.	  4-­‐8a).	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To	   investigate	   whether	   binding	   of	   the	  MR	   altered	   CD45	   activity,	   a	   phosphatase	   activity	  
assay	  was	  established	   together	  with	   the	  master	   student	   Jessica	  König.	   To	   this	  end,	  CD8+	  
DesTCR	  T	  cells	  were	  incubated	  with	  either	  wildtype	  or	  MR-­‐/-­‐	  BMDCs,	  T	  cells	  were	  isolated,	  
lysed	  and	  CD45	  was	  immunoprecipitated.	  The	  phosphatase	  activity	  was	  determined	  in	  the	  
presence	   or	   absence	   of	   the	   CD45	   inhibitor	   SF1670	   by	   addition	   of	   the	   CD45-­‐specific	  
substrate	   4-­‐nitrophenyl	   phosphate	   (4-­‐NPP)	   (57)	   whose	   turnover	   could	   be	   measured	   by	  
colorimetry	  at	  405nm.	  	  
The	   CD45	   inhibitor	   SF1670	   reduced	   the	   signal	   to	   background	   levels	   similar	   to	   control	  
samples,	   in	  which	   no	   CD45	  was	   immunoprecipitated	   (Fig.	   4-­‐8b).	   The	   CD45	   phosphatase	  
activity	   of	   T	   cells	   that	  were	   cultured	  with	  wildtype	  BMDCs	  was	  decent	   compared	   to	   the	  
CD45	   phosphatase	   activity	   of	   T	   cells	   that	   were	   primed	   by	   MR-­‐/-­‐	   BMDCs	   which	   was	  
significantly	  higher	  (Fig.	  4-­‐8b).	  
Similar	   results	   were	   obtained	   with	   HEK293T	   cells	   bearing	   (HEK-­‐MR)	   or	   lacking	   the	   MR	  
(HEK).	   Together	   with	   the	   diploma	   student	   Melanie	   Nehring,	   a	   phosphatase	   assay	   was	  
performed	  with	  T	  cells	  that	  have	  been	  incubated	  with	  HEK-­‐MR	  or	  HEK	  cells.	  Again,	  it	  could	  
be	  shown	  that	  in	  the	  presence	  of	  the	  MR	  the	  CD45	  phosphatase	  activity	  was	  significantly	  
diminished	  compared	  to	  samples	  lacking	  the	  MR	  (Fig.	  4-­‐8c).	  
	  
It	   was	   further	   investigated	   whether	   the	   above-­‐described	   inactivation	   of	   CD45	   also	   had	  
down-­‐stream	   effects	   on	   Lck	   as	   a	   direct	   substrate	   of	   CD45.	   Together	   with	   Maria	  
Embgenbroich,	  CD8+	  DesTCR	  T	  cells	  were	  incubated	  with	  either	  wildtype	  or	  MR-­‐/-­‐	  BMDCs.	  
Thereafter,	  we	  analyzed	  the	  phosphorylation	  of	  Lck	  at	  the	  tyrosine	  Y505.	  At	  this	  tyrosine	  
residue,	  CD45	  is	  able	  to	  remove	  an	  inhibitory	  phosphate.	  	  
The	  Western	   blot	   in	   figure	   4-­‐8d	   shows	   a	   drastic	   reduction	   of	   phosphorylated	   Lck	   in	   the	  
absence	  of	   the	  MR	  on	  BMDCs	  compared	  to	  T	  cells	   that	  were	   incubated	  with	  MR-­‐bearing	  
wildtype	   BMDCs.	   The	   quantification	   of	   the	   ratio	   between	   pLck	   to	   Actin	   revealed	   an	  
approximately	  2,5-­‐fold	  decrease	  of	  Y505	  pLck	  in	  the	  knock-­‐out	  treated	  T	  cells	  compared	  to	  
wildtype	  primed	  T	  cells	  (Fig.	  4-­‐8d).	  	  
To	  attest	   that	   this	  effect	  was	   really	  due	   to	   the	   influence	  of	   the	  MR,	   the	  experiment	  was	  
additionally	   performed	   together	   with	   Annegret	   Zweynert	   with	   only	   MR-­‐/-­‐	   BMDC	   in	   the	  
presence	   of	   FcMR	   or	   control	   protein.	   Also	   in	   these	   experiments,	   an	   increase	   in	   Lck	  
phosphorylation	  in	  the	  presence	  of	  the	  MR	  could	  be	  observed	  (Fig.	  4-­‐8e).	  These	  outcomes	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verify	  that	  the	  MR	  inhibits	  CD45	  phosphatase	  activity	  upon	  binding	  and	  inhibition	  of	  CD45	  
results	  in	  a	  tolerogenic	  state	  of	  the	  T	  cells	  accompanied	  with	  decreased	  cytotoxicity.	  	  
Fig.	  4-­‐8:	  Impairment	  of	  CD45	  activity	  led	  to	  decreased	  T	  cell	  cytotoxicity	  and	  could	  be	  induced	  by	  the	  MR.	  	  
(a)	  Wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  co-­‐cultured	  for	  three	  days	  with	  DesTCR	  T	  cells	  in	  the	  presence	  or	  absence	  
of	   40mM	   CD45	   specific	   inhibitor	   SF1670.	   T	   cells	   were	   purified	   by	   density	   gradient	   centrifugation	   and	  
distinctly	   CFSE-­‐labeled	   target	   cells	   or	   control	   cells	  were	   added	   in	   different	   ratios	   to	   the	   T	   cells.	   After	   four	  
hours,	   the	  ratio	  of	  target	  cells	  to	  control	  cells	  was	  analyzed	  by	  flow	  cytometry	  and	  the	  specific	  cytotoxicity	  
was	  calculated.	  (b)	  DesTCR	  T	  cells	  were	  incubated	  for	  one	  hour	  with	  wildtype	  or	  MR-­‐/-­‐	  BMDCs,	  T	  cells	  were	  
lysed	  and	  Protein	  G	  agarose	  beads	  which	  were	  either	  coupled	  with	  an	  αCD45	  or	  left	  untreated	  (control)	  were	  
added	   for	   one	   hour.	   Beads	   were	   washed	   and	   incubated	   over	   night	   with	   2mM	   CD45-­‐specific	   substrate	   4-­‐
nitrophenyl	  phosphate	   (4-­‐NPP)	   in	   the	  presence	  or	  absence	  of	  1µM	  CD45	   inhibitor	  SF1670.	  Turnover	  of	   the	  
substrate	  was	  analyzed	  by	  colorimetry	  at	  405nm.	  (c)	  See	  (b),	  but	  instead	  of	  wildtype	  and	  MR-­‐/-­‐	  BMDCs,	  MR-­‐
bearing	   HEK293T	   (HEK-­‐MR)	   cells	   or	   MR-­‐lacking	   HEK293T	   (HEK)	   cells	   were	   used.	   (d)	   DesTCR	   T	   cells	   were	  
incubated	   for	   the	   indicated	   time	   points	   with	   wildtype	   or	   MR-­‐/-­‐	   BMDCs,	   T	   cells	   were	   lysed	   and	   Western	  
blotting	  was	  performed.	  Membranes	  were	   stained	  with	  either	  antibodies	  against	  Y505	  phosphorylated	  Lck	  
(pLck)	  or	  Actin	  as	  loading	  control.	  The	  ratio	  between	  pLck	  and	  Actin	  was	  quantified	  using	  ImageJ	  software.	  (e)	  
FcMR	  or	  huIgG1-­‐control	  protein	  were	  complexed	  with	  an	  αhuman	  antibody.	  10µg/mL	  complexed	  constructs	  
were	  added	  to	  a	  co-­‐culture	  of	  MR-­‐/-­‐	  BMDCs	  and	  DesTCR	  T	  cells	  and	  incubated	  for	  five	  minutes.	  T	  cells	  were	  
lysed	   and	  Western	   blotting	  was	   performed.	  Membranes	  were	   stained	  with	   either	   antibodies	   against	   Y505	  
phosphorylated	  Lck	  (pLck)	  or	  Actin	  as	  loading	  control.	  The	  ratio	  between	  pLck	  and	  Actin	  was	  quantified	  using	  
ImageJ	  software.	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4.3 	   The	  Mannose	  Receptor	   led	   to	  a	  differential	   gene	  expression	  
profile	  in	  T	  cells	  
Since	  the	  MR	  obviously	  influenced	  the	  signaling	  cascade	  of	  activated	  T	  cells,	  the	  impact	  of	  
the	  MR	  on	  gene	  expression	  modifications	  was	  examined	  adopting	  a	  cDNA	  microarray.	  For	  
this	  purpose,	  CD8+	  DesTCR	  T	  cells	  were	  incubated	  for	  zero,	  four,	  18	  and	  48	  hours	  with	  MR-­‐/-­‐	  
BMDCs	   in	   the	  presence	  of	  either	  FcMR	  or	  control	  protein.	  Afterwards,	  CD8+	  T	  cells	  were	  
FACS	  sorted,	  RNA	  isolated,	  reverse-­‐transcribed	  into	  cDNA	  and	  the	  samples	  were	  applied	  to	  
gene	   array	   analysis	   (in	   close	   cooperation	   with	   Prof.	   Joachim	   Schultze	   and	   Dr.	   Astrid	  
Draffehn).	  
	  
Bioinformatics	   revealed	   clustering	   of	   replicates	   within	   the	   same	   samples	   plus	   rough	  
clustering	   among	   the	   different	   incubation	   durations.	   The	   gene	   expression	   heat	   map	   in	  
Figure	  4-­‐9a	  shows	  a	  clear	  distinction	  of	  samples	  that	  were	  incubated	  in	  the	  presence	  of	  the	  
MR	  and	  of	  the	  ones	  incubated	  in	  the	  absence	  of	  the	  MR	  throughout	  all	  time	  points.	  	  
	  
To	   elicit	   potential	   key-­‐players	   in	   this	   re-­‐programming	   process,	   literature	   research	   was	  
performed	  by	  Dr.	  Astrid	  Draffehn,	  screening	  for	  differentially	  expressed	  genes	  associated	  
with	   T	   cell	   tolerance	   and/or	   anergy.	   49	   candidate	   genes	   were	   found,	   whereof	   34	   were	  
expressed	   in	   all	   tested	   conditions	   and	   16	   showed	   a	   differential	   expression	   compared	   to	  
naive	  T	  cells	  during	  the	  exercised	  time	  course.	  These	  16	  genes	  were	  depicted	  in	  a	  heat	  map	  
in	  figure	  4-­‐9b,	  indicating	  their	  log2	  expression	  levels	  for	  all	  three	  conditions	  (naive,	  isotype	  
control	  and	  FcMR)	  and	  time	  points	  (t=	  4h,	  18h	  and	  48h).	  Additionally,	  the	  fold	  change	  (FC)	  
of	   isotype	  control-­‐	  or	  FcMR-­‐treated	  cells	  relative	  to	  naive	  cells	  plus	  the	  FC	  ratio	  between	  
both	  treatments	  was	  calculated.	  	  
	  
Candidate	  genes	  showing	  a	  strong	  regulation	  were	  further	  visualized	  in	  their	  time	  course,	  
comparing	  T	  cells	  under	  the	   influence	  of	  the	   isotype	  control	  protein	  or	  the	  FcMR	  protein	  
relative	   to	   naive	   T	   cells	   (Fig.	   4-­‐9c).	   Amongst	   them	   were	   Ctla-­‐4	   (Cytotoxic	   T-­‐lymphocyte	  
Antigen	  4),	  Egr1,	  2	  and	  3	  (Early	  growth	  response	  protein	  1,	  2	  and	  3)	  and	  Jmjd3	  (Jumonji	  
domain	  containing	  3).	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Egr1,	  2	  and	  3	  were	  up-­‐regulated	  at	  the	  early	  time	  point	  (4h)	  relative	  to	  naive	  T	  cells	  
(Fig.	   4-­‐9b,	   c)	   and	   showed	   an	   increased	   transcription	   under	   the	   influence	  of	   FcMR	  
compared	   to	   control-­‐treated	   samples	   (Fig.	   4-­‐9c).	   For	   all	   three	   genes	   there	   was	   a	  
sharp	   drop	   in	   their	   transcription	   for	   the	   intermediate	   (18h)	   and	   late	   (48h)	   time	  
points.	  For	  the	  18	  hours	  time	  point,	  the	  transcription	  levels	  were	  quite	  diverse,	  for	  
Egr1	  having	  been	  higher	  in	  the	  FcMR-­‐treated	  sample,	  for	  Egr2	  having	  been	  slightly	  
higher	   in	   the	  control	   sample	  and	  having	  been	  equal	   for	  Egr3	   (Fig.	  4-­‐9c).	  However,	  
the	   late	   time	   point,	   again	   showed	   a	   clear	   picture	   with	   all	   genes	   having	   been	  
transcribed	  weaker	  in	  the	  FcMR-­‐treated	  samples	  compared	  to	  control	  sample	  (Fig.	  
4-­‐9c).	  	  
The	  transcription	  level	  of	  Jmjd3	  could	  also	  be	  determined	  to	  be	  strongly	  enhanced	  upon	  
T	  cell	  activation	  relative	  to	  naive	  cells	  (Fig.	  4-­‐9b,	  c).	  Moreover,	  the	  expression	  is	  elevated	  in	  
FcMR	   treated	   samples	   compared	   to	   the	  control	   samples	   for	  all	   time	  points,	  emphasizing	  
Jmjd3	  as	  a	  putative	  candidate	  to	  be	  further	  investigated	  (Fig.	  4-­‐9c).	  	  
However,	   Ctla-­‐4	   showed	   the	   most	   prominent	   differences	   during	   the	   time	   course	   with	  
strong	  up-­‐regulation	  upon	  T	  cell	  activation	  relative	  to	  naive	  cells.	  In	  the	  presence	  of	  FcMR,	  
the	   transcription	  of	  Ctla-­‐4	  was	   robustly	   increased	  compared	  to	  samples	   treated	  with	   the	  
control	  protein.	  This	  was	  especially	  the	  case	  for	  the	  intermediate	  (18h)	  and	  late	  (48h)	  time	  
points	  (Fig.	  4-­‐9).	  Amongst	  the	  selected	  genes	  Egr1,	  2	  and	  3,	  Jmjd3	  and	  Ctla-­‐4,	  CTLA-­‐4	  was	  
the	  only	  effector	  protein,	  whereas	  the	  others	  were	   involved	   in	  transcriptional	  regulation.	  
Furthermore,	   ligation	  of	  CD45	  had	  been	  demonstrated	  to	  up-­‐regulate	  CTLA-­‐4	  and	   induce	  
tolerance	  against	  allografts	  (113).	  Therefore,	  we	  decided	  to	  investigate	  whether	  impaired	  T	  
cell	  effector	  function	  in	  the	  presence	  of	  the	  MR	  might	  be	  due	  to	  up-­‐regulation	  of	  CTLA-­‐4	  
after	  MR-­‐induced	  inactivation	  of	  CD45.	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Fig.	  4-­‐9:	  The	  MR	  lead	  to	  differential	  gene	  expression	  profile	  in	  T	  cells.	  
DesTCR	   T	   cells	   were	   incubated	   for	   4h,	   18h	   or	   48h	   with	  MR-­‐/-­‐	   BMDCs	   in	   the	   presence	   of	   10µg/mL	   either	  
complexed	   isotype	   control	   protein	   or	   FcMR.	   Naïve	   T	   cells	   were	   not	   co-­‐cultured	   with	   BMDCs.	   RNA	   was	  
isolated	  from	  CD8+	  sorted	  T	  cells,	  reverse	  transcribed	  into	  cDNA	  and	  applied	  to	  micro	  array	  analysis.	  (a)	  Heat	  
map	  of	  hierarchical	  clustering	  of	  significantly	  variable	  transcripts.	  (b)	  Z-­‐transformed	  log2	  expression	  profiles	  
of	  differentially	  expressed	  genes	  during	  the	  time	  course,	  associated	  with	  T	  cell	  tolerance	  and/or	  anergy.	  Fold	  
change	   (FC)	   ratio	   of	   isotype	   control/FcMR	   protein	   treated	   samples	  was	   calculated.	   (c)	   Selected	   candidate	  
genes	   form	  b)	  were	   shown.	   Time	   course	  of	   relative	  expression	   levels	  of	   isotype	   control	   respectively	   FcMR	  
treated	  T	  cells	  compared	  to	  naïve	  T	  cells.	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4.4 	   The	   influence	  of	  the	  Mannose	  Receptor	  on	  T	  cells	  depended	  
on	  CD45	  and	  was	  mediated	  by	  CTLA-­‐4	  up-­‐regulation	  
4.4.1 CTLA-­‐4	  up-­‐regulation	  was	  detectable	  in	  the	  presence	  of	  the	  MR	  and	  by	  
inhibition	  of	  CD45	  
To	  additionally	  confirm	  the	  up-­‐regulated	  expression	  of	  CTLA-­‐4	   in	  the	  presence	  of	  the	  MR	  
on	  protein	  level,	  DesTCR	  T	  cells	  were	  co-­‐cultured	  with	  wildtype	  or	  MR-­‐/-­‐	  BMDCs	  for	  three	  
days	  and	  CTLA-­‐4	  expression	  on	  CD8+	  T	  cells	  was	  analyzed	  by	  flow	  cytometry.	  	  
	  
First	  of	  all,	  an	  enhanced	  number	  of	  CTLA-­‐4	  expressing	  CD8+	  T	  cells	  could	  be	  detected	  when	  
having	  been	  cultured	   in	   the	  presence	  of	  MR-­‐bearing	  wildtype	  BMDCs	  compared	   to	  MR-­‐/-­‐	  
BMDCs	   (Fig.	   4-­‐10a).	   Quantification	   revealed	   a	   significantly	   higher	   percentage	   of	   CTLA-­‐4	  
expressing	   cells	   (Fig.	   4-­‐10b)	   plus	   a	   significantly	   increased	   CTLA-­‐4	   mean	   fluorescence	  
intensity	  (MFI)	  of	  CD8+	  T	  cells	  (Fig.	  4-­‐10c).	  
	  
To	  investigate	  whether	  this	  increased	  expression	  was	  associated	  with	  CD45	  activity,	  which	  
was	   decreased	   in	   the	   presence	   of	   the	   MR	   (see	   Fig.	   4-­‐8a),	   CTLA-­‐4	   expression	   of	   MR-­‐/-­‐	  
primed	   T	   cells	   was	   examined	   in	   the	   presence	   of	   the	   CD45-­‐specific	   inhibitor	   SF1670.	   In	  
figure	  4-­‐10d	  one	  can	  see	  a	  clear	   increase	  of	  CTLA-­‐4	  expressing	  T	  cells	   in	   the	  presence	  of	  
the	  CD45	   inhibitor	   compared	   to	  T	   cells	  whose	  priming	  was	  performed	  without	   inhibitor.	  
Again,	   quantification	   resulted	   in	   significantly	   increased	   percentages	   of	   CTLA-­‐4+	   cells	   and	  
MFI	   of	   CTLA-­‐4	   on	   T	   cells	   in	   the	   presence	   of	   the	   CD45	   inhibitor	   (Fig.	   4-­‐10e,	   f).	   Thus,	   the	  
presence	  of	  the	  MR	  or	  the	  inhibition	  of	  CD45	  led	  to	  up-­‐regulation	  of	  CTLA-­‐4.	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Fig.	  4-­‐10:	  CTLA-­‐4	  up-­‐regulation	  was	  detectable	  in	  the	  presence	  of	  the	  MR	  and	  by	  inhibition	  of	  CD45.	  	  
(a)	  DesTCR	  T	  cells	  were	  incubated	  for	  three	  days	  with	  wildtype	  or	  MR-­‐/-­‐	  BMDCs,	  1µg/mL	  fluorescent-­‐coupled	  
αCTLA-­‐4	  or	   isotype	   control	   antibody	  were	   added	   to	   the	   supernatant	   for	   four	  hours.	   Cells	  were	  harvested,	  
stained	  for	  CD8	  and	  analyzed	  by	  flow	  cytometry.	  (b)	  Quantification	  of	  (a).	  (c)	  MFI	  of	  CTLA-­‐4	  of	  (a).	  (d)	  DesTCR	  
T	  cells	  were	  incubated	  for	  three	  days	  with	  MR-­‐/-­‐	  BMDCs	  in	  the	  presence	  or	  absence	  of	  40mM	  CD45	  inhibitor	  
SF1670,	  1µg/mL	  fluorescent-­‐coupled	  αCTLA-­‐4	  or	  isotype	  control	  antibody	  were	  added	  to	  the	  supernatant	  for	  
four	  hours.	  Cells	  were	  harvested,	  stained	  for	  CD8	  and	  analyzed	  by	  flow	  cytometry.	  (e)	  Quantification	  of	  (d).	  
(f)	  MFI	  of	  CTLA-­‐4	  of	  (d).	  %	  CTLA-­‐4+	  cells	  and	  MFI	  of	  CTLA-­‐4	  were	  determined	  after	  gating	  on	  CD8+	  cells.	  
	  
4.4.2 MR-­‐mediated	  suppression	  of	  cytotoxicity	  depended	  on	  CTLA-­‐4	  
To	  explore	  whether	  the	  diminishing	  effect	  of	   the	  MR	  on	  the	  cytotoxic	  capacity	  of	  CD8+	  T	  
cells	   was	   due	   to	   induced	   expression	   of	   CTLA-­‐4	   during	   T	   cell	   activation,	   further	   in	   vitro	  
cytotoxicity	  assays	  were	  performed.	  	  
	  
First,	  DesTCR	  T	  cells	  were	  activated	  by	  either	  wildtype	  or	  MR-­‐/-­‐	  BMDCs	  in	  the	  presence	  or	  
absence	  of	   soluble	  CTLA-­‐4	   (sCTLA-­‐4).	  Since	  CTLA-­‐4	  binds	   to	   the	  co-­‐stimulatory	  molecules	  
CD80/86	  with	  higher	  affinity	  than	  CD28	  does,	  it	  was	  possible	  to	  block	  these	  co-­‐stimulatory	  
molecules	   by	   addition	   of	   surplus	   sCTLA-­‐4.	   Figure	   4-­‐11a	   shows	   a	   clearly	   diminished	  
cytotoxicity	  of	  T	  cells	  which	  were	  primed	  by	  MR-­‐/-­‐	  BMDCs	  in	  the	  presence	  of	  sCTLA-­‐4.	  Their	  
cytotoxic	  capacities	  were	  diminished	  to	  levels	  comparable	  to	  wildtype	  primed	  T	  cells.	  The	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same	   results	   could	   be	   observed	   when	   T	   cells	   were	   activated	   by	   MR-­‐/-­‐	   BMDCs	   in	   the	  
presence	  or	  absence	  of	  FcMR	  with	  or	  without	  sCTLA-­‐4	  (Fig.	  4-­‐11b,	  together	  with	  Katharina	  
Koch).	  
This	   indicated	  that	   the	  reduced	  cytotoxic	  capacity	  of	  T	  cells	   that	  had	  been	  primed	   in	   the	  
presence	   of	   the	   MR	   might	   have	   been	   due	   to	   increased	   levels	   of	   the	   inhibitory	   protein	  
CTLA-­‐4.	  
	  
To	  further	  verify	  this	  hypothesis,	  we	  performed	  in	  vitro	  cytotoxicity	  assays	  in	  the	  presence	  
of	  an	  αCTLA-­‐4	  blocking	  antibody	  (a-­‐CTLA-­‐4).	  Addition	  of	  αCTLA-­‐4	  antibody	  had	  no	  effect	  on	  
T	  cells	  that	  were	  primed	  by	  MR-­‐/-­‐	  BMDCs	  alone	  or	  in	  the	  presence	  of	  control	  protein	  (Fig.	  
4-­‐11c,	  d).	  Noteworthy,	  in	  case	  of	  T	  cell	  priming	  by	  wildtype	  BMDCs,	  or	  by	  MR-­‐/-­‐	  BMDCs	  in	  
the	  presence	  of	   FcMR,	   the	   cytotoxic	   capacity	  was	   increased	   to	   levels	   comparable	   to	   the	  
knock-­‐out	  situation	  (Fig.	  4-­‐11c,	  d).	  
This	  showed	  that	  the	  MR-­‐mediated	  suppression	  of	  T	  cell	  cytotoxicity	  was	  indeed	  based	  on	  
increased	  expression	  levels	  of	  the	  inhibitory	  molecule	  CTLA-­‐4.	  
Fig.	  4-­‐11:	  MR-­‐mediated	  suppression	  of	  cytotoxicity	  depended	  on	  CTLA-­‐4.	  
(a)	  Wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  co-­‐cultured	  for	  three	  days	  with	  DesTCR	  T	  cells	  in	  the	  presence	  or	  absence	  
of	   1µg/mL	   soluble	   CTLA-­‐4	   protein	   (sCTLA-­‐4).	   T	   cells	   were	   purified	   by	   density	   gradient	   centrifugation	   and	  
distinctly	  CFSE-­‐labeled	   target	   cells	  or	   control	   cells	  were	  added	   to	   the	  T	   cells.	  After	   four	  hours,	   the	   ratio	  of	  
target	  to	  control	  cells	  was	  analyzed	  by	  flow	  cytometry	  and	  the	  specific	  cytotoxicity	  was	  calculated.	  (b)	  FcMR	  
or	  huIgG1-­‐control	   protein	  was	   complexed	  with	  an	  αhuman	  antibody.	   10µg/mL	   complexed	   constructs	  were	  
added	  to	  co-­‐cultures	  of	  DesTCR	  T	  cells	  with	  MR-­‐/-­‐	  BMDCs	  and	  incubated	  for	  three	  days.	  The	  following	  assay	  
was	  performed	  as	  in	  (a).	  (c)	  See	  (a)	  instead	  of	  sCTLA-­‐4,	  1µg/mL	  inhibitory	  αCTLA-­‐4	  antibody	  (a-­‐CTLA-­‐4)	  was	  
added.	  (d)	  See	  (b)	  instead	  of	  sCTLA-­‐4,	  1µg/mL	  inhibitory	  αCTLA-­‐4	  antibody	  was	  added.	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4.5 MR-­‐mediated	   CTLA-­‐4	   up-­‐regulation	   and	   cytotoxicity	  
suppression	  was	  circumvented	  under	  inflammatory	  conditions	  
The	  induction	  of	  tolerogenic	  effects	  obviously	  has	  to	  be	  reversible	  in	  case	  of	  infection.	  For	  
that	   reason,	   the	   MR-­‐mediated	   up-­‐regulation	   of	   the	   inhibitory	   molecule	   CTLA-­‐4	   was	  
investigated	  in	  the	  presence	  of	  inflammatory	  stimuli	  like	  CpG.	  	  
	  
To	   this	   end,	   DesTCR	   T	   cells	   were	   incubated	   for	   three	   days	   with	   either	   naive	   or	   CpG-­‐
stimulated	   wildtype	   cells	   and	   CTLA-­‐4	   staining	   was	   performed	   as	   described	   above.	  
Interestingly,	  the	  percentage	  of	  CTLA-­‐4-­‐expressing	  cells	  was	  distinctly	  diminished	  on	  T	  cells	  
that	   were	   activated	   by	   CpG-­‐stimulated	   BMDCs	   compared	   to	   activation	   by	   naive	   BMDCs	  
(Fig.	   4-­‐12a).	   Again,	   quantification	   of	   the	   percentage	   of	   CTLA-­‐4	   positive	   cells	   and	   the	  
verification	   of	   the	   MFI	   proved	   a	   significant	   decrease	   under	   the	   influence	   of	   CpG	   (Fig.	  
4-­‐12b,	   c).	   These	   results	   indicated	   that	   the	   enhancing	   effect	   of	   the	   MR	   on	   CTLA-­‐4	  
expression	  might	  be	  overruled	  under	  inflammatory	  conditions.	  
Fig.	  4-­‐12:	  MR-­‐mediated	  CTLA-­‐4	  up-­‐regulation	  could	  be	  circumvented	  under	  inflammatory	  conditions.	  
(a)	   Wildtype	   BMDCs	   were	   activated	   over	   night	   with	   5µg/mL	   CpG	   or	   left	   untreated.	   DesTCR	   T	   cells	   were	  
incubated	   for	   three	   days	   with	   activated	   or	   untreated	   BMDCs,	   1µg/mL	   fluorescent-­‐coupled	   αCTLA-­‐4	   or	  
isotype	  control	  antibody	  was	  added	  to	  the	  supernatant	  for	  four	  hours.	  Cells	  were	  harvested,	  stained	  for	  CD8	  
and	  analyzed	  by	  flow	  cytometry.	  (b)	  Quantification	  of	  (a).	  (c)	  MFI	  of	  CTLA-­‐4	  of	  (a).	  
	  
Yet,	  it	  had	  to	  be	  excluded	  that	  this	  effect	  might	  have	  been	  due	  to	  the	  fact	  that	  the	  MR	  was	  
invaginated	   upon	   CpG-­‐stimulation	   or	   due	   to	   differential	   expression	   of	   co-­‐stimulatory	  
molecules	  between	  CpG-­‐treated	  wildtype	  and	  MR-­‐/-­‐	  BMDCs.	  	  
According	  to	  this,	  the	  surface	  expression	  of	  the	  co-­‐stimulatory	  molecules	  CD80	  and	  CD86	  
was	  stained	  and	  surface	  MR	  expression	  on	  untreated	  and	  CpG-­‐activated	  wildtype	  and	  MR-­‐/-­‐	  
BMDCs	  was	  analyzed.	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An	   equally	   increased	   CD80	   and	   CD86	   expression	   was	   detectable	   on	   wildtype	   and	  MR-­‐/-­‐	  
BMDCs	  after	  CpG-­‐treatment	   compared	   to	  unstimulated	  BMDCs	   (Fig.	   4-­‐13).	   Furthermore,	  
even	   after	   CpG-­‐treatment,	   a	   considerable	   percentage	   of	  wildtype	   BMDCs	   still	   expressed	  
the	   MR	   on	   their	   surface	   and	   took	   up	   MR	   specific	   antibodies	   (Fig.	   4-­‐13).	   The	   reduced	  
antibody-­‐uptake	  capacity	  upon	  CpG	  activation	  of	  BMDCs	  may	  not	  necessarily	  go	  along	  with	  
decreased	  MR	   expression	   on	   the	   cell	   surface	   but	  might	   be	   due	   to	   an	   impaired	   antigen-­‐
uptake-­‐machinery	  (114,	  115).	  
Fig.	   4-­‐13:	   Neither	   differential	   expression	   of	   co-­‐stimulatory	  molecules	   on	  wildtype	   and	  MR-­‐/-­‐	   BMDCs	   nor	  
MR-­‐loss	  could	  be	  detected	  upon	  CpG	  treatment.	  
Wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  activated	  over	  night	  with	  5µg/mL	  CpG	  or	   left	  untreated.	  The	  following	  day,	  
BMDCs	  were	  either	  harvested	  and	  stained	  for	  CD80	  and	  CD86	  or	  received	  1µg/mL	  fluorescently	  labeled	  αMR	  
antibody	  for	  15	  minutes.	  Finally,	  cells	  were	  analyzed	  by	  flow	  cytometry.	  Control	  cells	  were	  left	  unstained.	  
	  
As	  described	  above,	  CTLA-­‐4	  up-­‐regulation	  could	  be	  achieved	  in	  the	  presence	  of	  the	  MR	  and	  
by	   inhibition	  of	  the	  CD45	  phosphatase	  activity.	  Then,	  the	  hypothesis	  was	  tested	  whether	  
inhibition	  of	  CD45	  also	  affected	  the	  CpG-­‐mediated	  suppression	  of	  CTLA-­‐4.	  	  
	  
Therefore,	   DesTCR	   T	   cells	   were	   incubated	   with	   naive	   MR-­‐/-­‐	   BMDCs	   in	   the	   presence	   or	  
absence	   of	   a	   CD45	   inhibitor.	   Alternatively,	   co-­‐culture	   took	   place	   with	   CpG-­‐stimulated	  
BMDCs	  plus	  CD45	  inhibitor.	  Stimulation	  of	  DesTCR	  T	  cells	  with	  MR-­‐/-­‐	  BMDCs	  led	  to	  only	  a	  
weak	   expression	   of	   CTLA-­‐4,	   though	   being	   strongly	   induced	   in	   the	   presence	   of	   CD45	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inhibitor	   (Fig.	  4-­‐14a).	  Noteworthy,	  after	  CpG	   treatment	  of	   the	  BMDCs,	   the	  expression	  of	  
the	  inhibitory	  molecule	  CTLA-­‐4	  on	  T	  cells	  was	  suppressed	  (Fig.	  4-­‐14a).	  Significant	  changes	  
of	  %	  CTLA-­‐4+	  cells	  and	  MFI	  of	  CTLA-­‐4	  on	  CD8+	  cells	  were	  proven	  by	  quantification	  in	  figure	  
4-­‐14b	  and	  c.	  
	  
To	   investigate	  whether	  the	  suppressed	  CTLA-­‐4	  expression	  under	   inflammatory	  conditions	  
was	  due	  to	  signaling	  via	  co-­‐stimulatory	  molecules	  like	  CD80/86	  on	  BMDCs	  with	  its	  counter-­‐
receptor	   CD28	   on	   T	   cells,	   inflammation	   was	   mimicked	   by	   application	   of	   a	   stimulating	  
αCD28	  antibody.	  If	  that	  assumption	  were	  true,	  the	  same	  effect	  on	  CTLA-­‐4	  expression	  had	  
to	  be	  seen	  in	  the	  presence	  of	  the	  αCD28	  antibody	  as	  under	  CpG	  influence.	  	  
In	   fact,	  T	  cells	   that	  were	  activated	  by	  MR-­‐/-­‐	  BMDCs	   in	   the	  presence	  of	  a	  αCD28	  antibody	  
showed	  a	   significantly	   reduced	  percentage	  of	  CTLA-­‐4	  expressing	  cells	   (Fig.	  4-­‐14d,	  e)	  plus	  
decreased	  amounts	  of	  CTLA-­‐4	  (Fig.	  4-­‐14f).	  
	  
Finally,	   it	  was	   examined	  whether	   inflammatory	   stimuli	   also	   have	   an	   impact	   on	   cytotoxic	  
capacities	  of	  CD8+	  T	  cells.	  Therefore,	  DesTCR	  T	  cells	  were	  primed	  either	  by	  naive	  or	  by	  CpG-­‐
stimulated	  wildtype	  or	  MR-­‐/-­‐	  BMDCs	  and	  the	  in	  vitro	  cytotoxicity	  was	  analyzed.	  	  
	  
Under	   steady-­‐state	   conditions,	   MR-­‐/-­‐-­‐primed	   T	   cells	   showed	   an	   increased	   cytotoxicity	  
compared	  to	  wildtype	  BMDC-­‐primed	  DesTCR	  T	  cells	  (Fig.	  4-­‐14g).	  Importantly,	  the	  cytotoxic	  
capacity	   of	   DesTCR	   T	   cells	   that	  were	   primed	   by	  wildtype	   BMDCs	   substantially	   increased	  
under	  the	  influence	  of	   inflammatory	  stimuli	  (Fig.	  4-­‐14g).	  The	  cytotoxicity	  was	  elevated	  to	  
an	   extent	   similar	   to	   T	   cells	   that	   were	   activated	   by	  MR-­‐/-­‐	   BMDCs	   (Fig.	   4-­‐14g).	   Plus,	   both	  
wildtype-­‐	   and	  MR-­‐/-­‐	   BMDC-­‐primed	   T	   cells	   showed	   an	   increased	   cytotoxic	   capacity	   under	  
inflammatory	  conditions	  compared	  to	  the	  steady-­‐state	  conditions	  (Fig.	  4-­‐14g).	  These	  data	  
highlight	   that	   the	   suppressive	   function	   of	   the	   MR	   on	   cytotoxicity	   under	   steady	   state	  
conditions	  can	  be	  circumvented	  in	  case	  of	  inflammation.	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Fig.	  4-­‐14:	   Inflammatory	  stimuli	  could	  prevent	  MR-­‐mediated	  up-­‐regulation	  of	  CTLA-­‐4	  and	  suppression	  of	  T	  
cell	  cytotoxicity.	  
(a)	  MR-­‐/-­‐	  BMDCs	  were	  activated	  over	  night	  with	  5µg/mL	  CpG	  or	  left	  untreated.	  DesTCR	  T	  cells	  were	  incubated	  
for	  three	  days	  with	  activated	  or	  untreated	  BMDCs	  in	  the	  presence	  or	  absence	  of	  50	  mM	  of	  the	  CD45-­‐specific	  
inhibitor	  methyl-­‐3,4-­‐dephostatin.	  After	   three	  days,	  1µg/mL	   fluorescent-­‐coupled	  αCTLA-­‐4	  or	   isotype	  control	  
antibody	  was	  added	  to	  the	  supernatant	  for	  four	  hours.	  Cells	  were	  harvested,	  stained	  for	  CD8	  and	  analyzed	  by	  
flow	  cytometry.	  (b)	  Quantification	  of	  (a).	  (c)	  MFI	  of	  CTLA-­‐4	  of	  (a).	  (d)	  DesTCR	  T	  cells	  were	  incubated	  for	  three	  
days	  with	  wildtype	  BMDCs	  in	  the	  presence	  or	  absence	  of	  a	  stimulatory	  αCD28	  antibody.	  1µg/mL	  fluorescent-­‐
coupled	   αCTLA-­‐4	   or	   isotype	   control	   antibody	   was	   added	   to	   the	   supernatant	   for	   four	   hours.	   Cells	   were	  
harvested,	  stained	  for	  CD8	  and	  analyzed	  by	  flow	  cytometry.	  (e)	  Quantification	  of	  (d).	  (f)	  MFI	  of	  CTLA-­‐4	  of	  (d).	  
(g)	  Wildtype	  BMDCs	  were	  activated	  over	  night	  with	  5µg/mL	  CpG	  or	   left	  untreated	  (Control).	  DesTCR	  T	  cells	  
were	  incubated	  for	  three	  days	  with	  activated	  or	  untreated	  BMDCs.	  T	  cells	  were	  purified	  by	  density	  gradient	  
centrifugation	  and	  distinctly	  CFSE-­‐labeled	  target	  cells	  or	  control	  cells	  were	  added	  in	  different	  ratios	  to	  the	  T	  
cells.	   After	   four	   hours	   the	   ratio	  of	   target	   to	   control	   cells	  was	   analyzed	  by	   flow	   cytometry	   and	   the	   specific	  
cytotoxicity	  was	  calculated.	  %	  CTLA-­‐4+	  cells	  and	  MFI	  of	  CTLA-­‐4	  were	  determined	  after	  gating	  on	  CD8+	  cells.	  	  	  	  
%	  CTLA-­‐4+	  cells	  and	  MFI	  of	  CTLA-­‐4	  were	  determined	  after	  gating	  on	  CD8+	  cells.	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4.6 	   In	   vivo,	   the	   MR	   increased	   the	   expression	   of	   CTLA-­‐4	  
accompanied	  with	  a	  decreased	  cytotoxicity	  
After	  having	  investigated	  the	  tolerogenic	  effect	  of	  the	  MR	  in	  vitro,	  further	  analysis	  should	  
determine	  whether	  this	  effect	  also	  held	  true	  in	  the	  in	  vivo	  situation.	  	  
	  
First,	   the	   CTLA-­‐4	   expression	   on	   T	   cells	   was	   examined	   after	   activation	   with	   wildtype	  
respectively	   MR-­‐/-­‐	   BMDCs	   in	   vivo.	   On	   this	   account,	   wildtype	   or	   MR-­‐/-­‐	   BMDCs	   were	  
transduced	   with	   an	   adenovirus	   encoding	   for	   Luciferase,	   OVA	   and	   GFP	   (AdLOG)	   or	   left	  
untreated	   (Control).	   To	   ensure	   that	   the	   transduction	   efficiency	   of	   wildtype	   and	   MR-­‐/-­‐	  
BMDCs	  was	  the	  same,	  the	  GFP	  expression	  of	  transduced	  BMDCs	  was	  determined	  48	  hours	  
after	  transduction	  by	  flow	  cytometry.	  Figure	  4-­‐15	  shows	  an	  equal	  transduction	  efficiency	  
of	  wildtype	  and	  MR-­‐/-­‐	  BMDCs.	  	  
Fig.	  4-­‐15:	  Equal	  transduction	  efficiencies	  were	  detected	  for	  wt	  and	  MR-­‐/-­‐	  BMDCs.	  
Wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  transduced	  for	  three	  hours	  with	  an	  adenovirus	  encoding	  Luciferase,	  OVA	  and	  
GFP	   (AdLOG)	   with	   an	  MOI	   of	   20	   or	   left	   non-­‐transduced	   (Control).	   After	   48h,	   transduction	   efficiency	   was	  
determined	  by	  flow	  cytometric	  analysis	  of	  GFP	  expression.	  
	  
Transduced	   BMDCs	   were	   injected	   i.v.	   into	   C57/Bl6J	   recipient	   mice.	   After	   six	   days,	  
splenocytes	  were	   isolated	  and	  stained	   for	  CTLA-­‐4,	  CD8	  and	  with	  SIINFEKL-­‐dextramers	   for	  
the	  MHC-­‐I	  OVA	  epitope.	  CTLA-­‐4	  expression	  on	  endogenous	  antigen-­‐specific	   (Dextramer+)	  
and	  antigen-­‐unspecific	  (Dextramer-­‐)	  CD8+	  T	  cells	  was	  monitored	  by	  flow	  cytometry.	  	  
	  
Despite	   similar	   transduction	   efficiencies,	   antigen-­‐specific	   endogenous	   CD8+	   T	   cells	   that	  
were	   primed	   by	   wildtype	   BMDCs	   revealed	   a	   significantly	   increased	   CTLA-­‐4	   expression	  
compared	  to	  T	  cells	  activated	  by	  MR-­‐/-­‐	  BMDCs	  (Fig.	  4-­‐16a).	   In	  contrast,	  antigen-­‐unspecific	  
CD8+	   T	   cells	   did	  not	   show	  any	  CTLA-­‐4	  up-­‐regulation,	   indicating	   that	   the	  up-­‐regulation	  of	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CTLA-­‐4	   indeed	  resulted	  from	  antigen-­‐specific	  T	  cell	  activation	   in	  the	  presence	  of	   the	  MR.	  
These	  results	  confirmed	  the	   findings	  of	   in	  vitro	  experiments	   (Fig.	  4-­‐10a)	  and	  emphasized	  
the	  hypothesis	  that	  the	  regulatory	  effect	  of	  the	  MR	  is	  a	  mechanism	  being	  relevant	  also	  in	  
vivo.	  	  
	  
Finally,	   it	   was	   investigated	  whether	   also	   in	   vivo	   the	  MR	   displayed	   the	   same	   tolerogenic	  
effect	   on	   T	   cell	   cytotoxicity	   which	   had	   been	   observed	   in	   vitro	   (Fig.	   4-­‐2).	   To	   this	   end,	  
wildtype	   or	   MR-­‐/-­‐	   BMDCs	   were	   transduced	   with	   AdLOG	   and	   injected	   into	   C57/BL6J	   as	  
described	  above.	  Control	  mice	  received	  non-­‐transduced	  BMDCs	  lacking	  the	  capacity	  for	  T	  
cell	  priming	  against	  OVA.	  Afterwards,	  C57/BL6	  splenocytes	  were	   isolated	  and	  target	  cells	  
were	  loaded	  with	  the	  OVA	  T	  cell	  peptide	  SIINFEKL	  (CFSEhigh).	  Control	  cells	  were	  not	  loaded	  
with	  peptide	   (CFSElow)	  and	  both	  cell	   types	  were	   injected	   into	   the	  mice.	   Four	  hours	   later,	  
spleens	  were	   isolated	  and	   the	   ratio	  between	   target	  and	  control	   cells	  was	  determined	  by	  
flow	  cytometry.	  	  
	  
Importantly,	  also	  in	  vivo	  it	  could	  be	  observed	  that	  T	  cells	  that	  were	  primed	  in	  the	  presence	  
of	  the	  MR	  showed	  a	  significantly	  reduced	  cytotoxic	  capacity	  compared	  to	  T	  cells	  that	  were	  
activated	  by	  MR-­‐/-­‐	  BMDCs	  (Fig.	  4-­‐16b,	  c).	  Thereby,	  the	  data	  from	  the	  shown	  in	  vitro	  studies	  
above	  could	  be	  confirmed	  and	  the	  influence	  of	  the	  MR	  on	  limiting	  the	  cytotoxic	  capacity	  of	  
endogenous	  T	  cells	  in	  vivo	  could	  be	  proved.	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Fig.	   4-­‐16:	   Also	   in	   vivo,	   the	   MR	   increased	   the	   expression	   of	   CTLA-­‐4	   accompanied	   with	   a	   decreased	  
cytotoxicity.	  
(a)	  Wildtype	  or	  MR-­‐/-­‐	  BMDCs	  were	  transduced	  for	  three	  hours	  with	  an	  adenovirus	  encoding	  Luciferase,	  OVA	  
and	  GFP	  (AdLOG)	  with	  an	  MOI	  of	  20.	  0,75*106	  adenovirally	  transduced	  or	  control	  BMDCs	  were	  injected	  i.v.	  
into	  C57/Bl6J	  mice.	  After	  6	  days,	   splenocytes	  were	   isolated	  and	  5*106	   cells	  were	   incubated	   for	   four	  hours	  
with	  2µg/mL	   fluorescently	   labeled	  αCTLA-­‐4	  or	   isotype	  control	  antibody.	  Cells	  were	  harvested,	  stained	  with	  
fluorescently	   labeled	   SIINFEKL-­‐dextramers	   and	   CD8	   antibody	   and	   analyzed	   by	   flow	   cytometry.	   CTLA-­‐4	  
expression	   of	   CD8+	   SIINFEKL-­‐dextramer+	   and	   SIINFEKL-­‐dextramer-­‐	   T	   cells	   was	   determined.	   (b)	  Wildtype	   or	  
MR-­‐/-­‐	  BMDCs	  were	  transduced	  for	  three	  hours	  with	  an	  adenovirus	  encoding	  Luciferase,	  OVA	  and	  GFP	  (AdLOG)	  
with	  an	  MOI	  of	  20	  or	  left	  non-­‐transduced	  (Control).	  1*106	  BMDCs	  were	  injected	  i.v.	  into	  C57/Bl6J	  mice.	  After	  
5	   days,	   splenocytes	   from	   C57/BL6	   mice	   were	   isolated,	   target	   cells	   were	   loaded	   with	   2µM	   OVA	   minimal	  
peptide	   SIINFEKL	   (stained	   CFSEhigh),	   non-­‐target	   cells	  were	   left	   untreated	   (stained	   CFSElow).	   Target	   cells	   and	  
non-­‐target	  cells	  were	  mixed	  equally	  and	  a	  total	  of	  10*106	  cells	  per	  mouse	  were	  injected	  i.v..	  Four	  hours	  later,	  
spleens	  were	   isolated	  and	  analyzed	  by	   flow	  cytometry.	  The	   ratio	  between	   target	  cells	  and	  non-­‐target	   cells	  
was	  determined.	  (c)	  Calculation	  of	  the	  specific	  cytotoxicity	  of	  (b).	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5 	   Discussion	  
The	   MR	   was	   so	   far	   known	   in	   the	   context	   of	   two	   immunogenic	   properties:	   inducing	  
immunity	   (87)	   and	   being	   induced	   under	   immune	   suppressive	   conditions	   (94,	   116,	   117).	  
This	  opposing	  behavior	  could	  until	  now	  neither	  be	  explained	  nor	  unified.	  Former	  studies	  
demonstrated	   that	   the	  MR	   is	   only	   capable	   to	   induce	   a	   potent	   immune	   response	   under	  
inflammatory	   conditions.	   However,	   in	   the	   absence	   of	   endotoxins,	   a	   tolerogenic	   state	   is	  
achieved	   (89,	   90).	   In	   the	   present	   study	   it	   is	   demonstrated	   that	   the	   MR	   represents	   a	  
molecular	   switch	   between	   induction	   of	   immunity	   and	   tolerance	   in	   CD8+	   T	   cells.	   The	  
decision	   towards	   the	   one	   or	   the	   other	   depends	   on	   the	   inflammatory	   condition	   of	   the	  
surrounding	  milieu.	  Furthermore,	   it	  was	  discovered	  that	   the	  MR	  mediates	   its	   tolerogenic	  
function	   by	   restricting	   the	   activity	   of	   CD45	   and	   up-­‐regulation	   of	   the	   inhibitory	  molecule	  
CTLA-­‐4.	  	  
	  
5.1 	   The	   Mannose	   Receptor	   in	   tolerance	   induction	   and	  
maintenance	  
The	  MR	  is	  expressed	  on	  a	  variety	  of	  cells	  that	  mediate	  tolerance	  and	  immune	  suppression.	  
Several	   reports	   describe	   extensive	  MR	   expression	   on	  M2-­‐differentiated	  macrophages	   in	  
the	   immunosuppressive	   environment	   of	   re-­‐occurring	   and	   vaccine-­‐resistant	   tumors	   (101-­‐
103,	  118).	  	  
Other	  tolerance-­‐mediating	  cells	  expressing	  the	  MR	  are	  liver	  sinusoidal	  endothelia	  cells	  (97,	  
119),	   uterine	   mucosal	   macrophages	   (99),	   oral	   macrophages	   and	   macrophages	   in	   the	  
lamina	  propria	  of	  the	  small	  intestine	  (100).	  	  
	  
In	   the	   present	   study	   a	   tolerogenic	   effect	   of	   the	  MR	   on	   CD8+	   T	   cells	   under	   steady	   state	  
conditions	  can	  be	  shown.	  Therefore	  it	  is	  conceivable	  that	  the	  above-­‐mentioned	  cells	  might	  
exert	   their	   suppressive	   function	  via	   the	  MR	  as	  well.	   Strengthening	   these	  observations,	   it	  
was	  proven	  that	  tumor-­‐associated	  macrophages	  (TAMs),	  being	  high	  in	  MR	  expression,	  can	  
be	   selectively	   eliminated	   by	   application	   of	   the	   chemotherapeutic	   agent	   docetaxel	   (103).	  
This	   deletion	   of	   MR-­‐bearing	   TAMs,	   results	   in	   a	   potent	   CTL	   response	   against	   tumor	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antigens.	  Therefore	  it	  is	  possible	  that	  also	  the	  immune-­‐suppressive	  function	  of	  TAMs	  might	  
be	  mediated	  via	  the	  MR.	  
	  
Furthermore	  it	  is	  published	  that	  anti-­‐inflammatory	  cytokines	  and	  agents	  like	  IL-­‐10,	  IL-­‐1RA,	  
IL-­‐4,	   dexamethasone	   and	   macrophage	   colony-­‐stimulating	   factor	   (M-­‐CSF)	   stimulate	   the	  
expression	   of	   the	   MR	   and	   support	   the	   differentiation	   of	   MR-­‐bearing	   immunregulatory	  
macrophages	  (94,	  99,	  116,	  117).	  	  
	  
5.2 	   The	   Mannose	   Receptor	   as	   molecular	   switch	   for	   tolerance	  
versus	  immunity	  
Quite	  contrary	  to	  the	  expression	  of	  the	  MR	  on	  tolerogenic	  cells,	  the	  MR	  has	  so	  far	  mainly	  
been	   known	   as	   a	   crucial	   player	   in	   the	   induction	   of	   immunity.	   Uptake	   of	   glycosylated	  
antigens	   by	   the	  MR	   leads	   to	   subsequent	   cross-­‐presentation	   towards	   CD8+	   T	   cells	   and	   a	  
potent	  immune	  response	  (60,	  87-­‐89).	  Noteworthy,	  this	  is	  only	  the	  case	  in	  the	  presence	  of	  
inflammatory	   stimuli	   (89).	   These	   observations	   go	   along	   with	   the	   presented	   data	   of	   this	  
study,	   proving	   that	   the	   tolerogenic	   effect	   of	   the	   MR	   under	   steady-­‐state	   conditions	   is	  
overcome	  after	  DC	  maturation.	  Comparable	  to	  Burgdorf	  et	  al.	  (89),	  the	  study	  at	  hand	  also	  
detects	   a	   strong	   induction	   of	   immunity	   in	   the	   presence	   of	   the	  MR	   under	   inflammatory	  
conditions.	  
	  
Combination	  of	   the	   facts	   that	   the	  MR	  expression	   is	   reduced	  by	  pro-­‐inflammatory	   stimuli	  
but	  increased	  by	  immune	  suppressive	  agents,	  indicates	  a	  favorably	  tolerogenic	  function	  of	  
the	  MR	  (67,	  94,	  96,	  99,	  116,	  117).	  Supportive	  to	  that	   is	  the	  observation	  that	  the	  immune	  
suppressive	   transcription	   factor	   PPARγ	   inhibits	   CD8+	   T	   cell	   activation	   by	   increased	  
expression	  of	  the	  MR	  and	  up-­‐regulation	  of	  the	  inhibitory	  molecule	  B7H1	  (104).	  
In	  line	  with	  that,	  it	  is	  shown	  in	  this	  work	  that	  the	  MR	  on	  DCs	  leads	  to	  increased	  expression	  
of	  the	  inhibitory	  molecule	  CTLA-­‐4	  on	  CD8+	  T	  cells	  and	  hence	  to	  T	  cell	  tolerance.	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5.3 CD45	  as	  crucial	  mediator	  for	  tolerance	  
The	   up-­‐regulation	   of	   CTLA-­‐4	   was	   reported	   to	   be	   mediated	   by	   CD45	   ligation	   (113).	  
Application	  of	   an	  anti-­‐CD45	  antibody	   in	   transplantation	  experiments	  and	  allergic	   asthma	  
yielded	  in	  allograft	  acceptance	  and	  decreased	  allergic	  responses	  (113,	  120).	  The	  ligation	  of	  
CD45	   could	   thereby	   be	   linked	   with	   up-­‐regulation	   of	   CTLA-­‐4	   and	   tolerance	   induction.	  
However,	  the	  impact	  of	  the	  applied	  antibody	  on	  CD45	  was	  not	  described.	  	  
	  
In	   this	   thesis,	   the	   interaction	   of	   the	  MR	   and	   CD45	   (58)	   is	   confirmed	   but	   additionally	   a	  
restraining	  effect	  of	   the	  MR	  on	  CD45	  activity	   is	  demonstrated.	   In	   the	  work	  at	  hand,	   it	   is	  
shown	   that	   the	   presence	   of	   the	   MR	   and	   inhibition	   of	   CD45	   are	   responsible	   for	   up-­‐
regulation	  of	  the	  inhibitory	  molecule	  CTLA-­‐4	  on	  the	  T	  cell	  surface.	  Accompanied	  with	  CTLA-­‐
4	  expression,	  there	  is	  a	  decreased	  cytotoxic	  capacity.	  Such	  a	  reduced	  cytotoxic	  capacity	  of	  
CD8+	  T	  cells	  might	  also	  be	  the	  reason	  for	  the	  enhanced	  allograft	  acceptance	  in	  the	  studies	  
of	  Fecteau	  et	  al.	  (113).	  It	  is	  thinkable	  that	  the	  CD45	  antibody	  used	  in	  their	  study,	  likewise	  
as	  the	  MR	  in	  the	  present	  study,	  could	  result	  in	  an	  inhibition	  of	  the	  CD45	  activity.	  Since	  the	  
results	  of	  this	  work	  show	  that	  a	  reduced	  CD45	  phosphatase	  activity	  leads	  to	  an	  enhanced	  
CTLA-­‐4	   expression,	   this	   might	   also	   be	   the	   modus	   operandi	   of	   the	   CD45	   antibody.	   This	  
assumption	  is	  supported	  by	  the	  fact	  that	  an	  anti-­‐CD45	  antibody	  is	  used,	  which	  targets	  the	  
isoform	   CD45RB.	   It	   could	   be	   shown	   by	   the	   work	   of	   Martinez-­‐Pomares	   et	   al.	   and	  
additionally	   in	   this	   study	   that	   the	  MR	  neither	  binds	   to	   the	   full-­‐length	   version	  CD45RABC	  
(230kDa)	  nor	  to	  the	  minimal	  form	  CD45R0	  (180kDa).	  This	  was	  verified	  by	  Western	  blotting	  
(see	  Fig.	  4-­‐7),	  where	  binding	  of	  the	  MR	  to	  CD45	  of	  intermediate	  molecular	  weight	  (approx.	  
200kDa)	  could	  be	  shown.	  It	  is	  under	  current	  investigation	  to	  determine	  the	  isoform	  being	  
bound	  by	  the	  MR	  but	  CD45RB	  is	  most	  likely,	  since	  only	  this	  isoform	  is	  expressed	  on	  naive	  
CD8	  T	  cells	  (see	  Fig.	  2-­‐9).	  Yet,	  as	  CD45RB	  is	  conceivable,	  the	  observed	  effect	  of	  Fecteau	  et	  
al.	  might	  also	  be	  accomplishable	  by	  application	  of	  the	  MR	  (113).	  
	  
As	   expected,	   the	   MR-­‐mediated	   inhibition	   of	   CD45	   also	   results	   in	   changes	   of	   the	   CD45	  
down-­‐stream	   target	   Lck	   in	   the	   TCR	   signaling	   cascade.	   It	   could	   be	   verified	   that	   in	   the	  
presence	  of	   the	  MR	  the	  phoshporylation	  status	  of	   the	  kinase	  Lck	  on	  the	  tyrosine	  Y505	   is	  
increased.	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As	  outlined	  in	  the	  introduction	  (see	  chapter	  2.6),	  the	  activity	  of	  Lck	  is	  complexly	  regulated.	  
Different	   combinations	   of	   phosphorylations	   on	   the	   inhibitory	   (Y505)	   or	   the	   catalytic	  
tyrosine	   Y394	   result	   in	   divergent	   signaling	   competence.	   In	   CD45-­‐/-­‐	   thymocytes	   and	   cell	  
lines,	  Lck	  is	  hyperphosporylated	  at	  its	  negative	  regulatory	  Y505,	  hence	  uncoupling	  the	  TCR	  
from	   intracellular	   signaling	   (121,	   122).	   This	   would	   result	   in	   a	   predominantly	   positive	  
regulatory	  function	  of	  CD45	  in	  T	  cell	  signaling	  (42).	  Surprisingly,	  the	  kinase	  activity	  of	  Lck	  in	  
CD45-­‐/-­‐	   cell	   lines	   is	   increased	   (123,	  124).	  This	   leads	   to	   two	  conclusions:	  Firstly,	   that	  CD45	  
can	  also	   target	   the	  catalytic	   tyrosine	  Y394	  and	  secondly,	   that	  despite	  phosphorylation	  of	  
the	  inhibitory	  Y505	  the	  kinase	  is	  still	  active	  due	  to	  the	  additional	  phosphorylation	  of	  Y394.	  
Hence,	  CD45	  obviously	  has	  additional	  negative	  regulatory	  functions	  on	  the	  activity	  of	  Lck	  
(125).	  	  
Which	  effect	  is	  dominating	  seems	  to	  be	  dependent	  on	  the	  availability	  of	  Lck	  for	  CD45	  as	  a	  
substrate.	  Hermiston	  et	  al.	  (42)	  discussed	  that	  in	  resting	  T	  cells,	  CD45	  is	  in	  close	  proximity	  
to	  Lck	  and	  dephosphorylates	  predominantly	  the	  negative	  regulatory	  Y505	  and	  to	  a	   lesser	  
extend	   Y394.	   This	   leads	   to	   a	   signaling-­‐competent,	  mostly	   unphosphorylated	   pool	   of	   Lck.	  
Upon	  TCR	  engagement,	  CD45	  is	  excluded	  from	  the	  forming	  immunological	  synapse	  (42,	  52)	  
and	  thereby	  retrieved	  from	  Lck.	  As	  a	  result,	  autophoshorylation	  of	  Y394	  leads	  to	  an	  active	  
form	  of	  Lck	  which	  might	  still	  be	  phosphorylated	  at	  Y505.	  	  
	  
A	  state	  of	  dual	  phosphorylation	  might	  also	  be	  the	  case	  for	  Lck	  in	  T	  cells	  that	  were	  activated	  
in	   the	   presence	   of	   the	   MR.	   In	   the	   depicted	   Western	   blot	   (see	   Fig.	   4-­‐8),	   only	   the	  
phosphorylation	  status	  of	  Y505	  is	  shown,	  lacking	  the	  correspondent	  analysis	  for	  Y394.	  This	  
issue,	   plus	   the	   analysis	   of	   the	   resulting	   kinase	   activity	   of	   Lck	   after	  MR-­‐mediated	   CD45-­‐
inhibition,	  are	  under	  current	  investigation.	  
	  
The	   importance	  of	   regulating	  the	  activity	  of	  CD45	  becomes	  obvious	  by	  the	  phenotype	  of	  
two	   different	   CD45	   mutants.	   CD45-­‐deficient	   mice	   (49,	   50,	   126)	   and	   humans	   (48,	   127)	  
develop	  a	  severe-­‐combined	  immunodeficiency.	  In	  contrast	  to	  that,	  mutant	  mice	  unable	  to	  
shut-­‐off	   CD45	   activity	   (CD45E613R)	   (56)	   suffer	   from	   profound	   lymphoproliferative	  
syndrome	  combined	  with	  severe	  autoimmune	  nephritis	  due	   to	  autoantibody	  production,	  
which	  results	   in	  early	  death.	  The	  present	  study	  shows	  a	  direct	  connection	  between	  CD45	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activity	   and	   CTLA-­‐4	   expression.	   The	   necessity	   of	   the	   inhibitory	   molecule	   CTLA-­‐4	   is	  
underlined	   by	   the	   phenotype	   of	   CTLA-­‐4-­‐deficient	   mice,	   which	   die	   within	   less	   than	   four	  
weeks	   after	   birth	   due	   to	   diffuse	   lymphoproliferative	   disease	   (36,	   128).	   These	   three	  
mutants	  (CD45-­‐/-­‐,	  CD45E613R	  and	  CTLA-­‐4-­‐/-­‐)	  clearly	  show	  the	  outcome	  of	  malregulation	  of	  
the	  molecules	  CD45	  and	  CTLA-­‐4.	  	  
Interestingly,	  the	  immunosuppressive	  function	  of	  CD45	  antibodies	  via	  CTLA-­‐4	  induction	  is	  
decreased	   under	   the	   influence	   of	   the	   Calcineurin-­‐inhibitor	   cyclosporine	   (129).	   Since	  
Calcineurin	  activates	  NFAT	  and	  its	  inhibition	  prohibits	  CD45-­‐mediated	  immunosuppression,	  
it	  is	  reasonable	  that	  the	  observed	  CTLA-­‐4	  up-­‐regulation	  upon	  CD45	  ligation	  is	  due	  to	  NFAT	  
signaling.	  
	  
5.4 Tolerance	  induction	  mediated	  by	  NFAT	  
Fehr	  et	  al.	  (130)	  could	  show	  that	  the	  Calcineurin-­‐dependent	  tolerance	  induction	  only	  is	  the	  
case	   for	   CD8+	   and	   not	   for	   CD4+	   T	   cells.	   Furthermore,	   they	   could	   prove	   that	   the	  
Calcineurin/NFAT	  pathway	  mediates	  mounting	  and	  maintenance	  only	  of	  the	  peripheral	  and	  
not	  of	  the	  central	  tolerance.	  	  
	  
The	   expression	   of	   NFAT	   itself	   is	   triggered	   by	   TCR	   stimulation,	   whereas	   co-­‐stimulatory	  
signals	   induce	   the	   expression	   of	   the	   interaction	   partner	   AP1.	   Under	   inflammatory	  
conditions,	   NFAT1	   interacts	   with	   the	   AP1	   and	   leads	   to	   expression	   of	   genes	   typical	   for	  
activated	   T	   cells	   (131).	   However,	   in	   the	   absence	   of	   AP1,	   other	   interaction	   partners	   for	  
NFAT	  come	  into	  play	  resulting	  in	  T	  cell	  activation	  and/or	  tolerance	  induction	  (132).	  	  
	  
Transcription	  factors	  of	  the	  EGR	  family	  (131)	  are	  alternative	  collaborators	  of	  NFAT.	  EGR1	  is	  
associated	  with	  T	  cell	  activation	  (133)	  and	  is	  elevated	  in	  its	  expression	  in	  the	  presence	  of	  
the	  MR	  compared	  to	  control	  samples	   in	  the	  present	  study	  (see	  Fig.	  4-­‐9c).	  Notably,	  this	   is	  
only	  the	  case	  for	  the	  early	  (4h)	  and	  intermediate	  (18h)	  time	  points.	  Later,	  between	  18h	  and	  
48h,	  there	   is	  a	  steep	  decrease	   in	   its	  expression	   in	  the	  presence	  of	  the	  MR.	   In	  contrast	  to	  
that,	   the	   level	   of	   EGR1	   remains	   stable	   for	   the	   intermediate	   and	   late	   time	   points	   in	   the	  
absence	  of	   the	  MR.	  This	   leads	  to	  a	  decreased	  expression	  of	  EGR1	  under	   the	   influence	  of	  
the	  MR.	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However,	  EGR2	  and	  EGR3	  are	  known	  for	  induction	  of	  T	  cell	  anergy	  by	  down-­‐regulation	  of	  
EGR1	   (134).	   In	  here,	   the	  presence	  of	   the	  MR	  during	   T	   cell	   activation	   leads	   to	  marginally	  
higher	  expression	  levels	  of	  EGR2	  and	  EGR3	  at	  an	  early	  time	  point	  (4h).	  	  
It	   is	   possible	   that	   this	   increased	   expression	   of	   EGR2	   and	   EGR3	   at	   early	   time	   points	   is	  
responsible	  for	  the	  subsequent	  down-­‐regulation	  of	  EGR1	  at	  the	  later	  time	  points.	  Yet,	  the	  
time	  frame	  of	  EGR2/3	  up-­‐regulation	  and	  subsequent	  EGR1	  down-­‐regulation	  appears	  quite	  
long	   for	   processes	   normally	   occurring	   within	   minutes	   or	   a	   few	   hours	   as	   common	   in	  
transcription	  regulation	  (134).	  Since	  EGR	  genes	  are	  described	  as	  important	  regulators	  in	  T	  
cell	   activation	   or	   induction	   of	   tolerance	   (133,	   134),	   we	   investigated	   whether	   they	   can	  
directly	  target	  the	  Ctla-­‐4	  promoter.	  However,	  bioinformatical	  approaches	  could	  not	  predict	  
direct	  binding	  capacities	  of	  EGR1,	  2	  or	  3	  to	  the	  Ctla-­‐4	  promoter.	  
	  
5.5 The	  role	  of	  CTLA-­‐4	  in	  tolerance	  induction	  
Besides	   the	   regulation	   of	   the	   EGR	   genes,	  NFAT	   also	  mediates	   the	   expression	  of	   another	  
very	  important	  gene	  in	  tolerance	  induction,	  namely	  Ctla-­‐4.	  Gibson	  et	  al.	  (135)	  showed	  the	  
binding	   of	   NFAT	   to	   the	   proximal	   promoter	   of	   Ctla-­‐4	   in	   CD3+	   human	   peripheral	   blood	  
mononuclear	  cells	  (PBMC).	  This	  promoter	  binding	  was	  accompanied	  with	  increased	  CTLA-­‐4	  
expression.	   A	   possible	   scenario	   of	   how	   the	   MR	   leads	   to	   tolerance	   is	   that	   upon	   MR-­‐
mediated	  inhibition	  of	  CD45	  the	  kinase	  Lck	  is	  hyperphosphorylated	  and	  thereby	  enhanced	  
in	   its	   activity.	   This	   enhancement	   might	   result	   to	   increased	   Ca2+	   release	   via	   the	  
Calcineurin/Calmodulin	  pathway	  and	  in	  turn	  to	  increased	  NFAT	  expression.	  Additionally	  to	  
the	   expression	   level	   of	   NFAT,	   also	   the	   retention	   time	   within	   the	   nucleus	   might	   be	  
prolonged	   under	   the	   influence	   of	   the	   MR.	   As	   a	   consequence,	   enriched	   nuclear	   NFAT	  
possibly	  binds	  to	  the	  CTLA-­‐4	  promoter	  resulting	  in	  its	  increased	  transcription	  accompanied	  
with	  induction	  of	  tolerance.	  
	  
The	   importance	  of	  NFAT-­‐mediated	  tolerance	   induction	  becomes	  obvious	  by	  the	   fact	   that	  
NFAT	   is	   able	   to	   induce	   forkhead	   box	   P3	   (Foxp3)	   expression,	  which	   is	   a	  marker	   for	   CD4+	  
regulatory	  T	  cells	  (Treg)	  (136).	  Foxp3	  can	  in	  turn	  interact	  with	  NFAT	  and	  up-­‐regulates	  CTLA-­‐4	  
expression	   in	   CD4+	   CD25+	   Treg	   (137,	   138).	   Wing	   et	   al.	   (139)	   reported	   that	   only	   lacking	  
expression	  of	  CTLA-­‐4	  on	  Treg	  is	  sufficient	  to	  cause	  autoimmune	  disease,	  allergies	  and	  tumor	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growth.	   Interestingly,	   additional	   defects	   in	   CTLA-­‐4	   expression	   in	   T	   effector	   cells	   even	  
pronounce	  the	  pathology.	  This	  highlights	  the	  importance	  in	  CTLA-­‐4	  regulation	  in	  Treg	  as	  well	  
as	  in	  T	  effector	  cells.	  	  
	  
The	   significance	   of	   CTLA-­‐4	   is	   further	   stressed	   by	   the	   various	   therapeutic	   approaches	  
targeting	   CTLA-­‐4	   (140).	   Anti-­‐CTLA-­‐4	   antibodies	   are	   however	   antagonistic	   rather	   than	  
agonistic	   and	   worsen	   autoimmune	   disease	   like	   EAE	   (141).	   They	   were	   therefore	   used	   in	  
many	  different	  tumor-­‐treatments	  (e.g.	  brain,	  breast,	  ovaries,	  colon),	  either	  applied	  solely	  
or	  in	  combination	  with	  e.g.	  radiation	  therapy	  (142).	  	  	  
For	  autoimmune	  disease	  therapies,	  a	  soluble	  form	  of	  CTLA-­‐4	  (sCTLA-­‐4)	  is	  used	  instead.	  This	  
is	   a	   widely	   investigated	   co-­‐stimulatory	   therapy,	   applied	   for	   murine	   models	   of	   systemic	  
lupus	  erythematosus	  (SLE)	  (143),	  experimental	  allergic	  encephalo-­‐myelitis	  (EAE)	  (144-­‐146),	  
allergic	  contact	  dermatitis	  (147),	  rheumatoid	  arthritis	  (RA)	  (148)	  and	  type	  1	  diabetes	  (T1D)	  
(149).	   Furthermore	   sCTLA-­‐4	   is	   able	   to	   promote	   long-­‐term	   graft	   survival	   (147,	   148,	   150).	  
Approaches	  using	  sCTLA-­‐4	  are	  favorable	  compared	  to	  systemic	  immune	  suppression,	  since	  
only	  T	  cells	  -­‐	  and	  not	  all	  immune	  cells	  -­‐	  are	  targeted.	  	  
	  
Due	  to	  its	  capacity	  to	  induce	  CTLA-­‐4	  expression,	  also	  the	  application	  of	  the	  soluble	  form	  of	  
the	  MR	  might	  lead	  to	  the	  same	  immune	  suppressive	  effect	  and	  might	  be	  an	  alternative	  in	  
treatment	   of	   the	   above-­‐mentioned	   autoimmune	   disease.	   This	   and	   the	   still	   unanswered	  
question	  whether	  the	  MR-­‐mediated	  induction	  of	  CTLA-­‐4	  is,	  as	  speculated,	  due	  to	  enhanced	  
NFAT-­‐binding	  to	  the	  Ctla-­‐4	  promoter,	  has	  to	  be	  experimentally	  tested	  in	  the	  future.	  	  
	  
5.6 Influence	  of	  the	  Mannose	  Receptor	  on	  DC-­‐T	  cell	  interactions	  
Marangoni	   et	   al.	   (151)	   showed	   via	   multiphoton	   intravital	   microscopy	   that	   tolerance	  
induction	  is	  connected	  with	  delayed	  nuclear	  export	  of	  NFAT.	  Whether	  the	  MR	  also	  leads	  to	  
prolonged	  transcriptional	  activity	  in	  the	  nucleus,	  remains	  to	  be	  investigated.	  Yet,	  the	  study	  
of	  Maragoni	   et	   al.	   connected	   this	   tolerance	   induction	  with	   a	   predominance	   of	   unstable	  
interactions	   between	   APCs	   and	   T	   cells.	   Divergent	   to	   this,	   the	   present	   data	   indicate	  
prolonged	  interactions	  between	  tolerance	  inducing	  MR-­‐bearing	  DCs	  and	  T	  cells	  compared	  
to	  MR-­‐lacking	  DCs.	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At	   the	   first	  glance,	   the	  observation	  of	  prolonged	  DC-­‐T	  cell	   contact	   in	   tolerance	   induction	  
might	   sound	   contradictory	   to	   the	   general	   agreement	   that	   long-­‐lasting	   contact	   durations	  
between	  APCs	  and	  T	  cells	  result	  in	  efficient	  T	  cell	  priming,	  whereas	  short	  interactions	  lead	  
to	  tolerance	  induction	  (152-­‐155).	  Mostly,	  these	  long-­‐lasting	  interactions	  accompanied	  with	  
T	  cell	  priming	  were	  seen	  under	  inflammatory	  conditions	  whereas	  tolerance	  induction	  was	  
reported	  under	  non-­‐inflammatory	  conditions	  (154,	  156,	  157).	  	  
	  
This	  study	  indicates	  that	  the	  MR	  also	  influences	  contact	  durations	  of	  DC-­‐T	  cell	  interactions	  
under	  non-­‐inflammatory	  conditions.	  These	  findings	  are	  supported	  by	  Van	  Vliet	  et	  al.	  (57),	  
proving	   the	   contribution	   of	   the	   lectin	   MGL	   in	   DC-­‐T	   cell	   contacts.	   They	   detected	   an	  
increased	   retention	   of	   Jurkat	   cells	   and	   peripheral	   blood	   lymphocytes	   by	   an	   MGL-­‐
transfected	   cell	   line	   compared	   to	   untransfected	   cells.	   A	   further	   supportive	   fact	   for	   the	  
prolonged	  DC-­‐T	  cell	  interaction	  in	  the	  presence	  of	  the	  MR,	  despite	  tolerance	  induction,	  are	  
reports	  about	  increased	  integrin	  expression	  in	  CD45-­‐deficient	  cells	  (53,	  54).	  This	  increased	  
integrin	   expression	   in	   macrophages	   and	   T	   cells	   is	   due	   to	   enhanced	   Src	   family	   kinase	  
activity,	   to	  which	   also	   Lck	   belongs.	   As	   already	   highlighted,	   the	  MR	   is	   able	   to	   inhibit	   the	  
phosphatase	  CD45	  in	  T	  cells.	  Thereby,	  CD45	  is	  disabled	  to	  dephosphorylate	  Lck	  neither	  on	  
its	   catalytic	   tyrosine	   Y394,	   nor	   on	   its	   inhibitory	   tyrosine	   Y505,	   which	   may	   result	   in	  
increased	  Lck	  activity.	   In	   turn,	  T	   cells	  which	  get	   into	   contact	  with	  MR-­‐bearing	  DCs	  might	  
also	  up-­‐regulate	  integrins	  and	  thereby	  increase	  the	  contact	  duration.	  	  
	  
It	  is	  nevertheless	  reported	  that	  not	  only	  the	  contact	  duration	  alone,	  but	  also	  cytokines	  and	  
chemokines	  in	  concert	  determine	  the	  fate	  of	  T	  cells	  towards	  immunity	  or	  tolerance	  (153).	  
The	  data	  from	  van	  Vliet	  et	  al.	  and	  my	  own	  work	  furthermore	  indicate	  that	  besides	  these,	  
other	  factors,	  like	  lectins,	  play	  an	  important	  role	  during	  the	  interaction	  of	  APCs	  and	  T	  cells.	  
Finally,	  it	  was	  proven	  that	  the	  contribution	  of	  the	  MR	  to	  the	  DC-­‐T	  cell	  interaction	  not	  only	  
influences	  its	  duration	  but	  also	  results	  in	  tolerance	  induction	  in	  CD8+	  T	  cells.	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5.7 	   The	  Mannose	  Receptor	  as	  target	  for	  dampening	  the	  immune	  
response	  
The	   ability	   of	   the	  MR	   to	   cross-­‐present	   antigens	   led	   to	   the	  possibility	   to	   induce	   a	   potent	  
immune	  response	  by	  targeting	  the	  MR	  for	  vaccination	  strategies.	  As	  a	  matter	  of	  fact,	  many	  
attempts	  were	  in	  vain	  and	  resulted	  in	  T	  cell	  tolerance	  (90,	  91).	  In	  these	  studies,	  immunity	  
could	  only	  be	  induced	  by	  co-­‐application	  of	  endotoxins	  (90,	  93).	  Chieppa	  et	  al.	  (92)	  further	  
stated	   that	   it	   also	   strongly	   depends	   on	   the	   kind	   of	   MR-­‐targeting	   whether	   anergy	   or	  
immunity	  is	  caused.	  This	  is	  supported	  by	  the	  detection	  that	  the	  specific	  MR-­‐targeting	  via	  3-­‐
sulfo-­‐LewisA	  and	  tri-­‐GlcNAc	  (N-­‐acetylglucosamine)	   is	  able	  to	   induce	  potent	  CD8+	  response	  
even	  in	  the	  absence	  of	  inflammatory	  agents	  (158).	  	  
	  
These	  observations	  further	  strengthen	  the	  fact	  that	  one	  has	  to	  consider	  the	  dual	  function	  
of	   the	  MR	  being	  either	   induction	  of	   immunity	  or	   tolerance	  when	  antigens	  were	  targeted	  
towards	   the	   MR.	   Either	   a	   strong	   adjuvant	   has	   to	   be	   co-­‐administered	   or	   only	   certain	  
antigens-­‐conjugates	   can	   be	   used	   to	   induce	   a	   strong	   immune	   response	   which	   would	   be	  
desirable	  for	  example	  for	  tumor-­‐vaccinations.	  	  
	  
Otherwise,	   MR-­‐targeting	   will	   lead	   to	   immune-­‐suppression	   which	   however	   could	   be	  
beneficial	   for	   targeting	   assays	   aiming	   at	   dampening	   the	   immune	   response	   as	   in	  
autoimmune	  diseases	  like	  EAE,	  (159,	  160).	  	  
A	   different	   approach	   in	   the	   treatment	   of	   autoimmune	   diseases,	   apart	   from	   antigen	  
targeting	  towards	  the	  MR,	  could	  be	  to	  systemically	  facilitate	  the	  quantity	  of	  the	  MR.	  This	  
may	  be	  achieved	  by	  the	  application	  of	  agents	  known	  to	  induce	  the	  MR	  expression.	  
	  
Adorini	   et	   al.	   described	   an	   enhanced	  MR	   expression	   upon	   treatment	   of	   human	  myeloid	  
dendritic	   cells	  with	   1,25(OH)2D3	   (active	   vitamine	  D)	   and	   the	   preventive	   effect	   of	   VitD	   in	  
mouse	  models	   of	   autoimmune	   disease	   like	   SLE,	   EAE,	   RA	   and	   T1D	   (161).	   Although	   these	  
effects	  were	  not	  pinpointed	   to	  be	  due	   to	   the	  MR,	   it	  would	  be	  worth	   repeating	   it	   in	  MR-­‐
deficient	  mice.	  Thereby,	  one	  could	  investigate	  whether	  and	  to	  which	  extend	  the	  improving	  
capacity	  of	  VitD	  is	  mediated	  by	  increased	  MR	  expression.	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The	   expression	   of	   the	  MR	  might	   also	   be	   triggered	   in	   vivo	   by	   application	   of	   VitD.	   It	   was	  
shown	  by	  Munger	  et	  al.	  (162)	  that	  intake	  of	  VitD	  and	  incidence	  of	  multiple	  sclerosis	  (MS)	  is	  
inversely	   correlated.	   Furthermore,	   in	   the	   northern	   hemispheres	   with	   less	   sunlight	   and	  
hence	   lower	  VitD	   levels	   the	  severity	  of	  MS	   is	   increased	   (163).	  VitD	  supplementation	  also	  
had	  preventive	  effects	  on	  development	  of	  rheumatoid	  arthritis	  (164).	  	  
	  
A	   systemic	   application	   of	   IL-­‐10,	   which	   might	   also	   lead	   to	   enhanced	   MR	   expression,	   is	  
controversially	   discussed.	   Not	   in	   all	   application	   models	   did	   IL-­‐10	   reveal	   immune-­‐
suppressive	  functions;	  immune-­‐stimulatory	  effects	  could	  also	  be	  observed.	  Thus,	  it	  has	  to	  
be	  carefully	  investigated	  which	  disorder	  at	  which	  developmental	  stage	  can	  be	  treated	  with	  
which	   concentration	   of	   systemically	   administered	   IL-­‐10	   (165).	   For	   IL-­‐4,	   another	   MR-­‐
inducing	   cytokine,	   Ghoreschi	   et	   al.	   (166)	   could	   achieve	   positive	   effects	   in	   treatment	   of	  
psoriasis	   patients.	  Whether	   systemic	   administration	  of	   IL-­‐10	  or	   IL-­‐4,	   besides	  many	  other	  
effects,	   also	   leads	   to	   enhanced	   expression	   of	   the	   MR	   and	   thus	   might	   decrease	   the	  
pathology	  of	  autoimmune	  disease	  remains	  to	  be	  investigated.	  
	  
Since	  the	  expression	  of	  the	  MR	  directly	  correlates	  with	  its	  shedding,	  the	  above	  mentioned	  
treatments	  may	   not	   only	   enhance	   surface	  MR-­‐expression	   on	   cells,	   but	   the	   shed	   variant	  
might	  be	  able	  to	  provide	  a	  humoral	  tolerogenic	  stimuli.	  	  
A	  soluble	  form	  of	  the	  mannose	  receptor	  could	  already	  be	  detected	  in	  serum	  of	  mice	  (77)	  
indicating	   its	   natural	   appearance	   in	   vivo.	   After	   shedding,	   the	  MR	   still	   retains	   its	   binding	  
capabilities	   as	   proven	   by	  Martinez-­‐Pomares	   et	   al.	   (77)	   and	   in	   the	   present	   study.	   In	   this	  
work,	  it	  was	  furthermore	  outlined	  that	  also	  the	  tolerogenic	  effect	  of	  the	  MR	  is	  still	  existent	  
when	  applied	  as	  soluble	  protein.	  Hence,	  the	  application	  of	  the	  soluble	  mannose	  receptor	  
might	  be	  a	  therapeutic	  tool	  in	  the	  treatment	  of	  CD8+	  T	  cell-­‐mediated	  autoimmune	  diseases	  
like	  MS,	  T1D	  and	  RA	  (167,	  168,	  169).	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5.8 	   Concluding	  remarks	  
The	  results	  of	  the	  study	  at	  hand	  could	  deliver	  an	  explanation	  as	  to	  the	  question	  why	  many	  
tolerance-­‐inducing	  cells	  express	  the	  MR,	  why	  MR-­‐targeting	  often	  led	  to	  anergy	  instead	  of	  
immunity	  and	  why	  co-­‐administration	  of	   strong	  adjuvants	   is	  necessary	   in	   these	   targeting-­‐
strategies.	  Additionally,	  it	  might	  be	  of	  help	  in	  further	  approaches	  of	  treating	  autoimmune	  
diseases.	  Still,	  there	  are	  many	  open	  questions	  to	  be	  answered.	  Is	  the	  tolerogenic	  effect	  of	  
the	  MR	  mediated	  via	  nuclear	  retention	  of	  NFAT?	  And	  would	  that	  be	  responsible	  for	  the	  up-­‐
regulation	  of	  CTLA-­‐4?	  Which	  other	  factors,	  if	  any,	  are	  involved?	  Is	  it	  possible	  to	  prevent	  or	  
improve	   pathological	   courses	   by	   application	   of	   the	   soluble	   MR?	   Does	   the	   MR	   also	  
influences	   CD4+	   T	   cells	   for	   example	   in	   their	   differentiation	   towards	   TH1	   or	   TH2	   T	   helper	  
cells?	   Hopefully,	   others	   and	  myself	   are	   able	   to	   shed	  more	   light	   into	   this	   topic	   and	   give	  
further	  insights	  into	  the	  function	  and	  regulation	  of	  the	  immune	  system.	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AdLOG.	  Adenovirus	  expressing	  Luciferase	  OVA	  GFP	  
Amp.	  Ampicillin	  
AP1.	  Activator	  protein	  1	  
APC.	  Antigen	  presenting	  cell,	  Allophycocyanin,	  
Antigen-­‐presenting	  cell	  
	  
BMDC.	  Bone	  marrow-­‐derived	  Dendritic	  cell	  
BSA.	  Bovine	  serum	  albumin	  
	  
CD.	  Cluster	  of	  differentiation	  
CFSE.	  Carboxyfluorescein	  succinimidyl	  ester	  
CpG.	  CpG-­‐dinucleotide,	  CpG-­‐dinucleotide	  
CR.	  Cystein	  rich	  domain	  
CRD.	  Carbohydrate	  recognition	  domain	  
Csk.	  C-­‐terminal	  Src	  kinase	  
CTL.	  Cytotoxic	  T	  lymphocyte	  
CTLA-­‐4.	  Cytotoxic	  T-­‐lymphocyte	  antigen	  4	  
CTLD.	  C-­‐type	  lectin-­‐like	  carbohydrate	  recognition	  
domain	  
	  
DAG.	  Diacyl	  glycerol	  
DC.	  Dendritic	  cell	  
DCs.	  Dendritic	  cells	  
DMEM.	  Dulbecco’s	  modified	  Eagle's	  medium	  
DTT.	  Dithiothreitol	  
	  
EAE.	  Experimental	  allergic	  encephalo-­‐myelitis	  
EDTA.	  Ethylenediaminetetraacetic	  acid	  
Egr.	  Early	  growth	  response	  protein	  
ELISA.	  Enzyme-­‐linked	  immunosorbent	  assay	  
ER.	  Endoplasmic	  reticulum	  
	  
FACS.	  Fluorescence-­‐activated	  cell	  sorting	  
FC.	  Fold	  change	  
FCS.	  Fetal	  calf	  serum	  
FDR.	  False	  discovery	  rate	  
FITC.	  Fluorescein	  
FNII.	  Fibronectin	  type	  II	  domain	  
Foxp3.	  Forkhead	  box	  P3	  
	  
GalNAc.	  N-­‐Acetylgalactosamine	  
GFP.	  Green-­‐fluorescent	  protein	  
GM-­‐CSF.	  Granulocyte-­‐macrophage	  colony-­‐stimulating	  
factor	  
	  
HEK.	  Human	  embryonic	  kidney	  cell	  




ICAM.	  Intercellular	  adhesion	  molecule	  1	  
ICOS.	  Inducible	  T	  cell	  costimulator	  
ICOSL.	  Inducible	  T	  cell	  costimulator	  ligand	  
IFN-­‐g.	  Interferon-­‐gamma	  
IFNR.	  Interferon	  receptor	  
IKK.	  Inhibitor	  of	  nuclear	  factor-­‐kappa	  B	  kinase	  
IL.	  Interleukin	  
IMDM.	  Iscove's	  modified	  Dulbecco's	  medium	  
InsP3.	  Inositol-­‐1,4,5-­‐triphosphate	  
ITAM.	  Immunoreceptor	  tyrosine-­‐based	  activation	  
motif	  
	  
Jmjd3.	  Jumonji	  domain	  containing	  3	  
	  
Kana.	  Kanamycin	  
kDa.	  kilo	  Dalton	  
	  
LAT.	  Linker	  for	  the	  activation	  of	  T	  cells	  
Lck.	  Lymphocyte-­‐specific	  protein	  tyrosine	  kinase	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MACS.	  Magnatic	  activated	  cell	  sorting	  
MAPK.	  Mitogen-­‐activated	  protein	  kinase	  
M-­‐CSF.	  Macrophage	  colony-­‐stimulating	  factor	  
MFI.	  Mean	  fluorescent	  intensity	  
MHC.	  Major	  histocompatibility	  complex	  
MHC	  I.	  MHC	  class	  I	  molecule	  
MHC	  II.	  MHC	  class	  II	  molecule	  
MOI.	  Multiplicity	  of	  infection	  
MR.	  Mannose	  Receptor	  
MR-­‐/-­‐.	  MR	  knockout	  
MS.	  Multiple	  sclerosis	  
	  
NFAT.	  Nuclear	  factor	  of	  activated	  T	  cells	  
NF-­‐kB.	  Nuclear	  factor-­‐kappa	  B	  




PAMP.	  Pathogen-­‐associated	  molecular	  pattern	  
PBMC.	  Peripheral	  blood	  mononuclear	  cells	  
PBS.	  Phosphate	  buffered	  saline	  
PBST.	  Phosphate	  buffered	  saline	  Tween-­‐20	  
PD.	  Programmed	  cell	  death	  
PD-­‐L.	  Programmed	  cell	  death	  ligand	  
PE.	  R-­‐Phycoerythrin	  
Pen/Strep.	  Penicillin/Streptomycin	  
PGS.	  Partek	  Genomics	  Suite	  
PKC.	  Protein	  kinase	  C	  
PLCg1.	  Phospholipase	  C	  gamma	  1	  
PPARg.	  Peroxisome	  proliferator-­‐activated	  receptor	  
gamma	  
PRR.	  Pattern-­‐recognition	  receptor	  
PtdIns(4,5)P2.	  Phosphatidylinositol-­‐4,5-­‐bisphosphate	  
	  




RA.	  Rheumatoid	  arthritis	  
RAS.	  Rat	  sarcoma	  
RCB.	  Red	  cell	  lysis	  buffer	  
RT.	  Room	  temperature	  
	  
SCID.	  Severe-­‐combined	  immunodeficiency	  
sCTLA-­‐4.	  Soluble	  chimeric	  CTLA-­‐4	  protein	  
SDS.	  Sodium	  dodecyl	  sulfate	  
SF1670.	  N-­‐(9,10-­‐Dioxo-­‐9,10-­‐dihydro-­‐phenanthren-­‐2-­‐
yl)-­‐2,2-­‐dimethyl-­‐propioamide	  
SLE.	  Systemic	  lupus	  erythematosus	  
SLP76.	  Scr	  homology	  2	  domain-­‐containing	  leukocyte	  
phosphoprotein	  of	  76kDa	  
Src.	  Sarcoma	  
	  
T1D.	  Type	  1	  diabetes	  
TAM.	  Tumor-­‐associated	  macrophage	  
TAP.	  Transporter	  associated	  with	  antigen	  processing	  
TBS.	  Tris	  buffered	  saline	  
TBST.	  Tris	  buffered	  saline	  Tween-­‐20	  
TCR.	  T	  cell	  receptor	  
TGF-­‐b.	  Transforming	  growth	  factor-­‐beta	  
TH.	  T	  helper	  type	  1	  cells	  
TH2.	  T	  helper	  type	  2	  cell	  
TLR.	  Toll-­‐like	  receptor	  




Y394.	  Tyrosine	  residue	  394	  
Y505.	  Tyrosine	  residue	  505	  
	  ZAP-­‐70.	  Zeta-­‐chain-­‐associated	  protein	  kinase	  of	  70	  kDa	  
